Document:

Stock Purchase Agreement

 Exhibit 10.8 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Asterisks denote omissions. 
 Execution Version 

 
  
 STOCK PURCHASE AGREEMENT 
 Dated as of December 11, 2009 

between 
 PFIZER,
INC. 
 and 
 DURATA THERAPEUTICS, INC. 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 DEFINITIONS; CERTAIN RULES OF CONSTRUCTION
	  	 	1	  
			
	 2.
	 	 PURCHASE AND SALE OF SHARES
	  	 	12	  
			
		 	 2.1.       Purchase and Sale of Shares
	  	 	12	  
			
		 	 2.2.       Purchase Price
	  	 	12	  
			
		 	 2.3.       The Closing
	  	 	13	  
			
		 	 2.4.       Closing Deliveries
	  	 	13	  
			
		 	 2.5.       Milestone Payment
	  	 	13	  
			
		 	 2.6.       FDA Confirmatory Milestone
	  	 	14	  
			
	 3.
	 	 REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY BY THE SELLER
	  	 	16	  
			
		 	 3.1.       Organization, Qualification; Subsidiaries
	  	 	16	  
			
		 	 3.2.       Capital Structure
	  	 	17	  
			
		 	 3.3.       Power and Authorization
	  	 	17	  
			
		 	 3.4.       Noncontravention
	  	 	17	  
			
		 	 3.5.       Litigation
	  	 	18	  
			
		 	 3.6.       Intellectual Property
	  	 	18	  
			
		 	 3.7.       Regulatory Compliance
	  	 	19	  
			
		 	 3.8.       Company Contracts
	  	 	20	  
			
		 	 3.9.       Employees and Consultants
	  	 	21	  
			
		 	 3.10.     Real Property
	  	 	22	  
			
		 	 3.11.     Environmental Matters
	  	 	22	  
			
		 	 3.12.     No Brokers
	  	 	22	  
			
		 	 3.13.     Taxes
	  	 	22	  
			
		 	 3.14.     Insurance
	  	 	24	  
			
		 	 3.15.     Governmental Authorizations
	  	 	24	  
			
		 	 3.16.     Books and Records
	  	 	24	  
			
		 	 3.17.     Asset and Liability Statement
	  	 	24	  
			
		 	 3.18.     No Undisclosed Liabilities
	  	 	25	  
			
		 	 3.19.     Compliance with Legal Requirements
	  	 	25	  

  
 - i -

							
			
		 	 3.20.     Seller’s Knowledge
	  	 	25	  
			
		 	 3.21.     Residual Assets
	  	 	25	  
			
		 	 3.22.     No Other Representations or Warranties
	  	 	25	  
			
	 4.
	 	 REPRESENTATIONS AND WARRANTIES REGARDING THE SELLER BY THE SELLER
	  	 	26	  
			
		 	 4.1.       Organization
	  	 	26	  
			
		 	 4.2.       Power and Authorization
	  	 	26	  
			
		 	 4.3.       Authorization of Governmental Authorities
	  	 	26	  
			
		 	 4.4.       Noncontravention
	  	 	26	  
			
		 	 4.5.       Shares
	  	 	27	  
			
		 	 4.6.       No Brokers
	  	 	27	  
			
		 	 4.7.       Indemnification
	  	 	27	  
			
		 	 4.8.       Other Contractual Obligations
	  	 	27	  
			
		 	 4.9.       RaQualia Agreement
	  	 	27	  
			
		 	 4.10.     Competing Products
	  	 	28	  
			
		 	 4.11.     Inventory
	  	 	28	  
			
	 5.
	 	 REPRESENTATIONS AND WARRANTIES OF THE BUYER
	  	 	28	  
			
		 	 5.1.       Organization
	  	 	28	  
			
		 	 5.2.       Power and Authorization
	  	 	28	  
			
		 	 5.3.       Authorization of Governmental Authorities
	  	 	28	  
			
		 	 5.4.       Noncontravention
	  	 	29	  
			
		 	 5.5.       Investment Experience; Investigation; Reliance
	  	 	29	  
			
		 	 5.6.       No Brokers
	  	 	30	  
			
		 	 5.7.       Budget
	  	 	30	  
			
		 	 5.8.       Corporate Status
	  	 	30	  
			
		 	 5.9.       No Other Representations or Warranties
	  	 	30	  
			
	 6.
	 	 COVENANTS
	  	 	30	  
			
		 	 6.1.       Closing
	  	 	30	  
			
		 	 6.2.       Conduct of Business
	  	 	31	  
			
		 	 6.3.       Buyer’s Access to Premises
	  	 	32	  
			
		 	 6.4.       Notice of Developments
	  	 	33	  
			
		 	 6.5.       Expenses
	  	 	33	  

  
 - ii -

							
			
		 	 6.6.       Exclusivity
	  	 	33	  
			
		 	 6.7.       Notices and Consents
	  	 	34	  
			
		 	 6.8.       FDA Confirmatory Milestone
	  	 	34	  
			
		 	 6.9.       Diligence
	  	 	34	  
			
		 	 6.10.     Confidentiality
	  	 	34	  
			
		 	 6.11.     Publicity
	  	 	36	  
			
		 	 6.12.     Further Assurances
	  	 	36	  
			
		 	 6.13.     Buyers Non-Transitory Corporation Covenant
	  	 	37	  
			
		 	 6.14.     Listed Transactions
	  	 	37	  
			
		 	 6.15.     Payment of Indebtedness
	  	 	37	  
			
	 7.
	 	 CONDITIONS TO THE BUYERS OBLIGATIONS AT THE CLOSING
	  	 	37	  
			
		 	 7.1.       Representations and Warranties
	  	 	37	  
			
		 	 7.2.       Performance
	  	 	37	  
			
		 	 7.3.       Stock Certificates
	  	 	38	  
			
		 	 7.4.       Compliance Certificate
	  	 	38	  
			
		 	 7.5.       Qualifications
	  	 	38	  
			
		 	 7.6.       Absence of Litigation
	  	 	38	  
			
		 	 7.7.       Ancillary Agreements
	  	 	38	  
			
		 	 7.8.       Excluded Assets; Excluded Liabilities
	  	 	38	  
			
	 8.
	 	 CONDITIONS TO THE SELLER’S OBLIGATIONS AT THE CLOSING
	  	 	38	  
			
		 	 8.1.       Representations and Warranties
	  	 	38	  
			
		 	 8.2.       Performance
	  	 	39	  
			
		 	 8.3.       Compliance Certificate
	  	 	39	  
			
		 	 8.4.       Qualifications
	  	 	39	  
			
		 	 8.5.       Absence of Litigation
	  	 	39	  
			
		 	 8.6.       Ancillary Agreements
	  	 	39	  
			
		 	 8.7.       Excluded Assets
	  	 	39	  
			
	 9.
	 	 TERMINATION
	  	 	39	  
			
		 	 9.1.       Termination of Agreement
	  	 	39	  
			
		 	 9.2.       Effect of Termination
	  	 	40	  

  
 - iii -

							
			
	 10.
	 	 INDEMNIFICATION
	  	 	40	  
			
		 	 10.1.     Indemnification by the Seller
	  	 	40	  
			
		 	 10.2.     Indemnity by the Buyer
	  	 	42	  
			
		 	 10.3.     Time for Claims
	  	 	43	  
			
		 	 10.4.     Third Party Claims
	  	 	44	  
			
		 	 10.5.     Other Limitations
	  	 	45	  
			
		 	 10.6.     Remedies Cumulative
	  	 	46	  
			
		 	 10.7.     Knowledge and Investigation
	  	 	46	  
			
		 	 10.8.     No Right of Set-Off
	  	 	46	  
			
		 	 10.9.     Exclusive Remedy
	  	 	46	  
			
	 11.
	 	 TAX MATTERS
	  	 	47	  
			
		 	 11.1.     Tax Indemnification
	  	 	47	  
			
		 	 11.2.     Straddle Period
	  	 	47	  
			
		 	 11.3.     Tax Sharing Agreements
	  	 	47	  
			
		 	 11.4.     Certain Taxes and Fees
	  	 	47	  
			
		 	 11.5.     Cooperation on Tax Matters
	  	 	48	  
			
		 	 11.6.     Tax Contests
	  	 	48	  
			
		 	 11.7.     Tax Returns
	  	 	48	  
			
		 	 11.8.     Other
	  	 	49	  
			
	 12.
	 	 MISCELLANEOUS
	  	 	49	  
			
		 	 12.1.     Notices
	  	 	49	  
			
		 	 12.2.     Succession and Assignment; No Third-Party Beneficiary
	  	 	50	  
			
		 	 12.3.     Amendments and Waivers
	  	 	51	  
			
		 	 12.4.     Entire Agreement
	  	 	51	  
			
		 	 12.5.     Exhibits; Listed Documents, etc
	  	 	51	  
			
		 	 12.6.     Counterparts
	  	 	51	  
			
		 	 12.7.     Severability
	  	 	51	  
			
		 	 12.8.     Headings
	  	 	51	  
			
		 	 12.9.     Construction
	  	 	52	  
			
		 	 12.10.  Governing Law
	  	 	52	  
			
		 	 12.11.  Dispute Resolution
	  	 	52	  
			
		 	 12.12.  Jurisdiction; Venue; Service of Process
	  	 	53	  

  
 - iv -

 EXHIBITS 
  

			
	 Exhibit 1(a)
	  	Excluded Assets
		
	 Exhibit 1(b)
	  	Excluded Liabilities
		
	 Exhibit 1(c)
	  	Included Assets
		
	 Exhibit 1(d)
	  	Included Liabilities
		
	 Exhibit 1(e)
	  	Inventory Transfer Agreement
		
	 Exhibit 1(f)
	  	Pleuromutilin Structure
		
	 Exhibit 1(g)
	  	RaQualia Assignment Agreement
		
	 Exhibit 1(h)
	  	Reverse TSA Assignment Agreement
		
	 Exhibit 1(i)
	  	Knowledge
		
	 Exhibit 1(j)
	  	Transition Services Agreement
		
	 Exhibit 2.5.1
	  	Form of Promissory Note
		
	 Exhibit 5.7
	  	Buyer’s Development and Commercialization Budget for the Product
		
	 Exhibit 6.2.1(f)
	  	Company Contract Modifications
		
	 Exhibit 7.4
	  	Form of Seller’s Compliance Certificate
		
	 Exhibit 8.3
	  	Form of Buyer’s Compliance Certificate
		
	SCHEDULES	  	
		
	 Schedule 1(a)
	  	Lincosamide Patents
		
	 Schedule 3
	  	Seller’s Disclosure Schedules
		
	 Schedule 4.3
	  	Authorization of Government Authorities
		
	 Schedule 4.4
	  	Noncontravention
		
	 Schedule 4.11
	  	Inventory Specifications
		
	 Schedule 5.3
	  	Authorization of Government Authorities
		
	 Schedule 5.4
	  	Noncontravention

  
 - v -

 STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT, dated as of December 11, 2009 (the “Execution Date”), is by and between
(i) Durata Therapeutics, Inc., a Delaware corporation (the “Buyer”) and, (ii) Pfizer, Inc., a Delaware corporation (the “Seller”) (the “Agreement”). 

THE PARTIES ENTER INTO THIS AGREEMENT ON THE BASIS OF THE FOLLOWING FACTS, INTENTIONS AND UNDERSTANDINGS: 

A. The Seller is the sole record and beneficial owner of all of the outstanding shares of capital stock (the “Shares”)
of Vicuron Pharmaceuticals Inc., a Delaware corporation and a wholly owned subsidiary of the Seller (the “Company”). 
 B. The Company has, prior to the Execution Date, advised Buyer that (i) the Company has assigned, sold, distributed or otherwise transferred all of the Excluded Assets (as defined below) to the
Seller, its Affiliates, its subsidiaries or third parties (or will do so prior to the Closing Date), and (ii) the Seller, its Affiliates, its subsidiaries or third parties have acquired all right, title and interest in and to all of the
Excluded Liabilities (as defined below) related thereto (or will do so prior to the Closing Date). 
 C. The Buyer desires to
purchase from the Seller, and the Seller desires to sell to the Buyer, all of the Shares for the consideration, and upon the terms and subject to the conditions set forth, in this Agreement. 

NOW THEREFORE, in consideration of the premises and mutual promises herein made, and in consideration of the representations, warranties,
and covenants herein contained, the Buyer and the Seller hereby agree as follows. 
 1. DEFINITIONS; CERTAIN RULES OF
CONSTRUCTION. As used herein, the following terms shall have the following meanings: 
 “Action” means any
claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), controversy, assessment, arbitration, investigation, hearing, charge, complaint, demand, notice,
whistle-blowing action or proceeding to, from, by or before any Governmental Authority or any Regulatory Authority. 

“Affiliate” means any entity directly or indirectly controlled by, controlling, able to control, or under common control
with, a specified Person, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common
control with”) means possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by
contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of such Person. For the avoidance of doubt,
(i) neither of the parties to this Agreement shall be deemed to be an “Affiliate” of the other solely as a result of their entering into this Agreement, and (ii)

  
 -1-

 
each stockholder of the Buyer on the Execution Date (“Buyer’s Original Affiliates”) shall be deemed to be an Affiliate of the Buyer so long as it owns beneficially not less
than 10% of the voting securities of the Buyer. 
 “Agreement” is defined in the Preamble. 

“Ancillary Agreements” means (i) the certificates delivered pursuant to Sections 7.4 and 8.3, (ii) the
Transition Services Agreement, the (iii) RaQualia Assignment Agreement, (iv) the Inventory Transfer Agreement, (v) the Reverse TSA Assignment Agreement, and (vi) the Promissory Note. 

“Anidulafungin”, also known as ERAXIS or ECALTA, means any finished or semi-finished good containing the compound having
the chemical name 1-[(4R, 5R)-4,5 Dihydroxy-N2-[[4”-pentyloxy)[1,1’:4’,1”-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B (including any analogs, stereoisomers and mixtures thereof (such as racemates), radiosomers,
metabolites, salts, solvates and polymorphs and prodrugs thereof) and all dosage strength and sizes thereof, together with all expansions and improvements thereon. 
 “Asset and Liability Statement” is defined in Section 3.17. 
 “Biosearch Manufacturing” means Biosearch Manufacturing Srl., an Italian limited liability company. 
 “Bona Fide Transaction” means an arms-length disposition transaction to a bona fide third party that is not an Affiliate of more than two of the Buyer’s Original Affiliates.

 “Budget” means the Buyer’s budget for securing Market Approval from the FDA in the U.S. for the Product
in cSSS1 in adults (including the Upfront Consideration) that is established in good faith by the Buyer, an initial draft of which has been delivered to the Seller prior to the Execution Date in the form attached hereto as Exhibit 5.7, as
such budget may from time to time be amended or modified by the Buyer in accordance with and subject to the provisions of Section 5.7. 
 “Business Day” means any weekend other than a weekend on which banks in New York City are authorized or required to be closed. 

“Buyer” is defined in the Preamble. 
 “Buyer Indemnified Person” is defined in Section 10.1.1. 

“Buyer’s Original Affiliates” is defined in the definition of Affiliates. 

“Buyout Period” is defined in Section 2.5.2. 

“CERCLA” is defined in Section 3.11.2. 
 “Change of Control,” with respect to the Buyer, means an event in which: (A) any other Person or group of Persons acting in concert (other than a Parent Entity of the Buyer or
Buyer’s 

  
 -2-

 
Original Affiliates) acquires beneficial ownership of securities of the Buyer representing more than 50% of the voting power of the then outstanding securities of the Buyer with respect to the
election of directors of the Buyer; (B) the Buyer enters into a merger, consolidation, scheme of arrangement or similar transaction with another Person, unless (i) the members of the Board of Directors of the Buyer immediately prior to
such transaction constitute more than 50% of the members of the Board of Directors of the Buyer (or a Parent Entity of the Buyer) immediately following such transaction, and (ii) the Persons who beneficially owned the outstanding voting
securities of the Buyer immediately prior to such transaction beneficially own securities of the Buyer representing at least 50% of the voting power with respect to the election of directors of the Buyer immediately following such transaction, or a
Parent Entity of the Buyer beneficially owns securities of the Buyer representing 100% of the voting power with respect to the election of directors of the Buyer immediately following such transaction; or (C) the Buyer sells to any Person(s),
in one or more related transactions, a majority of the property and assets of the Buyer. For purposes of this definition, a “Parent Entity” of the Buyer means any Person that acquires directly or indirectly, by merger or otherwise,
the capital stock of the Buyer if the holders of securities that represented 100% of the voting power with respect to the election of directors (“Voting Stock”) of the Buyer immediately prior to such acquisition directly own 100% of
the Voting Stock of the Parent Entity immediately after such acquisition and in the exact same percentages as they owned Voting Stock in the Buyer immediately prior to such acquisition. 

“Closing” is defined in Section 2.3. 

“Closing Date” means December 18, 2009, or such later date on which Closing actually occurs as the parties mutually
agree in writing in accordance with Section 2.3. 
 “Code” means the U.S. Internal Revenue Code of
1986, as amended. 
 “Commercially Reasonable” is defined in Section 6.9. 

“Company” is defined in the Recitals of this Agreement. 

“Company Acquisition Date” means September 14, 2005 (the date that the Company was acquired by the Seller).

 “Company Contracts” is defined in Section 3.8.1. 

“Company Patents” is defined in Section 3.6.1. 

“Company Trademarks” is defined in Section 3.6.2. 

“Confidential Information” is defined in Section 6.10.1. 

“Confidentiality Agreements” is defined in Section 6.10.2. 

“Consent” means any approval, consent, ratification, waiver, license, permit or other authorization (including any
Governmental Authorization). 

  
 -3-

 “Contemplated Transactions” means, collectively, the transactions
contemplated by this Agreement, including (a) the sale and purchase of the Shares, and (b) the execution, delivery and performance of the Ancillary Agreements. 
 “Contractual Obligation” means, with respect to any Person, any contract, agreement, deed, mortgage, lease, license, commitment, promise, undertaking, arrangement or understanding,
whether written or oral and whether express or implied, or other document or instrument (including any document or instrument evidencing or otherwise relating to any Debt) to which or by which such Person is a party or otherwise subject or bound or
to which or by which any property, business, operation or right of such Person is subject or bound. 
 “cSSSI”
means any indication for the treatment of complicated skin and skin structure infections. 
 “Debt” means, with
respect to any Person, all obligations (including all obligations in respect of principal, accrued interest, penalties, fees and premiums) of such Person (a) for borrowed money (including overdraft facilities), (b) evidenced by notes,
bonds, debentures or similar Contractual Obligations, (c) for the deferred purchase price of property, goods or services (other than trade payables or accruals incurred in the Ordinary Course of Business), (d) under capital leases (in
accordance with GAAP), (e) in respect of letters of credit and bankers’ acceptances, (f) for Contractual Obligations relating to interest rate protection, swap agreements and collar agreements, and (g) in the nature of Guarantees
of the obligations described in clauses (a) through (f) above of any other Person. 
 “Disclosing
Party” is defined in Section 6.10.1. 
 “Disclosure Schedule” is defined in Section 3.

 “Encumbrance” means any change, claim, community or other marital property interest, condition, equitable
interest, lien, license, option, pledge, security interest, mortgage, right of way, easement, encroachment, servitude, right of first offer or first refusal, buy/sell agreement and any other restriction or covenant with respect to, or condition
governing the use, construction, voting (in the case of any security or equity interest), transfer, receipt of income or exercise of any other attribute of ownership). 
 “Enforceable” means, with respect to any Contractual Obligation stated to be Enforceable by or against any Person, that such Contractual Obligations is a legal, valid and binding
obligation of such Person enforceable by or against such Person in accordance with its terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other
similar laws of general application affecting the rights and remedies of creditors and to general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at law). 

“Environmental Laws” means any applicable Federal, state or local Legal Requirements, in each case as amended and in
effect in the jurisdiction in which the applicable site or premises are located, pertaining to the protection of human health, safety or the environment, including without limitation, the following statutes and all regulations promulgated
thereunder. CERCLA; the Emergency Planning and Community Right-to-Know Act, 42 U.S.C. § 11001 et seq.; the 

  
 -4-

 
Resource Conservation and Recovery Act, 42 U.S.C. § 6901 et seq.; the Federal Water Pollution Control Act, 33 U.S.C. § 1251 et seq.; the Federal Clean Air Act, 42 U.S.C. § 7401 et
seq.; the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. § 136 et seq.; the Toxic Substance Control Act, 15 U.S.C. § 2601 et seq.; the Oil Pollution Act of 1990, 33 U.S.C. § 2701 et seq.; the Hazardous Materials
Transportation Act, as amended, 49 U.S.C. § 1801 et seq.; the Atomic Energy Act, 42 U.S.C. § 2014 et seq.; any state or local statute or similar effect; and any Laws relating to protection of the environment which regulate the management
or disposal of biological agents or substances including medical or infectious wastes. 
 “Excluded Assets”
means (i) all interest in, and assets held by, the Italian branch of the Company, (ii) all direct or indirect equity or other interests in Biosearch Manufacturing and Vicuron Pharmaceuticals Italy, (iii) the assets related to the
Anidulafungin franchise, including the assets set forth on Exhibit 1(a) attached hereto, (iv) the manufacturing plant and real estate assets of the Company including real estate relating to Vicuron Pharmaceuticals Italy, Biosearch
Manufacturing, the Pisticci Plant, and the Geranzano Research Center and any other assets not directly relating to the Product or the Residual Assets For the avoidance of doubt the Excluded Assets shall not include the Included Assets 

“Excluded Liabilities” means all Liabilities relating directly or indirectly to the Excluded Assets (including any
environmental liabilities arising out of any Environmental Laws and any foreign equivalents thereof) or Hazardous Materials (including those treated as such under foreign equivalents of Environmental Laws) relating to Vicuron Pharmaceuticals Italy,
Biosearch Manufacturing, the Pisticci Plant or the Geranzano Research Center, and those Liabilities set forth on Exhibit 1(b). 

“Execution Date” is defined in the Preamble. 
 “FDA” means the U.S. Food and Drug Administration of the United States Department of Health and Human Services or any successor agency thereof. 

“FDA Confirmatory Milestone” means an FDA Response which specifically confirms or indicates from Type Meeting or other
Formal FDA Meeting that Marketing Approval in the U.S. for the Product in cSSSI in adults shall require evidence from Study 8 and/or Study 9 only or no more than one additional successful Phase III Trial (appropriately powered and designed in
addition to Study 8 and Study 9). 
 “FDA Milestone Period” is defined in Section 2.6.1. 

“FDA Response” means the FDA’s final written minutes of Formal FDA Meeting Special Protocol Assessment Letter, or
any other written correspondence from the FDA following Formal FDA Meeting that addresses the number and type of additional successful Phase III Trials required to receive Marketing Approval in the U.S. for the Product in cSSSI in adults.

 “FDACM Notice” is defined in Section 2.6.1. 

“FDCA” is defined in Section 3.7.1. 

  
 -5-

 “Final Termination Date” is defined in Section 9.1(b). 

“First Commercial Sale” means, with respect to the Product, the first commercial sale of the Product (i) in the
United States after Marketing Approval has been granted for the Product in cSSSI in adults in the United States or (ii) in any of the United Kingdom, Germany, Italy, Spain, or France after (a) Marketing Approval has been granted by the
European Medicines Agency or (b) Marketing Approval has been granted by Regulatory Authority in any three of the following five countries: United Kingdom, Germany, Italy, Spain, and France in each of (a) and (b), for the Product in cSSSI
in adults in the applicable foregoing country. 
 “First Commercial Sale Date” is defined in Section 2.5.1

 “Formal FDA Meeting” means Type A, Type B or Type C meeting as described in the FDA Guidance for Industry,
“Formal Meetings Between the FDA and Sponsors or Applicants” (Revision 1, May 2009) at which the number and type of additional successful Phase III Trials required to receive Marketing Approval in the U.S. for the Product in cSSSI in
adults is discussed. 
 “Fundamental Representations and Warranties” is defined in Section 10.1.2.

 “GAAP” means generally accepted accounting principles in the United States as in effect from time to time.

 “Geranzano Research Center” means the research center located in Via Lepetit 34, 21040 Gerenzano VA, Italy.

 “Government Order” means any order, writ, judgment, injunction, decree, stipulation, ruling, determination
or award entered by or with any Governmental Authority. 
 “Governmental Authorization” means any Consent
issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Legal Requirement. 
 “Governmental Authority” means any United States federal, state or local or any foreign government or political subdivision thereof, or any multinational organization or authority or any
authority agency or commission, in each case, entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power any court or tribunal (or any department bureau or division thereof), or any
arbitrator or arbitral body. 
 “Guarantee” means with respect to any Person, (a) any guarantee of the
payment or performance of, or any contingent obligation in respect of, any Debt or other Liability of any other Person, (b) any other arrangement whereby credit is extended to any obligor (other than such Person) on the basis of any promise or
undertaking of such Person (i) to pay the Debt or other Liability of such obligor, (ii) to purchase any obligation owed by such obligor, (iii) to purchase or lease assets under circumstances that are designed to enable such obligor to
discharge one or more of its obligations, or (iv) to maintain the capital, working capital, solvency or general financial condition of such obligor, and (c) any Liability as general partner of partnership or as venturer in joint venture in
respect of Debt or other obligations of such partnership or venture. 

  
 -6-

 “Hazardous Materials” means (a) any chemicals materials or substances
defined as or included in the definition of “hazardous substances,” “hazardous wastes,” “hazardous materials,” “chemical substances,” “toxic substances,” “toxic pollutants,”
“pollutants,” “contaminants,” “pesticides,” or “oil” as defined in any applicable Environmental Law or (b) any petroleum or petroleum products, radioactive materials, asbestos-containing materials,
polychlorinated biphenyls, urea formaldehyde foam insulation, radon and any other substance defined or designated as hazardous toxic or harmful to human health safety or the environment under any Environmental Law. 

“Included Assets” means those assets of the Company relating directly to the Product including those assets described on
Exhibit 1(c) attached hereto For the avoidance of doubt, the Included Assets shall not include the Excluded Assets. 

“Included Liabilities” means all Liabilities set forth on Exhibit 1(d) and all other Liabilities relating
directly to the Included Assets other than (i) any Liabilities arising out of breach of or inaccuracy in any of Sellers representations and warranties in Sections 3 and 4 of this Agreement or in any Ancillary Agreement and
(ii) all Excluded Liabilities for which the Seller has agreed to indemnify the Buyer under Section 10.1.1(d). For the avoidance of doubt, the Included Liabilities shall not include the Excluded Liabilities. 

“Indemnified Party” means, with respect to any Indemnity Claim, the party asserting such claim under
Section 10.1 or 10.2, as applicable. 
 “Indemnifying Party” means, with respect to any
Indemnity Claim, the Buyer or the Seller under Section 10.1 or 10.2, as applicable, against whom such claim is asserted. 
 “Indemnity Cap” is defined in Section 10.1.2(a). 

“Indemnity Claim” means claim for indemnity under Section 10.1 or 10.2, as applicable. 

“Inventory Transfer Agreement” means that certain Inventory Transfer Agreement by and among Pfizer Overseas LLC and the
Buyer, to be executed on or before the Closing Date, the form of which is attached hereto as Exhibit 1(e). 

“Knowledge” is defined in the definition of Seller’s Knowledge. 

“Legal Requirement” means any United States federal, state or local or foreign law, statute, standard, ordinance, code,
rule, act, regulation resolution or promulgation, or any Government Order, or any license franchise permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. 

“Liability” means, with respect to any Person, any liability or obligation of such Person whether known or unknown
whether asserted or unasserted, whether determined, determinable or otherwise, whether absolute or contingent, whether accrued or unaccrued whether liquidated or unliquidated whether incurred or consequential whether due or to become due and whether
or not required under GAAP to be accrued on the financial statements of such Person. 

  
 -7-

 “Licensed Patents” is defined in Section 3.6.1. 

“Lincosamide Asset” means the Patents identified on Schedule 1(a) and all know-how, data and other intellectual
property owned by the Company as of the Execution Date that relate directly to the compounds described and disclosed in such Patents. 
 “Losses” is defined in Section 10.1.1. 

“Market” means any regulatory jurisdiction for which the Company obtains Marketing Approval for the Product, other than
Japan, including, at such time the Company obtains Marketing Approval for the Product in such countries the United States and all current and future member countries of the European Union. 

“Marketing Approval” means, with respect to the Product in any regulatory jurisdiction and for any indication, the
approval of all Regulatory Authorities required to authorize the marketing of the Product in such jurisdiction for such indication. 
 “Material Adverse Effect” means, with respect to any Person, any development in, change in, or effect on, the business operations, assets, condition or prospects (financial or otherwise)
of such Person which, when considered either individually or in the aggregate, together with all other adverse developments, changes, or effects with respect to which such phrase is used in this Agreement, is, or is reasonably likely to be,
materially adverse to the business, operations, assets (including in the case of the Company the Product) condition or prospects financial or otherwise of such Person taken as whole. 

“Milestone Buyout” is defined in Section 2.5.2. 

“Milestone Payment” is defined in Section 2.2. 

“Ordinary Course of Business” means an action taken by any Person in the ordinary course of such Persons business which
is consistent with the past customs and practices of such Person (including past practice with respect to quantity, amount, magnitude and frequency standard employment and payroll policies and past practice with respect to management of working
capital and interactions with Regulatory Authorities) which is taken in the ordinary course of the normal day-to-day operations of such Person. 
 “Organizational Documents” means with respect to any Person (other than an individual), (a) the certificate or articles of incorporation or organization and any joint venture,
limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all by-laws, voting agreements and similar documents
instruments or agreements relating to the organization or governance of such Person in each case as amended or supplemented. 

“Owned Patents” is defined in Section 3.6.1. 

  
 -8-

 “Parent Entity” is defined in the definition of Change of Control.

 “Patents” means all patents and applications in any country or region (including PCT filings and provisional
applications), together with any and all patents that have issued or in the future issue therefrom, including any and all divisional continuations, continuations-in-part, re-examination certificates, substitutions, registrations, confirmations,
extensions, supplementary protection certificates, confirmation patents, patents of additions, certificates of invention, utility model and design patents, renewals, reissues of or relating to any of the aforesaid patents and/or patent applications,
as applicable. 
 “Permitted Encumbrance” means (a) statutory liens for current Taxes, special assessments
or other governmental charges not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in accordance with GAAP,
(b) mechanics’, materialmen’s, carriers’, workers’, repairers’, and similar statutory liens arising or incurred in the Ordinary Course of Business which liens have not had and are not reasonably likely to have Material
Adverse Effect on the Person subject to such liens, (c) zoning, entitlement, building and other land use regulations imposed by Governmental Authorities having jurisdiction over any real property which are not violated in any material respect
by the current use and operation of the real property, (d) deposits or pledges made in connection with, or to secure payment of, workers compensation, unemployment insurance, old age pension programs mandated under applicable Legal Requirements
or other social security, (e) covenants, conditions, restrictions easements, encumbrances and other similar matters of record affecting title to but not adversely affecting current occupancy or use of the real property in any material respect,
and (f) restrictions on the transfer of securities arising under federal and state securities Legal Requirements. 

“Person” means any individual or corporation, association, partnership, limited liability company, joint venture, joint
stock or other company, business trust, trust, organization, Governmental Authority or other entity of any kind. 

“Phase III Trial” means pivotal clinical study designed to establish the safety and effectiveness of drug product for
its proposed intended use and which if it successfully meets the protocol defined end-points and applicable statistical criteria, is intended to be submitted to Regulatory Authorities in Market as part of an application for Marketing Approval.

 “PHSA” is defined in Section 3.7.1. 

“Pisticci Plant” means the manufacturing site located in Via Pomarico 75015 Pisticci Scalo (MT) Italy. 

“Pleuromutilin Asset” means all know-how, data, and other intellectual property owned by the Company as of the Execution
Date that relates directly to compounds of the polycyclic formula represented by the chemical structure set forth on Exhibit 1(f). 
 “Post-Closing Tax Period” means any Tax period other than Pre-Closing Tax Period. 
 “Pre-Closing Tax Period” is defined in Section 11.1. 

  
 -9-

 “Product Transfer” is defined in Section 2.5.3. 

“Product” means all pharmaceutical formulations and dosage forms of dalbavancin or any salt prodrug, hydrate, solvate,
metabolite, or polymorph form of dalbavancin. 
 “Promissory Note” is defined in Section 2.5.1.

 “Purchase Price” is defined in Section 2.2. 

“Qualified Successor” is defined in Section 2.5.3. 

“RaQualia” means RaQualia Pharma Inc. 
 “RaQualia Agreement” means that certain Dalbavanein Marketing Rights Agreement by and between Pfizer Inc and RaQualia Pharma, Inc. dated as of June 30, 2008 as amended. 

“RaQualia Assignment Agreement” means that certain agreement by and among the Seller and the Buyer, to be executed on or
before the Closing Date, the form of which is attached hereto as Exhibit 1(g). 
 “Receiving Party” is
defined in Section 6.10.1. 
 “Regulatory Authorities” means the FDA and comparable regulatory or
Governmental Authorities in any Market in the world. 
 “Representative” means with respect to any Person, any
director, officer, employee, agent, consultant, advisor, or other representative of such Person, including legal counsel accountants and financial advisors. 
 “Residual Assets” means the Lincosamide Asset and the Pleuromutilin Asset. 
 “Reverse TSA Assignment Agreement” means that certain Assignment Agreement by and between Pfizer Overseas LLC and the Buyer, to be executed on or before the Closing Date, the form of
which is attached hereto as Exhibit 1(h). 
 “Securities Act” means the Securities Act of 1933, as
amended. 
 “Seller” is defined in the Preamble. 

“Seller Documentation” is defined in Section 6.3. 

“Seller Indemnified Person” is defined in Section 10.2.1. 

“Sellers Dispute Notice” is defined in Section 2.6.5. 

“Seller’s Knowledge” or “Knowledge” means the actual knowledge of the individuals listed on
Exhibit 1(i) attached hereto which list includes such individuals’ titles and operating responsibilities with respect to the Company or other relationship to the Company through which such individuals would have acquired such actual
knowledge. 

  
 -10-

 “Seller Payment” is defined in Section 2.6.1. 

“Shares” is defined in the Recitals to this Agreement. 

“Special Indemnity Cap” is defined in Section 10 1.2(c). 

“Special Protocol Assessment” means an FDA review of, and written agreement with, a study sponsor regarding the proposed
clinical protocols for one or more Phase III Trials whose data will form the primary basis for an efficacy claim for drug product as further described in the FDA Guidance for Industry, Special Protocol Assessments (May 2002). 

“Special Protocol Assessment Letter” means written correspondence from the FDA to study sponsor documenting the outcome
of Special Protocol Assessment. 
 “Stockholders And Subscription Agreement” means that certain Stockholders
And Subscription Agreement to be executed on or before the Closing Date, by and among the Buyer and the investors party thereto. Neither the Company nor the Seller are parties to the Stockholders And Subscription Agreement, have the right to rely
thereon or are third-party beneficiaries thereof. 
 “Straddle Period” is defined in Section 11.2.

 “Study 8” means the Phase III Trial for the Product known as VER001-8. 

“Study 9” means the Phase III Trial for the Product known as VER001-9. 

“Tax” or “Taxes” means (a) any and all federal, state, local, or foreign income, gross receipts,
license, payroll, employment, ,excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security (or similar including FICA), unemployment, disability,
real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum estimated or other tax of any kind or any charge of any kind in the nature of (or similar) to taxes whatsoever, including any interest,
penalty, or addition thereto, whether disputed or not, and any Liability for the payment of any amounts of the type described in clause (a) of this definition as result of being member of an affiliated, consolidated, combined or unitary
group for any period as result of any tax sharing or tax allocation agreement, arrangement or understanding, or as result of being liable for another Person’s taxes as transferee or successor by contract or otherwise. 

“Tax Return” means any return, declaration, report, claim for refund or information return or statement relating to
Taxes, including any schedule or attachment thereto and including any amendment thereof. 
 “Termination Date”
is defined in Section 9.1. 
 “Third Party Claim” is defined in Section 10.4.1.

 “Third Party Confidential Information” is defined in Section 6.10.3. 

  
 -11-

 “Threshold Amount” is defined in Section 10.1.2(a). 

“Total Project Cost” means the good faith estimate of the Buyer’s Board of Directors of the total cost (including
the Upfront Consideration) required to secure Marketing Approval from the FDA in the U.S for the Product in cSSSI in adults, taking into account all information available to the Buyer, including (i) the FDA Response, (ii) Buyer’s
correspondence and filings with the FDA after the Closing Date, (iii) any correspondence and filings with the FDA included in the Seller Documentation furnished to the Buyer pursuant to Section 6.3 of this Agreement, and
(iv) any correspondence and filings with the FDA furnished to Buyer pursuant to the Transition Services Agreement. 

“Transition Services Agreement” means the transition services agreement to be executed on or before the Closing Date
between the Buyer and the Seller relating to (a) the transfer of certain Seller Documentation and other records, technology and materials relating to the Included Assets, and (b) certain consulting services, the form of which is attached
hereto as Exhibit 1(j). 
 “Treasury Regulations” means the regulations promulgated under the Code.

 “Type A Meeting” means meeting between study sponsor and the FDA to discuss an otherwise stalled product
development program, as described in the FDA Guidance for Industry, “Formal Meetings Between the FDA and Sponsors or Applicants” (Revision 1, May 2009). 
 “Upfront Consideration” is defined in Section 2.2. 

“Vicuron Pharmaceuticals Italy” means Vicuron Pharmaceuticals Italy, Srl. 

Except as otherwise explicitly specified in this Agreement to the contrary, (a) references to Section Article Exhibit or Schedule
means Section or Article of or Schedule or Exhibit to, this Agreement, unless another agreement is specified, (b) the word including shall be construed as “including without limitation,” (c) references to a particular statute or
regulation shall be construed to include all rules and regulations thereunder and any predecessor or successor statute, rules or regulation, in each case as amended or otherwise modified from time to time, (d) words in the singular or plural
form shall include the plural and singular form, respectively, and (e) references to particular Person shall include such Persons successors and assigns to the extent not prohibited by this Agreement. 

2. PURCHASE AND SALE OF SHARES. 
 2.1. Purchase and Sale of Shares. At the Closing, subject to the terms and conditions of this Agreement, the Seller shall sell transfer and deliver to the Buyer, and the Buyer shall purchase from
the Seller, the Shares, including all of the Sellers right, title and interest in and to all of the Shares. 
 2.2. Purchase
Price. The aggregate consideration for the Shares shall be (a) Nine Million Seven Hundred Fifty Thousand Dollars ($9,750,000) paid to the Seller by the Buyer (the “Upfront Consideration”), plus subject to and in accordance
with the terms of this Agreement (including Section 2.5.2), the Seller’s contingent right to receive final payment of Twenty Five Million Dollars ($25,000,000) (the “Milestone Payment”) from the Buyer, as more
particularly set forth in Section 2.5 (collectively, the “Purchase Price”). 

  
 -12-

 2.3. The Closing. The purchase and sale of the Shares (the
“Closing”) shall take place at the offices of Ropes Gray LLP at 1211 Avenue of the Americas, New York, New York or at such other place as the Buyer and Seller may mutually agree in writing on the Closing Date. If on or prior to
December 18, 2009 the conditions set forth in Sections 7 and 8 and have not been satisfied or waived in writing by the Buyer or the Seller, as applicable, subject to any rights of termination as set forth in Section 9,
the Closing shall take place on such other date, not later than the fifth Business Day following the satisfaction of such conditions, as the Buyer and the Seller may mutually agree in writing. Except as otherwise provided in Section 9,
the failure to consummate the purchase and sale of the Shares provided for in this Agreement on the date and time and at the place specified herein shall not relieve any party to this Agreement of any obligations under this Agreement. 

2.4. Closing Deliveries. The parties hereto shall take the actions set forth in this Section 2.4 at the Closing, in
each case, subject to satisfaction or written waiver of the conditions set forth in Sections 7 and 8. 
 2.4.1.
The Buyer shall deliver to the Seller the Upfront Consideration (by wire transfer of immediately available federal funds to the account furnished to the Buyer by the Seller) against delivery to the Buyer of certificates evidencing the Shares duly
endorsed (or accompanied by duly executed stock transfer powers). The Seller shall furnish its account information to the Buyer in writing not fewer than [**] Business Days prior to the scheduled Closing Date. 

2.4.2. The parties hereto will execute and deliver the Ancillary Agreements. 

2.4.3. The Buyer shall pay to Pfizer Overseas LLC the “Purchase Price” under the Inventory Transfer Agreement, as such term is
defined in the Inventory Transfer Agreement. 
 2.5. Milestone Payment. 

2.5.1. Subject to Section 2.5.2, within [**] Business Days after the occurrence of the First Commercial Sale of the Product
(the “First Commercial Sale Date”), Buyer shall pay to Seller (by wire transfer of immediately available federal funds to the account furnished by the Seller), without demand or offset, the Milestone Payment; provided,
however, that the Buyer may, in its sole discretion, elect to defer payment of all or portion of the Milestone Payment for period of up to five years from the First Commercial Sale Date upon written notice thereof to the Seller and the
execution and delivery to the Seller, within such [**] Business Day period, of promissory note in favor of the Seller in the form attached hereto as Exhibit 2.5.1 in the principal amount of the Milestone Payment being so deferred (the
“Promissory Note”). 
 2.5.2. The Buyer shall have the option, in the Buyer’s sole discretion,
exercisable at any time by the Buyer commencing on the Closing Date and expiring on the earlier of (i) [**] days prior to the date on which [**] for the Product, and (ii) [**] months

  
 -13-

 
following the [**] for the Product (the “Buyout Period”) to make one-time payment to the Seller in the amount of $20,000,000 in cash in lieu of, and in full satisfaction of, its
obligation to pay the Milestone Payment (the “Milestone Buyout”). In any case, Buyer shall, promptly after becoming aware thereof, notify Seller in writing of the date that the events described in clauses (i) and (ii) of
this Section 2.5.2 occur. Upon exercise of the Milestone Buyout, in the Buyer’s sole election in accordance with the provisions of this Section 2.5.2, and payment in full in cash of the Milestone Buyout to the Seller,
the Buyer’s obligations to make the Milestone Payment under Section 2.5.1 shall automatically terminate and shall no longer be deemed due or payable by the Buyer. 

2.5.3. Subject to Section 12.2, if, after the Closing, and if any portion of the Purchase Price remains unpaid, and the
Buyer or any of its permitted successors or assigns (a) effects Change of Control, or (b) sells, exclusively licenses, or otherwise transfers, or causes the Company to sell, exclusively license or otherwise transfer, all or substantially
all of its or the Company’s rights, title and interest in and to the Product (a “Product Transfer”), such transaction shall be made only with Qualified Successor, except that such transaction may be made with Person that is not
Qualified Successor with the Seller’s prior written consent; provided, however, that if the Buyer or any of its permitted successors or assigns requests and receives such consent from the Seller, the per annum interest rate on the
Promissory Note shall automatically increase to fourteen percent (14%). If permitted Change of Control or other permitted Product Transfer occurs pursuant to the foregoing sentence, the permitted acquirer or successor shall unconditionally assume
all of the Buyer’s obligations under this Agreement, including the obligations set forth in Section 2.5, Section 6.8, and Section 6.9. As used in this Section, a “Qualified Successor” means
Person having: 
 (a) market capitalization in excess of $[**] (or in the case of privately held company,
valuation of its total outstanding equity securities based on its most recently completed arms-length equity financing or an independent valuation of its equity pursuant to Rule 409A under the Internal Revenue Code, in excess of $[**]; and

 (b) a tangible net worth in excess of $[**]; and 

(c) a debt to equity ratio of no more than [**]. 

2.6. FDA Confirmatory Milestone. 
 2.6.1. Subject to the terms of Section 2.6.5, the Seller shall promptly, and in no event later than [**] days, after the date on which the Buyer provides the Seller with the FDACM Notice (as
defined below), make one-time payment to the Buyer in the amount of Six Million Dollars ($6,000,000) (the “Seller Payment”), without demand or offset, if, between the Closing Date and the date that is [**] days after the Closing
Date (as such period may be extended pursuant to Section 2.6.3, the “FDA Milestone Period”), following Type Meeting to discuss Special Protocol Assessment or any other Formal FDA Meeting, the Buyer provides written
notice to the Seller (the “FDACM Notice”) certifying that (i) the Buyer did not receive an FDA Response that meets the FDA Confirmatory Milestone, and (ii) the Buyer has reasonably and in good faith determined that, as
direct result of the FDA Response failing to meet the FDA Confirmatory Milestone, the Total Project Cost will exceed: 
 (a) the total project expenses set forth in the Budget, and, as result, the Buyer has determined, in its sole discretion, that it would no longer be Commercially Reasonable to continue the Buyer’s
efforts to seek to develop and commercialize the Product and the Buyer’s Board of Directors has resolved to terminate the business operations relating to the Product and to liquidate or otherwise wind down the business and operations of the
Buyer; provided, however, that the Seller Payment shall not be payable by the Seller in the event such liquidation or winding down is effected by means of disposition of any of Buyer’s business, assets (including the Product) or
Company shares in transaction that is not Bona Fide Transaction; or 

  
 -14-

 (b) $[**]. 

2.6.2. (a) Subject to Section 12.11.2(d), any past due amount of the Seller Payment payable by the Seller to the Buyer
under Section 2.6.1, and (b) any past due amount of the Milestone Payment not evidenced by the Promissory Note executed and delivered by Buyer pursuant to Section 2.5.1, shall, in each such case, bear interest
(compounded annually) at per annum rate of [**]% (calculated on the basis of 360-day year) from and after the date such Seller Payment or Milestone Payment, as the case may be, was due until such amount is paid in full. 

2.6.3. Notwithstanding anything in Section 2.6.1, or elsewhere in this Agreement, to the contrary, the FDA Milestone Period
may be extended by the Buyer as set forth in Section 2.6.4, in the Buyer’s sole discretion, upon written notice to the Seller if one or both of the following occurs: 

(a) the Buyer has taken all Commercially Reasonable actions to receive an FDA Response during the FDA Milestone Period,
but Buyer has not received the FDA Response within the FDA Milestone Period through no delay or other fault of Buyer, and/or 
 (b) the Seller breaches its obligations under Section 1 of the Transition Services Agreement and such breach causes the Buyer to not receive an FDA Response within the FDA Milestone Period.

 2.6.4. In the event of one or more delays described in Section 2.6.3, the term “FDA Milestone Period”
shall thereafter mean the period between (1) the Closing Date and (2) the date that occurs the following number of days after the Closing Date: 
 (a) For delay described in Section 2.6.3(a), 270 days plus the total number of days between (and including) the following two dates: 

(i) the date that is 270 days after the Closing Date, and 

(ii) the earlier of (x) 14 days after the date that the Buyer has received the FDA Response, and (y) the date
that is 365 days after the Closing Date. 

  
 -15-

 (b) For delay described in Section 2.6.3(b), 270 days
plus the total number of days between (and including) the following two dates: 
 (i) the date on which
Seller breaches an obligation under Section 1 of the Transition Services Agreement that causes the Buyer to not receive an FDA Response within the FDA Milestone Period, and 

(ii) the date on which such breach is cured in accordance with the Transition Services Agreement. 

(c) For delays under both Section 2.6.3(a) and Section 2.6.3(b), 270 days plus the greater
of the number of days that would be added to the FDA Milestone Period under Section 2.6.4(a) or Section 2.6.4(b). 
 2.6.5. In the event the Seller elects to contest the Buyer’s FDACM Notice certification described in Section 2.6.1(ii)(b), the Seller shall so notify the Buyer in writing within [**] days
after Seller’s receipt of the FDACM Notice specifying in reasonable detail the basis for Seller’s contest (“Sellers Dispute Notice”), whereupon the dispute shall be resolved pursuant to and in accordance with the dispute
resolution procedures set forth in Section 12.11. 
 3. REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY BY THE
SELLER. 
 Except as set forth in the disclosure schedule (with specific reference to the particular Section or subsection of
this Agreement to which the information set forth in such disclosure schedule relates; provided, however, that any information set forth in one Section of the disclosure schedule shall be deemed to apply to each other Section or
subsection of the disclosure schedule and of this Section 3 to which its relevance is readily apparent on its face) delivered on or prior to the Execution Date and attached hereto as Schedule 3 (the “Disclosure
Schedule”), the Seller represents and warrants to the Buyer as follows; provided, however, notwithstanding anything in this Agreement or any Ancillary Agreement to the contrary, the Seller makes no representation or warranty
of any nature whatsoever with respect to the Residual Assets, express or implied, directly or indirectly, other than the representations and warranties of the Seller set forth in Section 3.21, and any representations and warranties of
the Seller in this Section 3 with respect to the Company or its business, assets, products, properties, conditions, prospects, operations, activities, obligations or liabilities shall not in any way cover, refer to or be affected by the
Residual Assets: 
 3.1. Organization, Qualification; Subsidiaries. The Company is (a) duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization with full corporate power and authority to conduct its business as now being conducted, to own and use the properties, assets and products (including the Product)
that it purports to own or use and to perform all of its obligations under this Agreement, the Ancillary Agreements and the Company Contracts; and (b) is duly qualified to do business as foreign corporation and in good standing in each
jurisdiction where such qualification is required to own or use its property and products (including the Product) or otherwise conduct its business, except where the failure to so qualify has not had, and is not reasonably likely to have, Material
Adverse 

  
 -16-

 
Effect on the Company. The Company has delivered to the Buyer true, correct and complete copies of the Company’s Organizational Documents. The Company’s Organizational Documents so made
available are in full force and, effect and since being made so available to Buyer, have not been amended or modified. As of the Closing Date, the Company shall have no direct or indirect subsidiaries. 

3.2. Capital Structure. The entire authorized capital stock of the Company consists of 1,000 Shares of common stock, par value
$0.01 per share, of which 1,000 Shares are issued and outstanding and no Shares are held in treasury. All of the issued and outstanding Shares have been duly authorized and are validly issued, fully paid, and nonassessable, and are owned
beneficially and of record by the Seller, free and clear of any Encumbrance, and were not issued in violation of any preemptive rights or similar rights of any stockholder or in violation of any Contractual Obligation, Securities Act requirement, or
any Legal Requirement. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contractual Obligations or commitments that could require the Company to issue, sell
or otherwise cause to become outstanding any of its capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.
There are no voting trusts, proxies or other agreements or understandings with respect to the voting of the capital stock of the Company. The Company is not party to any Contractual Obligation to acquire any equity securities or other securities of
any Person or any direct or indirect equity or ownership interest in any other business. 
 3.3. Power and Authorization.
The consummation of the Contemplated Transactions is within the power and authority of the Company. 
 3.4.
Noncontravention. The consummation of the Contemplated Transactions will not directly or indirectly (with or without notice or lapse of time) (a) contravene, conflict with or violate or give any Governmental Authority, Regulatory
Authority or other Person the legal right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any provision of any Contractual Obligation, Company Contract, Legal Requirement or Government Order
applicable to the Company or any of the assets or products (including the Product) owned or used by the Company, (b) contravene, conflict with or result in breach or violation of, or default under or give any Person the right to declare default
or exercise any remedy under, or to accelerate the maturity or performance of, or to cancel, terminate or modify, any Company Contract, (c) require any action by (including any authorization, consent or approval) or in respect of (including
notice to), any Person under any Company Contract, (d) result in the creation or imposition of an Encumbrance upon, or the forfeiture of, any asset of the Company, (e) contravene, conflict with, or result in breach or violation of, or
default under, the Company’s Organizational Documents or any resolution adopted by the board of directors, committee of the board of directors or stockholders of the Company, except, in the cases of clauses (a) through (d) above, as
would not, either individually or in the aggregate, be reasonably likely to have Material Adverse Effect on the Company. Except as set forth in Section 3.4 of the Disclosure Schedule, the Seller is not and the Company is not, and will
not be required to give any notice to, or obtain any Consent from any Governmental Authority or other Person in connection with the consummation or performance of any of the Contemplated Transactions or any Contractual Obligations. 

  
 -17-

 3.5. Litigation. 

3.5.1. There is no Action pending or, to the Seller’s Knowledge, threatened against or affecting the Company, or, to the
Seller’s Knowledge, investigation by any Governmental Authority or Regulatory Authority involving, the Company or that otherwise relates to, or may affect the business of, or any of the assets or products (including the Product) owned or used
by, the Company; or that challenges, or that may have the effect of preventing, delaying, making illegal, or otherwise interfering with, consummation of or performance under any of the Contemplated Transactions or any of the Contractual Obligations.
The Actions listed in Section 3.5 of the Disclosure Schedule shall not have Material Adverse Effect on the business, operations, assets, condition, or prospects of the Company. 

3.5.2. There is no Government Order outstanding against the Company or to which the Company, or any of the assets or products (including
the Product) owned or used by the Company, is subject. The Company is, and at all times since the Company Acquisition Date has been, in full compliance with all of the terms and requirements of each Government Order to which it, or any of the assets
or products (including the Product) owned or used by it, is or has been subject. The Seller has no Knowledge that any event has occurred or circumstance exists that may constitute or result in (with or without notice or lapse of time) violation of,
or failure to comply with, any term or requirement of any Government Order to which the Company, or any of the assets or products (including the Product) owned or used by the Company, is subject. The Company has, to the Seller’s Knowledge, not
received at any time since the Company Acquisition Date any notice or other written communication from any Governmental Authority, Regulatory Authority or any other Person regarding any actual or alleged violation of, or failure to comply with, any
term or requirement of any Government Order to which the Company, or any of the assets or products (including the Product) owned or used by the Company, is or has been subject, except, in the cases of the second sentence in this
Section 3.5.2 above, for any actual or alleged non-compliance or violation that would not, either individually or in the aggregate, be reasonably likely to have Material Adverse Effect on the Company. 

3.6. Intellectual Property. 
 3.6.1. Company Patents. Section 3.6.1 of the Disclosure Schedule lists all of the Patents owned solely by the Company or which the Company has any ownership rights, and/or has
exclusively licensed, as of the Execution Date (excluding any Patents pertaining solely to the Excluded Assets), setting forth in each case the jurisdictions in which the Patents have been issued, and patent applications have been filed and
identifying which Patents are owned by the Company (“Owned Patents”) and which are licensed to the Company, (“Licensed Patents”) (collectively, the “Company Patents”). The Company is the sole owner
of all right, title and interest in and to the Owned Patents, free and clear of any Contractual Obligation, mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien, lease, sublease, option or charge of any kind, limitations
on transfer or any subordination arrangement in favor of third party. The Company has the right to use the Licensed Patents in accordance with the terms of the applicable license and such license is in full force and effect and unmodified from the
versions, if any, last provided to the Buyer prior to the Execution Date, and the Company is not in breach or default thereunder, except as would not, either individually or in the aggregate, have Material Adverse Effect on the Company. 

  
 -18-

 3.6.2. Company Trademarks. Section 3.6.2 of the Disclosure Schedule
lists all of the trademarks that have been registered, and trademark applications that have been filed, and registered trademark rights (or trademark rights for which applications for registration have been filed) owned solely by the Company as of
the Execution Date (excluding any trademarks, trademark applications and other trademark rights pertaining solely to the Excluded Assets), setting forth in each case the owner thereof and the jurisdictions in which each of such trademarks have been
registered and trademark applications have been filed (collectively, the “Company Trademarks”). The Company owns or has adequate rights to use the Company Trademarks. 

3.6.3. Enforceability. Except as set forth in Section 3.6.3 of the Disclosure Schedule, since the Company Acquisition
Date, to the Seller’s Knowledge, neither the Seller nor the Company has entered into any Contractual Obligations with any Person not to assert any charge of infringement of the Company Patents or Company Trademarks against such Person.

 3.6.4. No Infringement; No Challenge. Except as set forth in Section 3.6.4 of the Disclosure Schedule,
since the Company Acquisition Date, to the Seller’s Knowledge, neither the Seller nor the Company has received written notice or any written “offer to license” from any Person claiming an ownership interest in the Company Patents or
the Company Trademarks, nor has the Seller or the Company received any written notice asserting that the Seller or the Company infringes or misappropriates any intellectual property of any Person or constitutes unfair competition or trade practices
under any Contractual Obligation or the applicable Legal Requirements of any jurisdiction Except as provided in Section 3.6.4 of the Disclosure Schedule, there is no pending or, to the Seller’s Knowledge, threatened claims
(including interferences, oppositions and similar Actions) challenging the validity of the Company Patents. Except as set forth in Section 3.6.4 of the Disclosure Schedule, no Person has contested or asserted in writing to the Company
that the Company Patents are not valid or enforceable. 
 3.6.5. No Infringement by Third Parties. To the Seller’s
Knowledge, no Person is infringing or misappropriating the Company Patents or the Company Trademarks. 
 3.7. Regulatory
Compliance. Except as set forth in Section 3.7 of the Disclosure Schedule: 
 3.7.1. FDCA. The Company
is, and has been since the Company Acquisition Date, in compliance in all material respects with the applicable provisions of the Federal Food and Drug and Cosmetic Act (“FDCA”), as amended, and the applicable rules, regulations,
and requirements adopted by the FDA thereunder, including those relating to establishment registration, registration of clinical trials, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good
laboratory practices, good clinical practices, product listing, labeling, and recordkeeping and filing of reports. To the Seller’s Knowledge, there are no pending, completed, or threatened actions against the Company relating to any of the
foregoing (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation), except for regular inspections in the Ordinary Course of Business. The Company has conducted all clinical
trials that took place after 

  
 -19-

 
the Company Acquisition Date substantially in accordance with good clinical practices and all applicable Legal Requirements, Governmental Orders, Regulatory Authorities and the stated protocols
for such clinical trials and all Contractual Obligations, except as would not, either individually or in the aggregate, have Material Adverse Effect on the Company. The Company is in compliance with all applicable adverse event reporting
requirements pertaining to the clinical trials that took place after the Company Acquisition Date in the United States and outside of the United States under applicable Legal Requirements, Governmental Orders, Governmental Authority, Regulatory
Authorities and with all applicable Contractual Obligations, except as would not, either individually or in the aggregate, have Material Adverse Effect on the Company. The Company is not debarred under the Generic Drug Enforcement Act of 1992 or
otherwise excluded from, or restricted in any manner from, participation in any government program related to pharmaceutical products and, to the Seller’s Knowledge, does not employ or use the services of any individual who is debarred or
otherwise excluded or restricted. 
 3.7.2. Regulatory Filings. The Company has made available to the Buyer
(A) true and correct copies of U.S. new drug application number [**] and the U.S. investigational new drug application number [**], in each case, with respect to the Product, and has provided the Buyer with all material data and records
associated with such applications, (B) true and correct copies of the application number [**] for community marketing authorization for the Product in Europe dated [**], and (C) all material correspondence to and from the FDA and other
Governmental Authorities pertaining to the Product. 
 3.7.3. Notices. Neither the Company nor any Subsidiary has
received any notice or other communication, whether written or non-written, from the FDA or any other Regulatory Authority, which: (i) enjoins production at any facility of the Company or any of its Subsidiaries; (ii) imposes clinical hold
on any clinical investigation by the Company or any of its Subsidiaries; (iii) enters or proposes to enter into U.S consent decree of permanent injunction with the Company or any of its Subsidiaries; or (iv) otherwise alleges any violation
of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have Material Adverse Effect on the Company. 

3.7.4. Violations; Costs. To the Seller’s Knowledge, the Company has not received, at any time since the Company Acquisition
Date, any written notice or other communications (other than notices or communications concerning routine or periodic inspections or reviews) from any Governmental Authority, Regulatory Authority or any other Person regarding (i) any actual or
alleged, violation of, or failure to comply with, any Legal Requirement, or (ii) any actual or alleged obligation on the part of the Company to undertake, or to bear all or any portion of the costs of, any remedial action with respect to any
such violation or failure. 
 3.8. Company Contracts. 

3.8.1. Contractual Obligations of the Company. 

(a) A true, correct and complete list of all material Contractual Obligations of the Company relating to the Included
Assets and the Included Liabilities, including any amendments thereto (the “Company Contracts”), is set forth in 

  
 -20-

 
Section 3.8.1 of the Disclosure Schedule. The Seller has delivered or made available to the Buyer, a true, correct and complete copy of each such Company Contract that exists as of
the Execution Date. 
 (b) Each Company Contract is legally binding arrangement of the Company and is in full
force and effect. Except as would not, either individually or in the aggregate, be reasonably likely to have Material Adverse Effect on the Company, or as otherwise set forth in Section 3.8.1 of the Disclosure Schedule, the Company is
not in breach or default under any Company Contract. To the Seller’s Knowledge, except as would not, either individually or in the aggregate, be reasonably likely to have Material Adverse Effect on the Company, or as otherwise set forth in
Section 3.8 of the Disclosure Schedule, no other party to Company Contract is (with or without the lapse of time or the giving of notice, or both) in breach or default thereunder. To the Seller’s Knowledge, since the Company
Acquisition Date, the Company has not received any written notice (a) that it has breached or defaulted under any Company Contract, or (b) of the intention of any party to any Company Contract to terminate such Company Contract, nor to the
Seller’s Knowledge, has the Company received oral notice of such breach, default or intent to terminate. Effective upon the Closing, except as set forth in Section 3.8.1 of the Disclosure Schedule, neither the Company nor the Buyer
shall be party to, or be bound by, any Contractual Obligation relating to, or constituting, the Excluded Assets or the Excluded Liabilities. With the sole exception of the RaQualia Agreement the Company has not entered into any agreement granting to
one or more Third Parties license to develop or commercialize the Product. 
 3.8.2. Other Contractual Obligations. No
contracts relevant to the Product, or any aspect thereof, exist by and between the Company and any other counter-party, or the Seller and any counter-party, except as set forth in Section 3.8.2 of the Disclosure Schedule. 

3.9. Employees and Consultants. As of the Execution Date, the Company has no employees (including part-time employees and
temporary employees), leased employees, independent contractors or consultants. The Company is not party to, or bound by, any currently effective employment contract, deferred compensation arrangement, bonus plan, incentive plan, profit sharing
plan, retirement agreement or other employee or director compensation plan or agreement or collective bargaining or other labor Contractual Obligations. No retired employee or director of the Company, or their dependents, is receiving benefits from
the Company or scheduled to, or otherwise eligible to, receive such benefits in the future. Except as would not reasonably be expected, individually or in the aggregate, to have Material Adverse Effect on the Company, since the Company Acquisition
Date, the Company has complied in all respects with all Legal Requirements relating to employment, equal employment opportunity, nondiscrimination, immigration, wages, hours, benefits, collective bargaining, the payment of social security and
similar taxes, occupational safety and health, and plant closings. The Company is not liable for the payment of any compensation, damages, taxes, fines, penalties, or other amounts, however designated, for failure to comply with any of the foregoing
Legal Requirements. 

  
 -21-

 3.10. Real Property. As of the Execution Date, the Company does not own any real
property or have any leasehold or other interest in real property (including any occupancy obligations), and is not bound by any lease for real property or occupancy obligation, and does not have any financial obligations to any Person with respect
thereto, including the Seller. 
 3.11. Environmental Matters. Notwithstanding anything else in this Agreement to the
contrary, this Section 3.11 shall constitute the sole representations and warranties with respect to environmental matters. 
 3.11.1. Except as set forth in Section 3.11.1 of the Disclosure Schedule, the Company is not in violation of, and has not been notified in writing by any Governmental Authority or Regulatory
Authority at any time since the Company Acquisition Date that it is in violation of, any Environmental Law. Except as set forth in Section 3.11.1 of the Disclosure Schedule, since the Company Acquisition Date, there has been no
generation, use, handling, storage or disposal of any Hazardous Materials by the Company in violation of any Environmental Law at any property currently owned or operated by, or premises leased or occupied by, the Company during the period of the
Company’s ownership, operation, lease or occupancy which created any requirement pursuant to Environmental Law for the Company to remediate such property. 
 3.11.2. No property currently or formerly owned or operated by, or premises currently or formerly leased or occupied by, the Company is listed, or proposed for listing, on the National Priorities List or
the Comprehensive Environmental Response, Compensation, and Liability Information System, both as maintained under the Federal Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”), or on any comparable
state governmental lists. The Company has not received written notification of any potential responsibility or Liability of the Company pursuant to the provisions of (a) CERCLA or (b) any similar Federal, state, local, foreign or other
Environmental Law. 
 3.12. No Brokers. The Company has no Liability of any kind to any broker, finder or agent with
respect to the Contemplated Transactions. 
 3.13. Taxes. 

3.13.1. All Tax Returns with respect to the Company and its branches and subsidiaries required to have been filed as of the Closing
Date, have been filed, and all such Tax Returns are true, correct and complete. All material Taxes due and payable on or before the Closing Date with respect to the Company and its branches and subsidiaries have been timely paid in full. 

3.13.2. The reserve for Taxes on the face of the most recent Company balance sheet (other than any notes thereto) is sufficient for all
accrued and unpaid Taxes, whether or not disputed, of the Company as of the Closing Date, and except for the disposition of the Excluded Assets and Excluded Liabilities, and Ordinary Course of Business activities, the Company has not incurred or
become subject to any Tax since the date of the most recent Company balance sheet that the Seller has provided to the Buyer. 

  
 -22-

 3.13.3. Neither the Company, nor the Seller, has received any written claim or deficiency
for any Tax asserted against the Company which has not been resolved and/or paid in full. Seller has no Knowledge of any pending, current or threatened Actions for the assessment or collection of Taxes with respect to the Company. 

3.13.4. Seller has no Knowledge of any liens for Taxes against the Company’s assets or products including the Product other than
liens that would constitute Permitted Encumbrance. 
 3.13.5. The Company has not waived any statute of limitations in respect
of Taxes or entered into any agreement extending the period for assessment or collection of any Taxes and on the Closing Date the Company will not be party to any Tax allocation or sharing agreement. The Company is not liable for the Taxes of any
other Person as transferee, by Contractual Obligation or otherwise, other than pursuant to Treasury Regulation § 1502-6 or any analogous or similar state, local, or foreign Legal Requirement for the Taxes of the consolidated group of which
Seller is the parent. 
 3.13.6. The Company has complied in all material respects with all applicable Legal Requirements
relating to the payment and withholding of Taxes from employees, shareholders and other Persons. 
 3.13.7. The Company has not
been the “distributing corporation” or the “controlled corporation” (in each case, within the meaning of Section 355(a)(1) of the Code) with respect to transaction described in Section 355 of the Code (a) within
the three (3)-year period ending as of the Execution Date, or (b) in distribution that could otherwise constitute part of a “plan” or “series of related transactions” (within the meaning of Section 355(e) of the Code)
that includes the Contemplated Transactions. 
 3.13.8. Since the Company Acquisition Date the Company has not engaged in
“reportable transaction,” as set forth in Treasury Regulation Section l.6011-4(b)(1). 
 3.13.9. Neither the Company
nor the Seller have received any written claim from any Tax authority in any jurisdiction in which the Company does not file Tax Returns, that the Company is, or may be, subject to any Tax by that jurisdiction. 

3.13.10. Since the Company Acquisition Date, the Company has not owned any interest in an entity that is characterized as partnership
for U.S federal income tax purposes. 
 3.13.11. The Company will not be required to include any item of income in, or exclude
any item of deduction from, taxable income for any period (or any portion thereof) ending after the Closing Date as result of any: (a) installment sale or other open transaction disposition made on or prior to the Closing Date; (b) prepaid
amount received on or prior to the Closing Date; (c) written and legally binding agreement with Governmental Authority or Regulatory Authority relating to Taxes; (d) election under Section 108(i) of the Code; or (e) change in
method of accounting in any taxable period ending on or before the Closing Date or as result of the Contemplated Transactions. 

  
 -23-

 3.14. Insurance. Neither the Seller nor the Company maintain an insurance policy that
applies exclusively to the Company. 
 3.15. Governmental Authorizations. Except as set forth in Section 15
of the Disclosure Schedule, (i) there are no Governmental Authorizations that are held by, or on behalf of the Company or that otherwise relate to the business of, or to any of the assets owned or used by, the Company, including the Product or
the Included Assets, and (ii) there are no other Governmental Authorizations necessary to permit the Company to lawfully conduct and operate its business in the manner in which it currently conducts and operates such business, and to permit the
Company to own and use its assets relating to the Product in the manner in which it currently owns and uses such assets. Section 3.15 of the Disclosure Schedule contains true, correct and complete list of all material Governmental
Authorizations that are held by, or held on behalf of, the Company or that otherwise relate to the business of, or to any of the assets owned or used by the Company relating to the Product. Each Governmental Authorization listed or required to be
listed in Section 3.15 of the Disclosure Schedule is valid and in full force and effect and is not subject to any outstanding late filing fees or penalties. Except as set forth in Section 3.15 of the Disclosure Schedule:

 (a) Except as would not, either individually or in the aggregate, be reasonably likely to have Material
Adverse Effect, to the Seller’s Knowledge, the Company, at all times since the Company Acquisition Date, has been, in compliance with all of the terms and requirements of each Governmental Authorization (including all authorizations from any
Regulatory Authority) identified or required to be identified in Section 3.15 of the Disclosure Schedule; and 
 (b) the Company has not received at any time since the Company Acquisition Date, any written notice or other communication from any Governmental Authority (including all authorizations from any Regulatory
Authority) or any other Person regarding (i) any actual or alleged violation of, or failure to comply with, any term or requirement of any Governmental Authorization (including all authorizations from any Regulatory Authority), or (ii) any
actual or proposed revocation, withdrawal, suspension, cancellation, termination of, or modification to any Governmental Authorization (including all authorizations from any Regulatory Authority). 

3.16. Books and Records. All of the post-Company Acquisition Date corporate books of account, corporate minute books, stock record
books, and other corporate records of the Company, true, complete and correct copies of which have been made available to the Buyer, are the only post-Company Acquisition Date corporate books and records of the Company that exist as of the Execution
Date. At the Closing, the Company shall cause true, correct and complete originals of all of the pre-Company Acquisition Date and post-Company Acquisition Date books and records to be in the actual, physical possession of the Buyer. 

3.17. Asset and Liability Statement. No audited financial statements for the Company have been prepared by the Seller or the
Company. The Seller has delivered to the Buyer true, correct and complete listing of all assets and liabilities of the Company dated as of the Execution Date, after giving effect to the disposition of the Excluded Assets and the

  
 -24-

 
Excluded Liabilities (the “Asset and Liability Statement”). To Seller’s Knowledge, the Asset and Liability Statement lists all assets and liabilities of the Company of
nature and type that would be required to be disclosed on the face of the Company’s balance sheet by GAAP, after giving effect to the disposition of the Excluded Assets and Excluded Liabilities. 

3.18. No Undisclosed Liabilities. Except as set forth on Section 3.18 of the Disclosure Schedule, to the Seller’s
Knowledge, the Company has no material liabilities, except for (a) liabilities reflected or reserved against in the Asset and Liability Statement, (b) liabilities constituting Included Liabilities, and (c) current liabilities not
exceeding Ten Thousand Dollars ($10,000) in the aggregate incurred in the Ordinary Course of Business since the date of the Asset and Liability Statement. 
 3.19. Compliance with Legal Requirements. To the Seller’s Knowledge, the Company is not currently in violation of, and has not, since the Company Acquisition Date, been in violation of, any
Legal Requirement, the violation of which would reasonably be expected, individually or in the aggregate, to have Material Adverse Effect on the Company. 
 3.20. Seller’s Knowledge. The individuals listed on Exhibit 1(i) attached hereto are employees of the Seller who have direct operating and legal responsibilities with respect to the
Company or the Seller in the principle subject areas covered by the representations and warranties in Section 3 and 4 that are qualified by Seller’s Knowledge. 

3.21. Residual Assets. To the Seller’s Knowledge, and except as would not reasonably be expected, either individually or in
the aggregate, to have Material Adverse Effect on the Company, (i) the Company owns and has sole and exclusive, good and marketable title to all of the Residual Assets, and (ii) there are no liens, claims, or encumbrances of any kind on
any of the Residual Assets. The Company has not, since the Company Acquisition Date, dosed any patients in any clinical trial with any drug candidates in the programs relating to the Residual Assets. 

3.22. No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS
SECTION 3 AND SECTION 4, NONE OF THE COMPANY, THE SELLER OR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY ON BEHALF OF THE COMPANY OR THE SELLER WITHOUT LIMITING THE GENERALITY OF THE FOREGOING,
EXCEPT AS SET FORTH IN THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS SECTION 3 AND SECTION 4, THE SELLER AND THE COMPANY MAKE NO REPRESENTATION OR WARRANTY WHATSOEVER, EXPRESS OR IMPLIED, REGARDING THE
ASSETS, PROPERTIES, BUSINESS OR BUSINESS PROSPECTS OF THE COMPANY, INCLUDING ANY WARRANTY AS TO MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE OR NONINFRINGEMENT. THE BUYER HEREBY ACKNOWLEDGES AND AGREES THAT THE BUYER IS PURCHASING THE SHARES AND
ACQUIRING THE COMPANY ON AN “AS-IS, WHERE-IS” BASIS, IN RELIANCE ON ONLY THOSE REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE SELLER EXPRESSLY SET FORTH IN THIS SECTION 3 AND SECTION 4. 

  
 -25-

 4. REPRESENTATIONS AND WARRANTIES REGARDING THE SELLER BY THE SELLER. 

The Seller hereby represents and warrants to the Buyer as follows; provided, however, notwithstanding anything in this
Agreement or any Ancillary Agreement to the contrary, the Seller makes no representation or warranty of any nature whatsoever with respect to the Residual Assets, express or implied, directly or indirectly, other than the representations and
warranties of the Seller set forth in Section 3.21, and any representations and warranties of the Seller in this Section 4 with respect to the Company or the Seller or their respective businesses, assets, products,
properties, conditions, prospects, operations, activities, obligations or liabilities shall not in any way cover, refer to or be affected by the Residual Assets: 
 4.1. Organization. The Seller is (a) duly organized, validly existing and in good standing under the laws of the State of Delaware with full corporate power and authority to perform its
obligations under this Agreement and the Ancillary Agreements, and (b) is duly qualified to do business as foreign corporation and in good standing in each jurisdiction where such qualification is required to own or use its property or
otherwise conduct its business, except where the failure to so qualify has not had, and is not reasonably likely to have, Material Adverse Effect on the Seller. 
 4.2. Power and Authorization. The execution delivery and performance by the Seller of this Agreement and each Ancillary Agreement to which it is (or will be) a party and the consummation of the
Contemplated Transactions are within the power and authority of the Seller. This Agreement and each Ancillary Agreement to which the Seller is (or will be) a party (a) has been (or, in the case of Ancillary Agreements to be entered into at or
prior to the Closing, will be) duly authorized by all necessary action on the part of the Seller and duly executed and delivered by the Seller, and (b) is (or in the case of Ancillary Agreements to be entered into at or prior to the Closing,
will be) a legal, valid and binding obligation of the Seller, Enforceable against the Seller in accordance with its terms. The Seller has the full corporate power and authority to own and use its assets and carry on its business as presently
conducted. 
 4.3. Authorization of Governmental Authorities. Except as disclosed on Schedule 4.3, no action by
(including any authorization consent or approval), or in respect of, or filing with, any Governmental Authority is required for, or in connection with, the valid and lawful (a) authorization, execution, delivery and performance by the Seller of
this Agreement and each Ancillary Agreement to which it is (or will be) a party, or (b) the consummation of the Contemplated Transactions by the Seller, except any such action or filing with any Governmental Authority which if not obtained or
made would not have Material Adverse Effect on the Seller or adversely affect the ability of the Seller to consummate the Contemplated Transactions. 
 4.4. Noncontravention. Except as disclosed on Schedule 4.4, neither the execution, delivery and performance by the Seller of this Agreement or any Ancillary Agreement to which the Seller is
(or will be) a party, nor the consummation of the Contemplated Transactions will directly or indirectly (with or without notice or lapse of time) (a) contravene, conflict with, or violate or give any Governmental Authority, Regulatory Authority
or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain 

  
 -26-

 
any relief under, any provision of any Legal Requirement or Government Order applicable to the Seller or any of the assets (including the Product) owned or used by the Seller,
(b) contravene, conflict with or result in breach or violation of, or default under, or give any Person the right to declare default or exercise any remedy under, or to accelerate the maturity or performance of or to cancel, terminate or
modify, any Contractual Obligation to which the Seller is party, (c) require any action by (including any authorization, consent or approval) or in respect of (including notice to), any Person under any Contractual Obligation to which the
Seller is party, (d) result in the creation or imposition of an Encumbrance upon, or the forfeiture of, any asset of the Seller, or (e) contravene, conflict with, or result in breach or violation of, or default under, the Seller’s
Organizational Documents or any resolution adopted by the board of directors, committee of the board of directors or stockholders of the Seller, except, in the cases of clauses (a) through (d) above, as would not, either individually or in
the aggregate, be reasonably likely to have Material Adverse Effect on the Seller. 
 4.5. Shares. Immediately prior to
the Execution Date, the Seller held of record and owned beneficially all of the Shares, and as of the Closing Date, the Seller will hold of record and beneficially all of the Shares, in both instances, free and clear of any restrictions on transfer
(other than any restrictions under the Securities Act and state securities Legal Requirements), Taxes (except Taxes payable by the Seller on the disposition thereof), liens, options, warrants, purchase rights, contracts, commitments, equities,
claims, Encumbrances and demands. The Seller is not party to any option, warrant, purchase right, or other Contractual Obligation that could require the Seller to sell, transfer or otherwise dispose of any capital stock of the Company (other than
this Agreement and the Contemplated Transactions). No legend or other reference to any purported Encumbrance (other than standard Securities Act of 1933 restricted stock legend) appears upon any certificate representing equity securities of the
Company. 
 4.6. No Brokers. Other than Liabilities which will be borne by the Seller, the Seller has no Liability of any
kind to any broker, finder or agent with respect to the Contemplated Transactions, and the Seller agrees to satisfy in full all such Liabilities. 
 4.7. Indemnification. The Seller has full power (corporate and otherwise) to make representations by, on behalf of and with respect to the Company, and to indemnify the Buyer for any breaches of
any representations, warranties or covenants by, on behalf of, and with respect to, the Company and the Seller. 
 4.8. Other
Contractual Obligations. As of the Closing Date and after giving effect to the transactions contemplated by this Agreement, no contracts relevant to the development or commercialization of the Product, or any aspect thereof, exist by and between
the Seller and any counter-party, except for those contracts that constitute Excluded Assets or that otherwise relate directly or indirectly to any Excluded Product (as defined in Exhibit 1(a)). 

4.9. RaQualia Agreement. The Seller has delivered to the Buyer true, correct and complete copies of the RaQualia Agreement as
amended through the Execution Date. The “Other RaQualia Agreements,” as defined in the RaQualia Agreement, are unrelated in all respects to the Company and the Included Assets. 

  
 -27-

 4.10. Competing Products. The Seller does not currently own or operate an existing
commercial drug program involving the commercialization of long-acting, once-a-week antibiotic for cSSSi in adults that is currently engaged in Phase III trial or later stage of commercialization, except for the Seller’s Zyvox product, and
excluding any programs at any stage of research, development or commercialization that Seller acquires in connection with (i) its acquisition of Wyeth or (ii) any other acquisition, license, or other transaction that occurs after the Execution Date.

 4.11. Inventory. As of the Execution Date, subject to de minimis adjustments due to breakage or loss in the ordinary
course, (a) the amount of Product contained in clinical drug product inventory lot number [**] located at the [**] facility is [**] vials and the stated expiration date for the Product in such lot is [**]; and (b) the amount of active
pharmaceutical ingredient for the Product located in the Seller’s [**] facility (i) in inventory lot number [**] is [**] and the expiration date for such active pharmaceutical ingredient is [**], and (ii) in inventory lot number [**]
is [**] and the stated expiration date for such active pharmaceutical ingredient is [**]. The Product and active pharmaceutical ingredient for the Product referenced in subsections (a) and (b) and of this Section 4.11 met the
specifications set forth on Schedule 4.11 on the most recent date prior to the Execution Date that such material was tested; provided, however, nothing herein shall be construed to represent or warrant that the clinical drug
inventory or active pharmaceutical ingredients referred to herein shall be in sufficient or suitable quality or condition for use by the Company or the Buyer after the Closing Date or that the stated expiration dates will remain valid after the
Closing Date. 
 5. REPRESENTATIONS AND WARRANTIES OF THE BUYER. 

The Buyer hereby represents and warrants to the Seller that: 
 5.1. Organization. The Buyer is (a) duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full corporate power and authority to
perform its obligations under this Agreement and the Ancillary Agreements, and (b) is duly qualified to do business as foreign corporation and in good standing in each jurisdiction where such qualification is required to own or use its property
or otherwise conduct its business, except where the failure to so qualify has not had, and is not reasonably likely to have, a Material Adverse Effect on the Buyer. 
 5.2. Power and Authorization. The execution, delivery and performance by the Buyer of this Agreement and each Ancillary Agreement to which it is (or will be) a party and the consummation of the
Contemplated Transactions are within the power and authority of the Buyer and have been duly authorized by all necessary action on the part of the Buyer. This Agreement and each Ancillary Agreement to which the Buyer is (or will be) a party
(a) has been (or, in the case of Ancillary Agreements to be entered into at or prior to the Closing, or, in the case of the Promissory Note if entered into after the Closing, will be) duly executed and delivered by the Buyer, and (b) is
(or in the case of Ancillary Agreements to be entered into at or prior to the Closing, or, in the case of the Promissory Note if entered into after the Closing, will be) a legal, valid and binding obligation of the Buyer, Enforceable against the
Buyer in accordance with its terms. The Buyer has the full corporate power and authority necessary to own and use its assets and carry on its business as presently conducted. 
 5.3. Authorization of Governmental Authorities. Except as disclosed on Schedule 5.3, no action by (including any authorization, consent or approval), or in respect of, or filing with, any
Governmental Authority is required for, or in connection with, the valid and lawful (a) authorization, execution, delivery and performance by the Buyer of this Agreement and each Ancillary Agreement to which it is (or will be) a party, or
(b) the consummation of the 

  
 -28-

 
Contemplated Transactions by the Buyer, except any filing with any Governmental Authority which if not obtained would not have Material Adverse Effect on the Buyer or adversely affect the ability
of the Buyer to consummate the Contemplated Transactions. 
 5.4. Noncontravention. Except as disclosed on Schedule
5.4, neither the delivery and performance by the Buyer of this Agreement or the execution, delivery and performance by the Buyer of any Ancillary Agreement to which it is (or will be) a party, nor the consummation of the Contemplated
Transactions will directly or indirectly (with or without notice or lapse of time) (a) contravene, conflict with or violate or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise
any remedy or obtain any relief under, any provision of any Legal Requirement or Government Order applicable to the Buyer or any of the assets owned or used by the Buyer, contravene, conflict with, or result in breach or violation of, or default
under or give any Person the right to declare default or exercise any remedy under, or to accelerate the maturity or performance of, or to cancel, terminate or modify, any Contractual Obligation to which the Buyer is party, (c) require any
action by (including any authorization, consent or approval) or in respect of (including notice to), any Person under any Contractual Obligation to which the Buyer is a party, (d) result in the creation or imposition of an Encumbrance upon, or
the forfeiture of, any asset of the Buyer, (e) contravene, conflict with, or result in breach or violation of, or default under, the Buyer’s Organizational Documents or any resolution adopted by the board of directors, committee of the
board of directors or stockholders of the Buyer, except, in the cases of clauses (a) through (d) through above as would not, either individually or in the aggregate, be reasonably likely to have Material Adverse Effect on the Buyer.

 5.5. Investment Experience; Investigation; Reliance. 

5.5.1. The Buyer has been advised and understands that the Shares have not been registered under the Securities Act, on the basis that
no distribution or public offering of the Shares is to be effected, except in compliance with applicable securities Legal Requirements or pursuant to an exemption therefrom, and that the Seller is relying in part on the Buyer’s representations
set forth in this Section 5.5. 
 5.5.2. The Buyer is purchasing the Shares for investment purposes, for its own
account, not as nominee or agent and not with view to the distribution of any part thereof. The Buyer has no present intention of selling, granting any participation in, or otherwise distributing the Shares in manner contrary to the Securities Act
or to any applicable state securities Legal Requirements. 
 5.5.3. The Buyer is an “accredited investor” within the
meaning of Regulation D, Rule 501(a) of the Securities Act. 
 5.5.4. The Buyer is able to bear the economic risk of the full
loss of the value of the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. 

5.5.5. In entering into this Agreement, purchasing the Shares and consummating the Contemplated Transactions, the Buyer is not relying
upon any representations 

  
 -29-

 
or warranties made by the Seller or the Company or any of their Representatives or Affiliates other than the representations and warranties set forth in this Agreement, it being acknowledged and
agreed by the Buyer that the representations and warranties of the Buyer set forth herein are fundamental to the Seller’s decision to enter into this Agreement, sell the Shares to the Buyer and to consummate the Contemplated Transactions.

 5.6. No Brokers. The Buyer has no Liability of any kind to any broker, finder or agent with respect to the
Contemplated Transactions for which the Seller could be liable. 
 5.7. Budget. On or immediately prior to the Closing,
subject to and pursuant to the terms of the Stockholders And Subscription Agreement, a confidential copy of which has been delivered to Seller under separate cover for informational purposes only, the Buyer shall have sufficient funds available to
it from the Buyer’s Original Affiliates to consummate the Closing and to perform its obligations under this Agreement. Attached hereto as Exhibit 5.7 is true and correct copy of an initial draft of the Budget; provided,
however, Buyer expressly reserves the right to reallocate any amounts within the Budget or to change any amounts set forth therein in any manner and at any time at the Buyer’s sole election after the Execution Date without the consent of
the Seller, and nothing in this Agreement or in the Budget shall in any way be construed to obligate the Buyer to expend all sums set forth in the Budget in the amounts or in the manner specified in the Budget; provided, further,
however, that no reduction in the total project expenses set forth in the form of Budget attached hereto as Exhibit 5.7 made by the Buyer after the Execution Date shall be taken into account or given any effect for purposes of
determining whether the Total Project Cost will exceed the total project expenses set forth in the Budget pursuant to Buyer’s certification under Section 2.6.1(a). 

5.8. Corporate Status. The Buyer (i) shall be classified as corporation for U.S federal income tax purposes prior to and
including the Closing Date, and (ii) has no current plan or intent (a) to change such classification (by election or otherwise), or (b) to liquidate, dissolve, or merge out of existence. 

5.9. No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS
SECTION 5, NEITHER THE BUYER NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY ON BEHALF OF THE BUYER. 
 6. COVENANTS. 
 6.1. Closing. Subject to the terms and conditions of this
Agreement, each of the parties hereto shall use its commercially reasonable efforts to take, or cause to be taken, as promptly as reasonably practicable, all actions and to do, or cause to be done, all things necessary, proper, or advisable in order
to consummate and make effective the Contemplated Transactions (including satisfaction, but not waiver, of the Closing conditions set forth in Sections 7 and 8) as soon as reasonably practicable and in any event prior to
December 30, 2009. 

  
 -30-

 6.2. Conduct of Business. 

6.2.1. Between the Execution Date and the Closing Date, the Seller shall, and shall cause the Company to: 

(a) conduct the business of the Company only in the Ordinary Course of Business; 

(b) other than as may be required in connection with the Company’s sale or disposition of the Excluded Assets to the
Seller, its Affiliates or third parties, and the assumption of the Excluded Liabilities by the Seller, its Affiliates or third parties, preserve intact the Company’s assets (including the Product and Included Assets), and maintain in effect all
Governmental Authorizations and authorizations of any Regulatory Authority; 
 (c) keep available the services
of the current agents of the Company, and maintain the relations and goodwill with all material suppliers, and others having material business relationships with the Company relating to the Included Assets or Included Liabilities; 

(d) confer with the Buyer concerning relevant operational matters of material nature (and all matters pertaining to the
Company concerning any Governmental Authority, Regulatory Authority and the FDA shall be deemed material); 

(e) otherwise report periodically to the Buyer concerning any material developments regarding the Product with any
Governmental Authority, Regulatory Authority and the FDA and any material developments regarding the Product or the business operations and finances of the Company; and 

(f) maintain all of the Company Contracts in full force and effect and unmodified from the versions last provided to the
Buyer prior to the Execution Date (except for modifications described on Exhibit 6.2.1(f) or any modifications as may be approved in writing by the Buyer). 
 6.2.2. From the Execution Date until the Closing Date, the Seller shall cause the Company to not: 
 (a) engage in any practice, take any action, or enter into any transaction outside the Ordinary Course of Business (other than as may be required in connection with the transfer, assignment, sale or
disposition of the Excluded Assets to the Seller, its Affiliates or third parties, and the assumption of the Excluded Liabilities by the Seller, its Affiliates or third parties); provided, however, in no event shall any sale or other
disposition or Encumbrance (or agreement to do so) with respect to the Included Assets occur; 
 (b) declare,
set aside, or pay any dividend or make any distribution with respect to its capital stock or redeem, purchase or otherwise acquire any of its capital stock (other than dividend or distribution solely of the Excluded Assets and/or Excluded
Liabilities to the Seller or proceeds received thereon); 

  
 -31-

 (c) except as set forth herein, directly or indirectly, sell or otherwise
transfer, offer, agree or commit (in writing or otherwise) to sell or otherwise transfer any of the Shares or any of the Included Assets or any interest in, or right relating to, any of the Shares or any of the Included Assets; 

(d) permit or offer, agree or commit( in writing or otherwise) to permit any Shares or any Included Assets to become
subject, directly or indirectly, to any Encumbrance; 
 (e) make, revoke or change any Tax election, change any
Tax method of accounting or adopt any new Tax method of account, or, without prior written notification to the Buyer, file an amended Tax Return, claim any refund of Taxes or settle or compromise any Liability relating to Taxes; 

(f) amend any of the Company’s Organizational Documents or effect or allow the Company to become party to any
recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction other than partial redemption transaction; 
 (g) incur any capital expenditures or indebtedness or create any new subsidiaries (other than in connection with the creation of any new subsidiaries as may be required in connection with the sale or
disposition of the Excluded Assets to the Seller, its Affiliates or third parties, and the assumption of Excluded Liabilities by the Seller, its Affiliates or third parties), or incur or increase any Included Liabilities other than to consummate the
transactions contemplated by this Agreement and the Ancillary Agreements; 
 (h) enter into, modify, or amend in
manner adverse to the Company, or terminate any Company Contract, or waive, release or assign any rights or claims thereunder, in each case, in manner adverse to the Company, other than any entry into, modification, amendment or termination of any
such Company Contract in the Ordinary Course of Business and which is disclosed to the Buyer in writing; or 

(i) enter into any transaction or take any other action that is reasonably likely to cause or constitute breach of any
representation or warranty of the Seller in this Agreement. 
 6.3. Buyer’s Access to Premises. From the Execution
Date until the Closing Date, subject to and in accordance with the Transition Services Agreement, the Seller and the Company shall, in each case, upon Buyer’s reasonable request, (a) permit the Buyer and its Representatives to have full
and free access (at all reasonable times and upon reasonable notice) to the Seller’s personnel with knowledge of the Company, and to all books, records, financial, scientific and operating data, correspondence and filings with the FDA, and
other information and other documents, in each case, pertaining to any of the Product, the Included Assets and the Included Liabilities (“Seller Documentation”), (b) furnish the Buyer and its Representatives with true and
correct copies of such Seller Documentation, and (c) furnish the Buyer and its Representatives with such additional information respecting any of the Company, the Included Assets, and the Included Liabilities as the Buyer may reasonably
request. 

  
 -32-

 6.4. Notice of Developments. From the Execution Date until the Closing Date, the
Company and the Seller shall give the Buyer prompt written notice (i) of any event, development or circumstance that, to the Seller’s Knowledge, affects (or may reasonably be expected to affect) the timing or likelihood of achieving the
FDA Confirmatory Milestone or (ii) of any material event, development or circumstance that, to the Seller’s Knowledge, could reasonably be expected to result in breach of, or inaccuracy in, any of the Seller’s representations and
warranties set forth in Sections 3 or 4; provided, however, that except as otherwise set forth in this Agreement, no such disclosure shall be deemed to prevent or cure any breach of, or inaccuracy in any representation or
warranty set forth in this Agreement. The Seller shall be entitled to deliver to the Buyer supplement to the Disclosure Schedule that discloses to the Buyer in reasonable detail (and which specifically references specific representation or warranty)
any facts and circumstances arising after the Execution Date that could constitute or result in breach of the representations and warranties set forth in Sections 3 or 4. The Buyer shall have the right to terminate this Agreement
pursuant to Section 9.1(f) within ten (10) days after receipt of such supplemental Disclosure Schedule if the supplemented provisions of such Disclosure Schedule disclose any facts and circumstances that would be reasonably likely
to have Material Adverse Effect on the Company or otherwise cause the conditions to the Closing in Section 7 (other than Sections 7.1, 7.2, and 7.4) not to be satisfied; provided, however, that if the
Buyer does not exercise such right to terminate this Agreement within the aforesaid ten (10) day period after receipt of such supplemental Disclosure Schedule, or if the Buyer consummates the Closing, the Buyer shall, in each such case, be
deemed to have accepted such supplemental Disclosure Schedule, and such supplemental Disclosure Schedule shall supersede and amend the original Disclosure Schedule, be treated for all purposes of this Agreement as the Disclosure Schedule and be
deemed to cure any breach of the specific representation or warranty on the original Disclosure Schedule to the extent such specific representation or warranty was modified on the supplemental Disclosure Schedule. 

6.5. Expenses. Except as expressly set forth in this Agreement, and subject to the Transition Services Agreement, each party
hereto shall bear its own legal and other expenses in connection with any due diligence and the negotiation, drafting, execution and performance of this Agreement, the Ancillary Agreements and any other agreements and other actions required to
consummate the Contemplated Transactions. 
 6.6. Exclusivity. From the Execution Date until the earlier of the
Termination Date or the Closing neither the Seller nor the Company shall (and the Company and Seller shall not permit their respective Affiliates or any of their or their Affiliates’ Representatives to) directly or indirectly: (a) solicit,
initiate, or encourage the submission of any proposal or offer from any Person relating to, or enter into or consummate any transaction relating to, the acquisition of any capital stock in the Company or any merger, recapitalization, share exchange,
sale of substantial assets (including the Product) (other than partial redemption of shares, sales of inventory in the Ordinary Course of Business or sales or other dispositions of the Excluded Assets) or any similar transaction or alternative to
the Contemplated Transactions, or (b) participate in any discussions or negotiations regarding, furnish any information with respect to, assist or participate in, or facilitate in any other manner any effort or attempt by any Person to do

  
 -33-

 
or seek any of the foregoing. The parties hereto agree that irreparable damage would occur in the event that the provisions in the preceding sentence of this Section 6.6 were breached
by the Company or the Seller. Accordingly, the parties hereto agree that the Buyer shall be entitled to seek an immediate injunction or injunctions to prevent breaches of the provision of this Section 6.6 and to enforce specifically the
terms and provisions hereof in any court of the United States or any state having jurisdiction, and that this remedy is in addition to any other remedy to which the Buyer may be entitled at law or in equity. 

6.7. Notices and Consents. 
 6.7.1. The Company. As promptly as practicable after the Execution Date, the Seller shall cause the Company to give all notices to, make all filings with, and use its commercially reasonable
efforts to obtain all Consents from any Governmental Authority or other Person as reasonably requested in writing by the Buyer. 
 6.7.2. Seller. The Seller shall give all notices to, make all filings with, and use its commercially reasonable efforts to obtain all Consents from, any Person as reasonably requested in writing by
the Buyer. 
 6.7.3. Buyer. The Buyer shall give all notices to, make all filings with and use its commercially
reasonable efforts to obtain all Consents from any Governmental Authority or other Person as reasonably requested in writing by the Seller. 
 6.8. FDA Confirmatory Milestone. After the Closing, and subject to the qualifications and limitations of the Budget, the Buyer shall, and shall cause its Affiliates and the Company to, use
Commercially Reasonable efforts to seek to achieve the FDA Confirmatory Milestone. 
 6.9. Diligence. After the Closing,
the Buyer shall, and shall cause the Company and the Affiliates and sublicensees of the Buyer and the Company to, use Commercially Reasonable efforts to develop the Product For the purpose of Section 6.8, Section 6.9, and
Section 2.6, acting in “Commercially Reasonable” manner or using “Commercially Reasonable” efforts means using those efforts and resources generally consistent with the usual practice of financially
viable biotechnology company in pursuing the development of its own pharmaceutical products that are of similar market potential as the Product, taking into account safety, tolerability, and efficacy of the Product and any developments in the
marketplace for pharmaceutical or biologic drugs negatively impacting the likely outcome of further development of the Product. This Section 6.9 shall have no force or effect once the Milestone Payment or Milestone Buyout has been paid
in full in accordance with Sections 2.5.1, and 2.5.2, as applicable. 
 6.10. Confidentiality. 

6.10.1. Except as otherwise provided in this Section 6.10, each party hereto (in each case the “Receiving
Party”) shall maintain in confidence and use only for purposes of this Agreement and the Ancillary Agreements, the terms and conditions of this Agreement and the Ancillary Agreements, any activities conducted in connection with, or pursuant
to this Agreement or the Ancillary Agreements, and any information, in any form or 

  
 -34-

 
medium (whether nor not it is labeled or otherwise identified as confidential), disclosed to such Receiving Party by the other party or its Representatives or Affiliates (in each case, the
“Disclosing Party”) in accordance with this Agreement or the Ancillary Agreements (collectively “Confidential Information.”) The Buyer agrees and acknowledges that the manuscript substantially in the form attached
as Exhibit B to that certain Research License Agreement between the Seller and the Company dated as of November 30, 2009, does not constitute Confidential Information of the Company, the Seller or the Buyer, and the Buyer consents to the
publication thereof. 
 6.10.2. The parties hereto acknowledge and agree that all information provided to the Buyer and its
Affiliates and Representatives by the Seller and its Affiliates and Representatives is hereby subject to the terms of those certain confidentiality agreements made between the Seller and each of New Leaf Venture Partners L.L.C (dated
November 19, 2008 as amended) Sofinnova Ventures Inc dated (November 19, 2008, as amended), Aisling Capital LLC (dated January 30, 2009, as amended), Domain Associates (dated February 2, 2009 as amended) and Canaan Partners (dated
July 20, 2009) (collectively the “Confidentiality Agreements” and (a) prior to the Closing, such information shall be deemed the Confidential Information of the Seller and hence the Buyer shall be considered Receiving
Party with respect thereto), and (b) after the Closing such information shall be deemed the Confidential Information of the Buyer and hence the Seller shall be considered Receiving Party with respect thereto), except to the extent such
information comprises or relates to the Excluded Assets (in which case the Buyer shall be considered Receiving Party with respect thereto). 
 6.10.3. The Buyer agrees that after the Closing Date, the Buyer shall, and shall use commercially reasonable efforts to, cause its Representatives, Affiliates and the Company, to not disclose to any third
parties and use only for the purposes of this Agreement and the Ancillary Agreements all Third Party Confidential Information that is disclosed, to the Buyer by the Seller. For purposes of this Agreement “Third Party Confidential
Information” means all information in the possession of the Seller with respect to or concerning any third party which is not necessary for the development and commercialization of the Product and is not otherwise Company asset.
Notwithstanding anything to the contrary herein, the foregoing provision shall not apply in the event the Buyer enters into separate agreement with an applicable third party, which such separate agreement governs the disclosure and use of such Third
Party Confidential Information. 
 6.10.4. In the event the Receiving Party is requested or required (in any Action,
interrogatory, subpoena, civil investigative demand, or similar process) to disclose any Confidential Information of the Disclosing Party or Third Party Confidential Information (in the case of the Buyer), the Receiving Party shall promptly notify
the Disclosing Party of the request or requirement so that the Disclosing Party may seek to obtain at its sole expense an appropriate protective order or waive compliance with the provisions of Section 6.10.1. If, in the absence of
protective order or the receipt of waiver hereunder, the Receiving Party is, on the advice of counsel, compelled to disclose any Confidential Information of the Disclosing Party or Third Party Confidential Information (in the case of the Buyer) to
any tribunal, such Party may disclose such information to the tribunal, provided, however, that such party shall use its reasonable efforts to obtain at the request of the Disclosing Party an order or other assurance that confidential
treatment shall be accorded to such portion of Confidential Information or Third Party Confidential Information as applicable required to be disclosed as the Disclosing Party shall designate. 

  
 -35-

 6.10.5. This Section 6.10 shall not apply to any information that (a) at
the time of disclosure or thereafter is generally available to the public (other than as result of disclosure directly by the Receiving Party or its Affiliates or Representatives), (b) is or becomes available to the Receiving Party from third
party source free of an obligation of confidentiality with respect to such information to the Disclosing Party, (c) is known by the Receiving Party, prior to its disclosure by the Disclosing Party, from third party source that is free of an
obligation of confidentiality to the Disclosing Party with respect to such information, provided that such prior knowledge can be proven by the Receiving Party’s written records, except to the extent such information comprises or relates to the
Excluded Assets, (d) is independently developed or acquired by the Receiving Party or its Affiliates or Representatives without access or reference to or use of the Confidential Information of the Disclosing Party. Further, the Seller may
disclose Confidential Information to any Persons involved in an assignment or potential assignment of the Sellers rights to receive the Milestone Payment from Buyer (including such Person or Persons’ directors, partners, members, officers,
lenders, investors and advisors), including (a) this Agreement (and all amendments hereto), and (b) correspondence related to, and notices given under, this Agreement; provided, however, that such Persons receiving such
Confidential Information from the Seller shall have agreed in writing to keep confidential and not disclose such information to any third party. 
 6.11. Publicity. No public announcement or disclosure shall be made by any party hereto with respect to the subject matter of this Agreement or the Contemplated Transactions without the prior
written consent of the Buyer and the Seller; provided, however, that the provisions of Section 6.10 and 6.11 shall not prohibit (a) any disclosure required by any applicable Legal Requirements (in which case the
disclosing party shall provide the other parties with the opportunity to review in advance the disclosure) or (b) any disclosure made in connection with the enforcement of any right or remedy relating to this Agreement or the Contemplated
Transactions. Notwithstanding anything herein to the contrary, the parties hereto agree that each party hereto may disclose to any and all Persons, without limitation of any kind, the Tax treatment and Tax structure (as such terms are used in Code
Sections 6011 and 6112 and the regulations thereunder) of the Contemplated Transactions. The authorization set forth in the preceding sentence is not intended to permit disclosure of any other information including (i) any portion of any
materials to the extent not related to the Tax treatment or Tax structure of the Contemplated Transactions, or (ii) any other term or detail not relevant to the Tax treatment or Tax structure of the Contemplated Transactions. 

6.12. Further Assurances. From and after the Closing Date, each of the parties hereto shall do, execute, acknowledge and deliver
all such further acts, assurances, deeds, assignments, transfers, conveyances and other instruments and papers as may be reasonably required or appropriate to carry out the Contemplated Transactions. Without limiting the generality of the foregoing,
from and after the Closing Date, the Buyer shall assign, transfer, and convey to the Seller without consideration, upon the Sellers written request, or upon the Buyer’s own initiative, any of the Company’s right, title and interest in and
to any of the Excluded Assets and Excluded Liabilities The Seller shall not take any action that is designed or intended to have the effect of discouraging any lessor, licensor, supplier, distributor or customer of the Company

  
 -36-

 
or other Person with whom the Company has relationship from maintaining the same relationship with the Company after the Closing as it maintained prior to the Closing. The Seller shall promptly
refer all customer inquiries and other inquiries relating to the Company to the Buyer, or the Company, as appropriate, from and after the Closing. 
 6.13. Buyers Non-Transitory Corporation Covenant. The Buyer is classified as corporation for U.S. federal income tax purposes and shall continue to be classified as corporation for U.S. federal
income tax purposes (a) at all times prior to and including the Closing Date and (b) at all times following the Closing Date until the date that is the earlier of (i) three (3) years following the Closing Date, or (ii) the
date on which the Buyer’s Board of Directors resolves to terminate the business operations relating to the Product and to liquidate or otherwise wind down the business and operations of the Buyer, but not if such liquidation or winding down is
effected by means of disposition of any of Buyer’s business, assets (including the Product) or Company shares in transaction that is not Bona Fide Transaction or (iii) the date that Buyer is merged into another entity treated as
corporation for U.S. federal income tax purposes. In the case of merger described in (iii), above, such merger shall not take place unless the corporation into which Buyer is merged succeeds to the terms of this covenant as if it were the Buyer.

 6.14. Listed Transactions. After Closing, neither Buyer or its stockholders or Affiliates nor Company shall take any
action or cause any action to be taken that would cause the transactions contemplated in this Agreement to be part of, or substantially similar to, the listed transaction identified in Notice 2008-111, 2008-51 IRB 1299. 

6.15. Payment of Indebtedness. The Seller shall pay or cause the Company to pay all indebtedness (including all liabilities and
payables on the Asset and Liability Statement) of the Company immediately prior to the Closing 
 7. CONDITIONS TO THE BUYERS
OBLIGATIONS AT THE CLOSING. 
 The obligations of the Buyer to consummate the Closing are subject to the fulfillment of each of
the following conditions (unless waived by the Buyer in writing in accordance with Section 12.3): 
 7.1.
Representations and Warranties. The representations and warranties of the Seller contained in this Agreement and in any Ancillary Agreement (a) that are not qualified by materiality or Material Adverse Effect shall be true, correct and
complete in all material respects at and as of the Closing with the same force and effect as if made as of the Closing, and (b) that are qualified by materiality or Material Adverse Effect shall be true, correct and complete in all respects at
and as of the Closing with the same force and effect as if made as of the Closing, in each case, other than representations and warranties that expressly speak only as of specific date or time, which shall be true, correct and complete (or true,
correct and complete in all material respects, as the ease may be) as of such specified date or time. 
 7.2.
Performance. The Company and the Seller shall have performed and complied in all material respects, with all agreements, obligations and covenants contained in this Agreement that are required to be performed or complied with by them at or
prior to the Closing. 

  
 -37-

 7.3. Stock Certificates. The Seller shall have delivered to the Buyer certificates,
duly endorsed (or accompanied by duly executed stock transfer powers) evidencing all of the Shares. 
 7.4. Compliance
Certificate. The Seller shall have delivered to the Buyer certificate substantially in the form of Exhibit 7.4. 

7.5. Qualifications. No provision of any applicable Legal Requirement and no Government Order shall prohibit the consummation of
any of the Contemplated Transactions. 
 7.6. Absence of Litigation. No Action shall be pending or threatened which may
result in Government Order (nor shall there be any Government Order in effect) (a) which would prevent, significantly delay, make illegal or otherwise interfere with the consummation of any of the Contemplated Transactions, (b) which would
result in any of the Contemplated Transactions being rescinded following consummation, or (c) which could limit or otherwise adversely affect the right of the Buyer to own the Shares (including the right to vote the Shares), to control the
Company, or to operate all or any portion of either the business or assets of the Company, including the Product. 
 7.7.
Ancillary Agreements. Each of the Ancillary Agreements to which the Buyer is party shall have been executed and delivered by the Seller. Without limiting the generality of the foregoing, Seller will have caused (i) Pfizer Overseas LLC to
enter into the Inventory Transfer Agreement, and (ii) Pfizer Italia S.r.l to enter into the Reverse TSA Assignment Agreement. 
 7.8. Excluded Assets; Excluded Liabilities. The Company shall have assigned, sold, distributed or otherwise transferred the Excluded Assets to the Seller, its subsidiaries, its Affiliates or third
parties, and the Seller shall have assumed or caused an Affiliate or third party to assume, as applicable, all of the Excluded Liabilities 
 8. CONDITIONS TO THE SELLER’S OBLIGATIONS AT THE CLOSING. 
 The obligations
of the Seller to consummate the Closing are subject to the fulfillment of each of the following conditions (unless waived by the Seller in writing in accordance with Section 12.3): 

8.1. Representations and Warranties. The representations and warranties of the Buyer contained in this Agreement and in any
Ancillary Agreement (a) that are not qualified by materiality or Material Adverse Effect shall be true, correct and complete in all material respects at and as of the Closing with the same force and effect as if made as of the Closing and
(b) that are qualified by materiality or Material Adverse Effect shall be true, correct and complete in all respects at and as of the Closing with the same force and effect as if made as of the Closing, in each case, other than representations
and warranties that expressly speak only as of specific date or time, which shall be true, correct and complete (or true, correct and complete in all material respects, as the case may be) as of such specified date or time. 

  
 -38-

 8.2. Performance. The Buyer shall have performed and complied with, in all material
respects, all agreements, obligations and covenants contained in this Agreement that are required to be performed or complied with by the Buyer at or prior to the Closing. 
 8.3. Compliance Certificate. The Buyer shall have delivered to the Seller certificate in the form of Exhibit 8.3. 
 8.4. Qualifications. No provision of any applicable Legal Requirement and no Government Order shall prohibit the consummation of any of the Contemplated Transactions. 

8.5. Absence of Litigation. No Action shall be pending or threatened which may result in Government Order, nor shall there be any
Government Order in effect, (a) which would prevent consummation of any of the Contemplated Transactions, or (b) which would result in any of the Contemplated Transactions being rescinded following consummation. 

8.6. Ancillary Agreements. Each of the Ancillary Agreements to which the Seller is party shall have been executed and delivered by
the Buyer. 
 8.7. Excluded Assets. The Company shall have assigned sold distributed or otherwise transferred the
Excluded Assets to the Seller, its Affiliates or third parties, and the Excluded Liabilities shall have been assumed by the Seller, its Affiliates or third parties. 
 9. TERMINATION. 
 9.1. Termination of Agreement. This Agreement maybe
terminated (the date on which the Agreement is terminated, the “Termination Date”) at any time prior to the Closing 
 (a) by mutual written consent of the Buyer and the Seller; 
 (b)
by either the Buyer or the Seller, so long as the Buyer or the Seller, respectively, is/are not then in breach of its/their obligations under this Agreement in any material respect, by providing written notice to the other at any time on or after
December 30, 2009 (the “Final Termination Date”) in the event that the Closing has not occurred on or prior to the Final Termination Date; 

(c) by either the Buyer or the Seller if final nonappealable Government Order permanently enjoining, restraining or
otherwise prohibiting the Closing shall have been issued by Governmental Authority of competent jurisdiction; 

(d) by the Buyer, so long as the Buyer is not then in breach of its obligations under this Agreement in any material
respect, if either (i) there shall have been material breach of, or inaccuracy in, any representation or warranty of the Seller contained in this Agreement as of the Execution Date or as of any subsequent date (other than representations or
warranties that expressly speak only as of specific date or time, with respect to which the Buyer’s right to terminate shall arise only in the event of breach of, or inaccuracy in, such representation or warranty as of such specified date or
time) which breach or inaccuracy would give rise, or could reasonably be expected to give rise, to failure of condition set forth in Section 7 and which is not cured on or prior to the

  
 -39-

 
earlier of (x) the [**] day following written notice of such breach, or (y) the Final Termination Date, or (ii) the Seller shall have breached or violated in any material respect
any of its covenants and agreements contained in this Agreement, which breach or violation would give rise, or could reasonably be expected to give rise, to failure of any condition set forth in Section 7 and such breach or violation is
not cured on or prior to the earlier of (A) the [**] day following written notice of such breach, or (B) the Final Termination Date; 
 (e) by the Seller, so long as the Seller is not then in breach of its obligations under this Agreement in any material respect, if either (i) there shall have been material breach of, or inaccuracy
in, any representation or warranty of the Buyer contained in this Agreement as of the Execution Date or as of any subsequent date other than representations or warranties that expressly speak only as of specific date or time, with respect to which
the Seller’s right to terminate shall arise only in the event of breach of, or inaccuracy in, such representation or warranty as of such specified date or time), which breach or inaccuracy would give rise, or could reasonably be expected to
give rise, to failure of condition set forth in Section 8 and which is not cured on or prior to the earlier of (x) the [**] day following notice of such breach, or (y) the Final Termination Date, or (ii) by the Buyer shall
have breached or violated in any material respect any of its covenants and agreements contained in this Agreement, which breach or violation would give rise, or could reasonably be expected to give rise, to failure of the condition set forth in
Section 8 and such breach or violation is not cured on or prior to the earlier of (A) the [**] day following notice of such breach, or (B) the Final Termination Date; or 

(f) by the Buyer pursuant to Section 6.4. 

9.2. Effect of Termination. In the event of the termination of this Agreement pursuant to Section 9.1, this Agreement,
other than the provisions of this Section 9.2 and Sections 3.12 (No Brokers), 4.6 (No Brokers) and 5.6 (No Brokers), 6.5 (Expenses) 6.10 (Confidentiality), 6.11 (Publicity) and 12
(Miscellaneous), shall then be null and void and have no further force and effect and all other rights and Liabilities of the parties hereunder shall terminate without any Liability of any party to any other party, except for Liabilities arising in
respect of breaches under this Agreement by any party on or prior to the Termination Date. Each party’s right of termination under Section 9.1 is in addition to any other rights it may have under this Agreement or otherwise, and the
exercise of right of termination shall not be an election of remedies. 
 10. INDEMNIFICATION. 

10.1. Indemnification by the Seller. 
 10.1.1. Indemnification. Subject to the limitations set forth in this Section 10, the Seller shall indemnify and hold harmless the Buyer and each of its Affiliates (including following
the Closing, the Company), and the Representatives and Affiliates of each of the foregoing Persons (each, a “Buyer Indemnified Person”), from, against, and in respect of, any and all Actions, Liabilities, Government Orders,
Encumbrances, losses, damages, bonds, dues, assessments, fines, penalties, Taxes, fees, costs (including costs of investigation, defense and 

  
 -40-

 
enforcement of this Agreement), expenses or amounts paid in settlement (in each case, including reasonable outside attorneys, and experts fees and expenses), whether or not involving Third Party
Claim (collectively “Losses”), incurred or suffered by the Buyer Indemnified Persons or any of them to the extent, directly or indirectly, resulting from, arising out of, or relating to: 

(a) any breach of, or inaccuracy in, any representation or warranty made by the Seller in Section 3 or
Section 4 of this Agreement or Section 1.5 of the Transition Services Agreement 
 (b) any
breach or violation of any covenant or agreement of the Seller (including, where applicable, any failure to cause the Company to comply with such covenant or agreement) in or pursuant to this Agreement or any Ancillary Agreement (other than any
breach of Seller’s obligations under Section 3 of the Transition Services Agreement (i.e., Consulting Services)); 
 (c) any fraud of the Seller or any pre-Closing fraud of the Company 
 (d) the Excluded Assets or the Excluded Liabilities (including, by definition, Liabilities arising out of any Environmental Laws and foreign equivalents thereof or Hazardous Materials (including those
treated as such under foreign equivalents of Environmental Laws) relating to Vicuron Pharmaceuticals Italy, Biosearch Manufacturing, the Pisticci Plant or the Geranzano Research Center); or 

(e) any claim, action or suit brought by RaQualia (or any successor or assignee thereof) that is based on the inaccuracy
of information contained in the recital set forth in the first sentence of the first full paragraph of the RaQualia Agreement that begins with “WHEREAS.” 
 10.1.2. Monetary Limitations. 
 (a) The Seller shall have
no obligation to indemnify the Buyer Indemnified Persons in respect of Losses arising from the breach of, or inaccuracy in, any representation or warranty pursuant to Section 10.1.1(a) or Losses arising from the breach of any covenant or
agreement to be performed prior to Closing pursuant to Section 10.1.1(b) unless the aggregate amount of all such Losses incurred or suffered by the Buyer Indemnified Persons exceeds [**] Dollars ($[**]) (the “Threshold
Amount”), in which case the Seller shall indemnify the Buyer Indemnified Persons or all such Losses, including the Threshold Amount, and not only to the extent such Losses exceed the Threshold Amount, and the Seller’s aggregate
Liability in respect of Indemnification Claims arising from the breach of, or inaccuracy in, any representation or warranty pursuant to Section 10.1.1(a) and Indemnification Claims brought after the Closing arising from the breach of any
covenant or agreement to be performed prior to the Closing pursuant to Section 10.1.1(b) shall not exceed [**] Dollars ($[**]) (the “Indemnity Cap”). 

(b) Notwithstanding anything to the contrary in Section 10.1.2(a), the monetary limitations in this
Section 10.1.2 shall not apply to 

  
 -41-

 
Indemnification Claims pursuant to Sections 10.1.1(a) in respect of breaches of, or inaccuracies in, representations and warranties set forth in Sections 3.1 (Organization),
3.2 (Capital Structure), 3.3 (Power and Authorization), 3.4(e) (Noncontravention of Organizational Documents), 3.11 (Environmental Matters) 3.12 (No Brokers), 3.13 (Taxes) 4.2 (Power and
Authorization) 4.4(e) (Noncontravention of Organizational Documents) and 4.6 (No Brokers) (said Sections 3.1, 3.2, 3.3, 3.4(e), 3.11, 3.12, 3.13, 4.2, 4.4(e) and 4.6
being hereinafter referred to collectively as the “Fundamental Representations and Warranties”). 
 (c) Notwithstanding anything to the contrary in Section 10.1.2(a) and Section 10.1.2(b) the Sellers aggregate Liability in respect of Indemnification Claims arising from the breach of or
inaccuracy in the representations or warranties set forth in Section 3.5.1 (Litigation) and Section 3.8.1(a) (Contractual Obligations of the Company) pursuant to Section 10.1.1(a), together with the Seller’s
aggregate Liability for Indemnification Claims brought after the Closing arising from the breach of any covenant or agreement to be performed prior to the Closing pursuant to Section 10.1.1(b) and Indemnification Claims arising from the
breach of, or inaccuracy in, any other representation or warranty pursuant to Section 10.1.1(a), other than in respect of the Fundamental Representations and Warranties shall not exceed [**] Dollars ($[**]) (the “Special
Indemnity Cap”). 
 (d) Notwithstanding anything to the contrary in this Agreement, Indemnification
Claims pursuant to Sections 10.1.1(c), 10.1.1(d) or 10.1.1(c), or for Losses arising from the breach of any covenant or agreement to be performed by Seller after the Closing pursuant to Section 10.1.1(b) other than any breach of
Sellers obligations under Section 3 of the Transition Services Agreement (i.e., Consulting Services) are not subject to any of the monetary limitations in this Section 10.1.2, including the Threshold Amount, the Indemnity Cap
and the Special Indemnity Cap. 
 10.2. Indemnity by the Buyer. 

10.2.1. Indemnification. Subject to the limitations set forth in this Section 10, the Buyer shall indemnify and hold
harmless the Seller and the Seller’s respective Affiliates (including, prior to the Closing, the Company), and the Representatives and Affiliates of each of the foregoing Persons (each, a “Seller Indemnified Person”) from,
against, and in respect of, any and all Losses incurred or suffered by the Seller Indemnified Persons or any of them to the extent directly or indirectly resulting from, arising out of or relating to: 

(a) any breach of or inaccuracy in any representation or warranty made by the Buyer in Section 5 of this
Agreement 
 (b) any breach or violation of any covenant or agreement of the Buyer in or pursuant to this
Agreement or any Ancillary Agreement 
 (c) any fraud of the Buyer or any post-Closing fraud committed by the
Company and 

  
 -42-

 (d) the ownership development use or operation of the Included Assets and
the Residual Assets by the Buyer or the Company after the Closing including the development commercialization marketing sale and promotion of the Product and the Residual Assets except to the extent such Losses result from breach of any
representation warranty or covenant of the Seller under this Agreement or any Ancillary Agreement or from any Excluded Liabilities for which the Seller has agreed to indemnify the Buyer under Section 10.1.1(d) and ii the failure of the
Buyer or the Company to discharge perform and satisfy in full the Included Liabilities 10.2.2. 
 10.2.2. Monetary
Limitations. The Buyer shall have no obligation to indemnify the Seller Indemnified Persons in respect of Losses arising from the breach of, or inaccuracy in, any representation or warranty pursuant to Section 10.2.1(a) or Losses
arising from the breach of any covenant or agreement to be performed prior to Closing pursuant to Section 10.2.1(b), unless the aggregate amount of all such Losses incurred or suffered by the Seller Indemnified Persons exceeds the
Threshold Amount, in which case the Buyer shall indemnify the Seller Indemnified Persons for all such Losses, including the Threshold Amount, and not only to the extent such Losses exceed the Threshold Amount, and the Buyer’s aggregate
Liability in respect of Indemnification Claims arising from the breach of, or inaccuracy in, any representation or warranty pursuant to Section 10.2 1(a) and Indemnification Claims brought after Closing arising from the breach of any
covenant or agreement to be performed prior to the Closing pursuant to Section 10.2.1(b) will not exceed Three Million Dollars ($3,000,000); provided, however, that the foregoing monetary limitations in this
Section 10.2.2 will not apply to Indemnification Claims pursuant to Sections 10.2.1(a) in respect of breaches of, or inaccuracies in, representations and warranties set forth in Sections 5.1 (Organization), 5.2
(Power and Authorization), 5.4(e) (Breach of Organizational Documents) or 5.6 (No Brokers). Indemnification Claims pursuant to Sections 10.2.1(c) or 10.2.1(d), or for Losses arising from the breach of any covenant or
agreement to be performed by the Buyer after the Closing pursuant to Section 10.2.l(b), are not subject to the monetary limitations set forth in this Section 10.2.2. 

10.3. Time for Claims. No claim may be made or suit instituted seeking indemnification pursuant to Sections 10.1.19(a),
10.1.l(b), 10.1.1(c), 10.2.1(a), 10.2.1(b), or 10.2.1(c) unless written notice describing the breach of, or inaccuracy in, any representation or warranty, or the breach or violation of any covenant or agreement, or
the purported fraud, in each case, in reasonable detail in light of the circumstances then known to the Indemnified Party, is provided to the Indemnifying Party: 

(a) at any time, in the case of any breach of, or inaccuracy in, the representations and warranties set forth in
Sections 3.1 (Organization), and 5.1 (Organization), 3.2 (Capital Structure), 3.3 (Power and Authorization) 4.2 (Power and Authorization) and 5.2 (Power Authorization) 3.4(e) (Noncontravention of
Organizational Documents), 4.4(e) (Noncontravention of Organizational Documents), 5.4(e) (Breach of Organizational Documents), 3.12 (No Brokers), 4.6 (No Brokers), and 5.6 (No Brokers); 

(b) at any time prior to the expiration of the applicable statute of limitations in the case of any claim or suit based
upon fraud or for any breach of or inaccuracy in the representations and warranties set forth in Section 3.11 (Environmental Matters) or Section 3.13 (Taxes); 

  
 -43-

 (c) at any time prior to June 30, 2011, in the case of (i) any
breach of, or inaccuracy in, any other representation and warranty in this Agreement, or (ii) any breach of any covenant or agreement to be performed prior to the Closing 
 Notwithstanding anything to the contrary in this Agreement, Indemnification Claims pursuant to Sections 10.1.1(d), 10.1.1(e), and 10.2.1(d) are not subject to the limitations set
forth in this Section 10.3. 
 10.4. Third Party Claims. 

10.4.1. Notice of Claim. If any third party notifies an Indemnified Party with respect to any Action (a “Third Party
Claim”) which may give rise to an Indemnification Claim against an Indemnifying Party under this Section 10, then the Indemnified Party shall promptly give written notice to the Indemnifying Party of such Third Party Claim;
provided, however, that no delay on the part of the Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation under this Section 10, except to the extent such delay
actually and materially prejudices the Indemnifying Party. 
 10.4.2. Assumption of Defense etc. The Indemnifying Party
shall be entitled to participate in the defense of any Third Party Claim that is the subject of written notice given by the Indemnified Party pursuant to Section 10.4.1. In addition, the Indemnifying Party shall have the right to defend
the Indemnified Party against the Third Party Claim with counsel of its choice reasonably satisfactory to the Indemnified Party so long as (a) the Indemnifying Party gives written notice to the Indemnified Party within [**] days after the
Indemnified Party has given written notice of the Third Party Claim that the Indemnifying Party shall indemnify the Indemnified Party from and against the entirety of any and all Losses the Indemnified Party may suffer resulting from arising out of,
relating to, in the nature of, or caused by the Third Party Claim to which the Indemnified Party is entitled to be indemnified under Section 10.1 or 10.2, (b) the Indemnifying Party provides the Indemnified Party with
evidence reasonably acceptable to the Indemnified Party that the Indemnifying Party shall have adequate financial resources, or ready access to adequate financial resources (which may, but need not, include defense costs from insurance) to defend
against the Third Party Claim and fulfill its indemnification obligations hereunder, (c) the Third Party Claim involves primarily money damages and does not seek material injunctive or other equitable relief against the indemnified Party,
(d) the Indemnified Party has not been advised by counsel in good faith that an actual conflict exists between the Indemnified Party and the Indemnifying Party in connection with the defense of the Third Party Claim, (e) the Third Party
Claim does not relate to or otherwise arise in connection with any criminal or regulatory enforcement Action or any patent, trademark or other intellectual property dispute, and (f) the Indemnifying Party conducts the defense of the Third Party
Claim actively and diligently. The Indemnified Party may retain separate co counsel at its sole cost and expense and participate in the defense of the Third Party Claim; provided, however, that the Indemnifying Party shall pay the fees
and expenses of separate co-counsel retained by the Indemnified Party that are incurred prior to Indemnifying Party’s assumption of control of the defense of the Third Party Claim. 

  
 -44-

 10.4.3. Limitations on Indemnifying Party. The Indemnifying Party shall not consent
to the entry of any judgment or enter into any compromise or settlement with respect to the Third Party Claim without the prior written consent of the Indemnified Party unless such judgment, compromise or settlement (a) provides for the payment
by the Indemnifying Party of money as sole relief for the claimant, (b) results in the full and general release of the Buyer Indemnified Persons or Seller Indemnified Persons, as applicable, from all Liabilities arising or relating to, or in
connection with, the Third Party Claim, or (c) contains no finding or admission of any violation of any Legal Requirements or the rights of any other Person. 
 10.4.4. Indemnified Party’s Control. If the Indemnifying Party does not deliver the written notice contemplated by clause (a), or the evidence contemplated by clause (b), of
Section 10.4.2 within [**] days after the Indemnified Party has given written notice of the Third Party Claim, or otherwise at any time fails to conduct the defense of the Third Party Claim actively and diligently, the Indemnified Party
may defend, and may consent to the entry of any judgment or enter into any compromise or settlement with respect to, the Third Party Claim; provided, however, that the Indemnifying Party shall not be bound by the entry of any such
judgment consented to, or any such compromise or settlement effected, without its prior written consent (which consent shall not be unreasonably withheld or delayed). In the event that the Indemnified Party conducts the defense of the Third Party
Claim pursuant to this Section 10.4.4, the Indemnifying Party shall (a) advance the Indemnified Party promptly and periodically for the costs of defending against the Third Party Claim (including reasonable outside attorneys’
fees and expenses, but excluding the expenses of any attorneys who are employees of the Indemnified Party), and (b) remain responsible for any and all other Losses that the Indemnified Party may incur or suffer resulting from, arising out of,
relating to, in the nature of or caused by the Third Party Claim to the fullest extent provided in this Section 10. 
 10.4.5. Consent to Jurisdiction Regarding Third Party Claim. The Buyer and the Seller, each in its capacity as an Indemnifying Party, hereby consents to the non-exclusive jurisdiction of any court
in which any Third Party Claim may be brought against any Indemnified Party for purposes of any claim which such Indemnified Party may have against such Indemnifying Party pursuant to this Agreement in connection with such Third Party Claim, and in
furtherance thereof, the provisions of Section 12.12 are incorporated herein by reference, mutatis mutandis. 

10.5. Other Limitations. 
 10.5.1. Insurance. The amount of any Losses shall be reduced or reimbursed, as the case may be, by any amount received by the Indemnified Party with respect thereto under any insurance coverage,
less all reasonable out-of-pocket costs incurred by the Indemnified Party in its pursuit of such amount. The Indemnified Party shall use commercially reasonable efforts to collect any amounts available under such insurance coverage. To the extent
that any insurance payment is actually recovered by an Indemnified Party after the related indemnification payment has been made by an Indemnifying Party pursuant to this Agreement, the Indemnified Party shall pay over to the Indemnifying Party the
amounts of such insurance payments (net of all legal costs and expenses incurred to collect the same) promptly after they are actually recovered. 

  
 -45-

 10.5.2. Mitigation. Indemnified Parties shall use commercially reasonable efforts to
mitigate any Losses that may provide the basis for an indemnifiable claim (that is, the Indemnified Parties shall mitigate such Losses in the same manner that they would mitigate such Losses in the absence of the indemnification provided for in this
Agreement provided, however, that the Indemnified Parties shall not be required to incur any undue expense or take any action that would cause undue hardship, including impairing its ability to conduct business). Any request for
indemnification of specific costs shall include invoices and supporting documents containing reasonably detailed information about the costs and/or damages for which indemnification is being sought. 

10.5.3. No Double Recovery. Notwithstanding anything herein to the contrary, no Indemnified Party shall be entitled to
indemnification or reimbursement under any provision of this Agreement for any amount to the extent such party has actually been indemnified or reimbursed for such amount under any other provision of this Agreement or otherwise. 

10.6. Remedies Cumulative. The rights of each Buyer Indemnified Person and Seller Indemnified Person under this
Section 10 are cumulative, and each Buyer Indemnified Person and Seller Indemnified Person, as the case may be, shall have the right in any particular circumstance, in its sole discretion, to enforce any provision of this
Section 10 without regard to the availability of remedy under any other provision of this Section 10. 

10.7. Knowledge and Investigation. If any condition contained in this Agreement or in any Ancillary Agreement based on the truth
and accuracy of any representation or warranty, or the performance of or compliance with, any covenant or agreement is expressly waived in writing by an Indemnified Party, the right of such Indemnified Party to indemnification pursuant to this
Section 10 based on such representation, warranty, covenant or agreement shall be deemed waived at Closing to the extent such waiver expressly states that such right to indemnification is also being waived. 

10.8. No Right of Set-Off. The Buyer expressly waives any and all right of set-off against the Milestone Payment, the Milestone
Buyout and the Promissory Note, including any and all right to apply the amount of any Losses referenced in this Section 10 against the Milestone Payment, the Milestone Buyout and the Promissory Note. 

10.9. Exclusive Remedy. Except for remedies that cannot be waived as matter of law or the equitable remedy of specific performance
in connection with the breach of any covenant contained in this Agreement, this Section 10 shall provide the sole and exclusive remedy following the Closing for any and all Losses sustained or incurred by any Indemnified Party relating
to or arising in connection with (a) any breach of, or inaccuracy in any representation or warranty made in connection with this Agreement, (b) any breach or violation of any covenant or agreement in or pursuant to this Agreement or any
Ancillary Agreement which does not require performance after the Closing Date or any other Losses that arise in connection with this Agreement or with respect to which indemnification is provided in this Section 10; provided, however,
the remedies provided in this Section 10 shall not be exclusive of, or limit, any other remedies that may be available to any Indemnified Party in the case of any Losses arising in connection with the commission of fraud or in connection
with any breach or violation of any covenant or agreement in Section 2. 

  
 -46-

 11. TAX MATTERS. 
 11.1. Tax Indemnification. The Seller shall indemnify, exonerate and hold free and harmless each Buyer Indemnified Person from and against any Losses attributable to (a) all Taxes (or
non-payment thereof) of the Company and its branches and subsidiaries, except for those Taxes that result from any transaction (or deemed transaction by way of any election or otherwise) caused by the Buyer outside the Ordinary Course of Business of
the Company and occurring on the Closing Date after the event of Closing (i) for all Taxable periods ending on or before the Closing Date, and (ii) the portion of the Taxable period ending on or before the Closing Date for any Taxable
period that includes, but does not end, on the Closing Date (each, a “Pre-Closing Tax Period”), (b) all Pre-Closing Tax Period Taxes of any other member of the affiliated, consolidated, combined or unitary group of which the
Company was member on or prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or any analogous or similar state, local, or foreign Legal Requirement (including all Taxes of the foreign branches and subsidiaries
included in the Excluded Assets), (c) any and all Taxes relating to Pre-Closing Tax Period of any Person imposed on the Company in the Company’s capacity as transferee or successor to such Person, by Contractual Obligation or otherwise,
and (d) all value added Taxes arising out of or relating to the transfer of assets under the Inventory Transfer Agreement. Nothing in this Section 11.1 shall limit or expand upon Seller’s liability for indemnification pursuant
to Section 10. 
 11.2. Straddle Period. In the case of any Taxable period that includes (but does not end
on) the Closing Date (a “Straddle Period”), the amount of any Taxes of the Company based upon or measured by net income or gain for the Pre-Closing Tax Period shall be determined based on an interim closing of the books as of the
close of business on the Closing Date, except that, any item caused by the Buyer outside the Ordinary Course of Business of the Company and resulting in Tax that is incurred after the event of Closing, but on the Closing Date, shall be allocated
solely to the Post-Closing Tax Period. The amount of Taxes other than Taxes of the Company based upon or measured by net income or gain for Straddle Period which relate to the Pre-Closing Tax Period shall be deemed to be the amount of such Tax for
the entire Taxable period multiplied by a fraction, the numerator of which is the number of days in the Taxable period ending on the Closing Date and the denominator of which is the number of days in such Straddle Period. 

11.3. Tax Sharing Agreements. All Tax sharing agreements or similar agreements and all powers of attorney with respect to or
involving the Company shall be terminated prior to the Closing and, after the Closing, the Company shall not be bound thereby or have any Liability thereunder. 
 11.4. Certain Taxes and Fees. 
 11.4.1. All transfer, documentary, sales
use stamp, registration and other such Taxes, and any conveyance fees or recording charges incurred in connection with the Contemplated Transactions, shall be paid by the Seller when due. Seller shall, at its own

  
 -47-

 
expense, file all necessary Tax Returns and other documentation with respect to all such Taxes, fees and charges incurred in connection with the Contemplated Transaction and, if required by
applicable Legal Requirements, Buyer shall (and shall cause its Affiliates to) join in the execution of any such Tax Returns and other documentation. 
 11.4.2. Seller shall timely pay in full all Taxes due and payable after the Closing Date with respect to the Company’s branches and subsidiaries that are included in the Excluded Assets. 

11.5. Cooperation on Tax Matters. The Buyer and the Seller shall cooperate fully, as and to the extent reasonably requested by the
other party, in connection with any Tax matters relating to the Company (including by the provision of reasonably relevant records or information). The party requesting such cooperation shall pay the reasonable out-of-pocket expenses of the other
party. 
 11.6. Tax Contests. Notwithstanding Section 10.4, the Seller shall have the responsibility for, and
the right to control, at the Seller’s sole expense, the audit and/or litigation (and disposition thereof) of any Tax Return relating to taxable periods ending on or prior to the Closing Date, and the Seller shall have the right to participate,
at its own expense, in the disposition of the audit of any Tax Return relating to periods ending after the Closing Date, if and to the extent that such audit or disposition thereof is reasonably likely to give rise to claim for indemnification under
either Sections 10.1 or 11.1. The Buyer shall have the right directly or through its designated representatives at Buyer’s sole expense, to review in advance and comment upon all submissions made by the Seller in the course of
audits or appeals thereof to any Governmental Authority relating to taxable periods ending on or prior to the Closing Date and to approve the disposition of any audit adjustment with respect to such periods, such approval not to be unreasonably
withheld or delayed. 
 11.7. Tax Returns. 
 11.7.1. The Seller shall prepare and file (or cause the Company to prepare and file), at Seller’s sole expense, all Tax Returns related to the Company that are due on or prior to the Closing Date,
and shall timely pay (taking into consideration any extensions for filing) any Taxes with respect thereto. 
 11.7.2. In
addition to Section 11.7.1, the Seller shall prepare and file, at Seller’s sole expense, (i) all the Seller combined or consolidated U.S. federal Tax Returns (income or non-income) of which Company is includible,(ii) all Seller
combined, unitary or consolidated state or local Tax Returns (income or non-income) of which the Company is includible, and (iii) all Italian Tax Returns (income and non-income) related to the Italian branches and subsidiaries that are included
in the Excluded Assets, and shall timely pay (taking into consideration any extensions for filing) any Taxes with respect to (i), (ii) and (iii), above. The Company shall provide, at the Company’s sole expense, all information in its
possession and not otherwise available to Seller required to be included in such returns as the Seller may reasonably request within [**] days of such request. 

  
 -48-

 11.7.3. The Company shall prepare and file, at the Company’s sole expense, all Tax
Returns related to the Company, other than those described in Section 11.7.1 and Section 11.7.2 that are due after the Closing Date (including those non-income Tax Returns and separate state and local income Tax Returns for
Taxable Periods ending after the Closing Date), and shall timely pay (taking into consideration any extensions for filing) any Taxes with respect thereto. 
 11.7.4. With respect to Section 11.7.3 at least [**] days prior to the date on which each such Tax Return is due (taking into consideration any extensions for filing), the Company shall submit
such Tax Return to the Seller for the Seller’s review, comment and approval, which approval shall not be unreasonably withheld or delayed, and shall not be withheld in any event if such Tax Return has been prepared substantially in accordance
with Company’s past practices. 
 11.8. Other. Any refund of Taxes received by any Person with respect to any Taxes
paid by Seller for Pre-Closing Tax Period, shall be the property of the Seller. 
 12. MISCELLANEOUS. 

12.1. Notices. All notices, requests, demands, claims and other communications required or permitted to be delivered, given or
otherwise provided under this Agreement must be in writing and must be delivered, given or otherwise provided: 

(a) by hand (in which case, it shall be effective upon delivery); 

(b) by facsimile (in which case, it shall be effective upon receipt of confirmation of good transmission); or 

(c) by overnight delivery by nationally recognized courier service (in which case, it shall be effective on the Business
Day after being deposited with such courier service); 
 in each case, to the address (or facsimile number) listed below: 

If to the Buyer, to it at: 
 Durata Therapeutics, Inc. 
 Times Square Tower 

7 Times Square, Suite 1603 
 Facsimile number: (646) 519-2782 
 Attention: Mr. Ron M. Hunt

 with copy to: 
 O’Melveny Myers LLP 
 2 Embarcadero Center, 28th Floor 

San Francisco, CA 94111 
 Facsimile number: (415) 984-8701 
 Attention: Peter T. Healy, Esq. 

  
 -49-

 If to the Seller, to it at: 

Pfizer Inc. 
 234
East 42nd Street 
 New York, NY 10017 
 Facsimile number: (212) 573-0768 
 Attention: Senior Vice President and
General Counsel 
 with copy to: 
 Ropes & Gray LLP 
 One International Place 

Boston, MA 02110 

Facsimile number: (617) 235-0223 
 Attention: Steven A. Wilcox, Esq. 
 Each of the parties to this Agreement may
specify different address or facsimile number by giving notice in accordance with this Section 12.1 to each of the other parties hereto. 
 12.2. Succession and Assignment; No Third-Party Beneficiary. Subject to the immediately following sentence, this Agreement shall be binding upon and inure to the benefit of the parties hereto and
their respective permitted successors and permitted assigns, each of which such permitted successors and permitted assigns shall be deemed to be party hereto for all purposes hereof. The Seller may assign or otherwise transfer any or all of its
rights or interests under this Agreement to receive any Milestone Payment (or Milestone Buyout, as applicable) from Buyer, with the consent of the Buyer, which such consent shall not be unreasonably withheld or delayed, and provided further, that
the Seller shall have entered into an indemnity and release in favor of the Buyer, confirming that Buyer’s obligations to the Seller to make any Milestone Payment or Milestone Buyout payment shall be deemed to be discharged and satisfied in
full to the extent Buyer makes such payments to the Seller’s designated assignee in accordance with the written payment instructions furnished to the Buyer by or on behalf of the Seller, in form and substance reasonably satisfactory to Buyer.
The Buyer, and other than as provided in the prior sentence, the Seller, may not assign, delegate or otherwise transfer either this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other
party. Notwithstanding the foregoing, without the consent of the other party, (a) each party hereto may (i) assign any or all of its rights and interests hereunder to one or more of its Affiliates, and (ii) designate one or more of
its Affiliates to perform its obligations hereunder, in each case, so long as the assigning party is not relieved of any Liability hereunder, and (b) the Buyer may assign and delegate this Agreement and all of its rights, interests and
obligations hereunder to Qualified Successor (i) in connection with Change of Control of Buyer with such Qualified Successor or (ii) in connection with Product Transfer to such Qualified Successor, so long as, in the case of subsections
(b)(i) and (b)(ii) of this Section 12.2, such Qualified Successor unconditionally assumes all of the Buyer’s Liabilities under this Agreement. Any such assignment and delegation of this Agreement made in conformity with subsection
(b)

  
 -50-

 
of this Section 12.2 shall operate to relieve the Buyer of its liabilities and obligations hereunder if such Qualified Successor expressly and unconditionally agrees in writing with
Seller that it shall be bound by and shall assume, pay and perform all of the Buyer’s obligations as set forth in Section 2.5.3 of this Agreement. Except as expressly provided herein, this Agreement is for the sole benefit of the
parties hereto and their permitted successors and permitted assignees and nothing herein expressed or implied shall give or be construed to give any Person, other than the parties hereto and such successors and assignees, any legal or equitable
rights hereunder 
 12.3. Amendments and Waivers. No amendment or waiver of any provision of this Agreement shall be
valid and binding unless it is in writing and signed, in the case of an amendment, by the Buyer and the Seller, or in the case of waiver, by the party against whom the waiver is to be effective. No waiver by any party hereto of any breach or
violation or default under, or inaccuracy in, any representation, warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent breach, violation, default under, or inaccuracy in, any such
representation, warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No delay or omission on the part of any party hereto in exercising any right, power or remedy under this
Agreement shall operate as waiver thereof. 
 12.4. Entire Agreement. This Agreement, together with the Ancillary
Agreements and any documents, instruments and certificates explicitly referred to herein, constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes any and all prior discussions, negotiations,
proposals, undertakings, understandings and agreements, whether written or oral, with respect thereto, except for the Confidentiality Agreements. 
 12.5. Exhibits; Listed Documents, etc. The listing or description of any item, matter or document in any Schedule hereto will be deemed to modify, qualify or disclose an exception to any
representation or warranty of any party made herein or in connection herewith to which it reasonably relates. 
 12.6.
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute but one and the same instrument. This Agreement shall become effective when duly
executed by each party hereto. 
 12.7. Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any
other jurisdiction. In the event that any provision hereof would, under applicable Legal Requirements, be invalid or unenforceable in any respect, each party hereto intends that such provision shall be construed by modifying or limiting it so as to
be valid and enforceable to the maximum extent compatible with, and possible under, applicable Legal Requirements. 
 12.8.
Headings. The headings contained in this Agreement are for convenience purposes only and shall not in any way affect the meaning or interpretation hereof. 

  
 -51-

 12.9. Construction. The parties have participated jointly in the negotiation and
drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any of the provisions of this Agreement. The parties intend that each representation, warranty and covenant contained herein shall have independent significance. Except as otherwise set forth herein, if any
party has breached or violated, or if there is an inaccuracy in, any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter
(regardless of the relative levels of specificity) which the party has not breached or violated, or in respect of which there is not an inaccuracy, shall not detract from or mitigate the fact that the party has breached or violated, or there is an
inaccuracy in, the first representation, warranty or covenant. 
 12.10. Governing Law. This Agreement, the rights of the
parties and all Actions arising in whole or in part under or in connection herewith, shall be governed by and construed in accordance with the domestic substantive Legal Requirements of the State of New York, without giving effect to any choice or
conflict of law provision or rule (other than Section 5-1401 and 5-1402 of the New York General Obligation Law) that would cause the application of the Legal Requirements of any other jurisdiction. 

12.11. Dispute Resolution. 
 12.11.1. If a dispute arises under this Agreement which cannot be resolved by the Buyer and the Seller prior to initiating an Action, either party hereto may invoke the dispute resolution procedure set
forth in this Section 12.11 by giving written notice to the other party hereto, designating an executive officer with appropriate authority to be its representative in negotiations relating to the dispute. Upon receipt of such written
notice, the other party hereto shall, within [**] days, designate an executive officer with similar authority to be its representative. The designated executive officers shall, following whatever investigation each deems appropriate, promptly enter
into discussions concerning the dispute. Neither party may commence an Action of any matter hereunder (other than injunctive or other equitable relief) until the expiration of [**] days after its notice designating such executive officers.

 12.11.2. Notwithstanding the last sentence of Section 12.11.1, in the event that the Seller elects to dispute
the Buyers FDACM Notice certification described in Section 2.6.1(ii)(b), the parties will submit the matter to non-binding mediation and binding arbitration as follows : 

(a) The parties shall first submit such dispute to panel of three (3) experts in the field of clinical development
of antibiotic drugs, one (1) expert to be appointed by the Seller within [**] days from the notice of initiation of arbitration, one (1) expert to be appointed by the Buyer within [**] days from the notice of initiation of arbitration, and
the third expert to be selected by mutual agreement of the Seller’s appointed expert and the Buyer’s appointed expert within [**] days of the date that the last of such experts was appointed. The three experts shall be instructed by the
parties to complete the arbitration within [**] days after selection of the final expert. The third expert shall be wholly independent of each party shall not have any conflicts of interest with either the Buyer, the Seller or the Company.

  
 -52-

 (b) If either party disagrees with the final decision of the panel of
experts under Section 12 11.2a, or the parties fail to select such panel of experts within [**] days from the notice of initiation of arbitration, the disputed matter shall be resolved in binding arbitration in New York, New York before
single independent arbitrator appointed jointly by the Seller and the Buyer. The arbitration shall be administered by JAMS pursuant to its (Comprehensive Arbitration Rules and Procedures) (Streamlined Arbitration Rules and Procedures) or, if agreed
by the Buyer and the Seller in writing, any alternate provider pursuant to its rules and procedures. 
 (c) Each
party hereto shall bear 50% of the experts’ and arbitrators’ fees and the applicable filing costs, but each party hereto shall bear sole responsibility for its own legal, accounting, advisory and other fees associated with proceedings
under Section 12.11.2a and Section 12.11.2b. The experts and arbitrator shall resolve only those matters in dispute. Judgment of the arbitrator on the award may be entered in any court having jurisdiction. This
Section 12.11.2 shall not preclude the parties hereto from seeking provisional remedies in aid of arbitration from court of appropriate jurisdiction. 

(d) During the pendency of any mediation or arbitration proceeding under Section 12.11.2a and
Section 12.11.2b, the Seller Payment shall not be due and interest thereon shall not begin to accrue and shall be suspended until the dispute has been finally resolved. 

12.12. Jurisdiction; Venue; Service of Process. 
 12.12.1. Jurisdiction. Subject to the provisions of Section 10.4.5 and Section 12.11, each party hereto, by its execution hereof, (a) hereby irrevocably submits to the
exclusive jurisdiction of the United States District Court for the Southern District of New York or any New York state court sitting in New York, New York, United States of America for the purpose of any Action between the parties arising in whole
or in part under or in connection with this Agreement, (b) hereby waives to the extent not prohibited by applicable Legal Requirements, and agrees not to assert, by way of motion, as defense or otherwise, in any such Action, any claim that it
is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such Action brought in one of the above-named courts should be dismissed on grounds of forum non
conveniens, should be transferred or removed to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this
Agreement or the subject matter hereof may not be enforced in or by such court and (c) hereby agrees not to commence any such Action other than before one of the above-named courts. Notwithstanding the previous sentence, party may commence any
Action in court other than the above-named courts solely for the purpose of enforcing an order or judgment issued by one of the above-named courts. 

  
 -53-

 12.12.2. Venue. Each party waives any claim and shall not assert that venue should
properly lie in any other location within the selected jurisdiction. 
 12.12.3. Service of Process. Each party hereby
(a) consents to service of process in any Action between the parties arising in whole or in part under or in connection with this Agreement in any manner permitted by New York Legal Requirements, (b) agrees that service of process made in
accordance with clause (a) or made by registered or certified mail, return receipt requested, at its address specified pursuant to Section 12.1, shall constitute good and valid service of process in any such Action and
(c) waives and agrees not to assert (by way of motion, as a defense, or otherwise) in any such Action any claim that service of process made in accordance with clause (a) or (b) does not constitute good and valid service of process.

 12.12.4. Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LEGAL REQUIREMENTS THAT CANNOT BE WAIVED,
THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY SHALL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE
CONTEMPLATED TRANSACTIONS, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING,
VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR ANY OF THE CONTEMPLATED TRANSACTIONS, AND SUCH PROCEEDING SHALL INSTEAD
BE TRIED IN COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT JURY. 
 [The remainder of this is page intentionally
blank] 

  
 -54-

 IN WITNESS WHEREOF, each of the undersigned has executed this Agreement as an agreement
under seal as of the Execution Date. 
  

					
	“BUYER”
	
	DURATA THERAPEUTICS, INC
		
	By:	 	 /s/ Dov. A. Goldstein

		 	Name:	 	Dov A. Goldstein
		 	Title:	 	Interim Co-President
		
	By:	 	 /s/ Ronald M. Hunt

		 	Name:	 	Ronald M. Hunt
		 	Title:	 	Interim Co-President
	
	“SELLER”
	
	PFIZER
		
	By:	 	 /s/ William Ringo

		 	Name:	 	William Ringo
		 	Title:	 	SVP, Worldwide Business Development, Strategy & Innovation

 EXHIBIT 1(A) 

EXCLUDED ASSETS 
  

	1.	All intellectual property owned or licensed by the Company relating to any research program, compound, drug, drug candidate or product other than the Product or the
Residual Assets, including [**] (collectively, the “Excluded Products”), including (A) the Patents set forth on Attachment 1 and (B) the trademarks, trade names and service marks set forth on
Attachment 2, together with the goodwill associated therewith; 

  

	2.	all know how relating to any Excluded Product, including all ideas, inventions, data (including clinical data), instructions, processes, formulas, formulation
information, SAR information, algorithms, assays, validations, package specifications, chemical specifications, chemical and finished goods analytical test methods, stability data, testing data, product specifications, information with respect to
expert opinion and information (whether or not patented or patentable) and technology owned or controlled by the Company or under which the Company has the right to grant sublicenses, as of the date of this Agreement, including all biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information related thereto and all correspondence with the FDA or other similar Governmental Authority
and all other documents pertaining to communications with the FDA or other similar Governmental Authority (including minutes of any FDA communications and applications for any regulatory approval of the Excluded Products, if any);

  

	3.	all knockout and transgenic mice and other animal models, cell lines, non-clinical and clinical tissue samples, microbial isolates, cDNA, genes, plasmids, constructs,
vectors, receptors, antibodies, and other proteins, crystals, compounds, solutions, formulations, bulk chemical materials, reference standards and other biological and chemical materials possessed by the Company as of the Effective Date that were
used at any time on or prior to the Effective Date (collectively, “Biological and Chemical Materials”) that are directly or indirectly related to any Excluded Product; 

 

	4.	all Contractual Obligations relating directly or indirectly to any Excluded Product, including those set forth on Attachment 3; 

 

	5.	all inventory of any Excluded Product including all intermediates, reference standards, cell lines, starting materials, filters and resins related to the manufacture
thereof; 

  

	6.	all customer and vendor lists relating directly to the Excluded Products; 

  

	7.	all books and records (including regulatory files) relating directly to the Excluded Products; 

	8.	all rights under or pursuant to all representations, warranties and guarantees or otherwise against manufacturers to the extent (A) relating to any Excluded Asset,
including any Excluded Products, and (B) transferable; 

  

	9.	all advertising, marketing, sales, product literature, promotional materials and data and all training materials in whatever medium (e.g., audio, visual, print or
electronic), in each case relating to the Excluded Products; 

  

	10.	all Governmental Authorizations relating to any Excluded Product, including those set forth on Attachment 4;  

 

	11.	all cash, cash equivalents, accounts receivable and notes receivable of the Company of any nature existing on the Closing Date; 

 

	12.	any stock, partnership interests, membership interests or other equity interests or other securities of any other Person owned directly or indirectly by the Company;
and 

  

	13.	the “Pfizer” name and logos. 

  
 - 2 -

 ATTACHMENT 1 TO EXHIBIT 1(A) 

 

	1.	List of [**] Patents attached. 

  

	2.	List of those Patents associated with [**]. 

  

	3.	List of [**] Patents attached. 

  
 3 

					
		 		 	Exhibit 1(a) – Excluded Assets
		 		 	Attachment 1 (patents)
	Pfizer Patent Department	 	Patent Family Report	 	[**] Patents

  

																											
	Family #	 	[**]	 	Operating Unit	 	[**]
	FormerDkt	 	[**]	 	Business Unit	 	
	Attorney	 	[**]	 	2nd Operating Unit	 	
	Resp Site	 	[**]	 	Assignee	 	[**]
	Title	 	[**]	 	First Filed Date	 	[**]
	 Inventors
	 	[**]
													
	 Docket#
	 	 Country
	 	 App. No.
	 	 App. Dt
	 	 Pat. No.
	 	 Grant Dt.
	 	 Exp. Dt
	 	 Status.
	 	 Sub Status
	 	 Case Type.
	 	 Relation Type.
	 	 Filing Type
	 	 Filing #

	[**]	 	[**]	 		 		 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

  

					
	Monday, July 27, 2009	 	Pfizer Inernal Use	 	Page 1 of 1

  

 Exhibit 1(a) – Excluded Assets 

Attachment 1 (patents) 
 Novartis Patents 
 [**] 

 

															
	 Applicant/Owner
	 	 Novartis Ref.
	 	 McCarter Ref.
	 	 Country
	 	 Appln. No.
	 	 Filing Date
	 	 Title
	 	 Status

Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total
of 13 pages were omitted. 
 [**] 

  
 1 

 Exhibit 1(a) – Excluded Assets 

Attachment 1 (patents) 
 [**] Patents 
  

																									
	 Docket
No
	  	Country	 	  	Application No.	 	 	Application Date	 	  	Patent No	  	Grant Date	  	Expiration
Date	  	Sub Status	 	  	 Legacy Code

									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	 	 	[**]	  	  		  		  		  	 	[**]	  	  	[**]

  
 2 

 Exhibit 1(a) – Excluded Assets 

Attachment 1 (patents) 
 [**] Patents 
  

																											
	 Docket
No
	  	Country	 	  	Application No.	 	  	Application Date	 	  	Patent No	  	Grant Date	  	Expiration
Date	 	  	Sub Status	 	  	 Legacy Code

									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  	 	[**]	  	  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  				  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  				  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  				  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  				  	 	[**]	  	  	[**]
									
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  		  		  				  	 	[**]	  	  	[**]

  
 3 

 ATTACHMENT 2 TO EXHIBIT 1(A) 

SEE ATTACHED. 

  
 4 

 Exhibit 1(a) – Excluded Assets 

Attachment 2 (trademarks) 
 Active Trademarks 
  

																											
	 TMID
	  	 Country
	  	Mark	  	Owner	  	Generic	  	Class	  	App. No.	  	App. Date	  	Reg. No.	  	Reg. Date	  	Renewal Date	  	Status	  	SubStatus	  	Remarks

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total of 19 pages were omitted. 

[**] 

  
 5 

 Exhibit 1(a) – Excluded Assets 

Attachment 2 (trademarks) 
 Inactive Trademarks 
  

																											
	 TMID
	  	 Country
	  	Mark	  	Owner	  	Class	  	Generic	  	App. No.	  	App. Date	  	Reg. No.	  	Reg. Date	  	Renewal Date	  	Status	  	SubStatus	  	Remarks

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total of 5 pages were omitted. 

[**] 

  
 6 

 ATTACHMENT 3 TO EXHIBIT 1 (A) 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total
of 5 pages were omitted. 
 [**] 

  
 7 

 ATTACHMENT 4 TO EXHIBIT 1 (A) 

[**] 
 [**] 

[**] 
 [**] 

[**] 
 [**] 

  
 8 

 EXHIBIT 1(B) 
 EXCLUDED LIABILITIES 
 [**] 
 [**] 

  
 9 

 EXHIBIT 1(C) 
 INCLUDED ASSETS 
  

	1.	All intellectual property owned or licensed by the Company relating directly to the Product or the Residual Assets including (A) the Patents set forth on
Attachment 1, and (B) the trademarks, trade names, service marks and domain names set forth on Attachment 2, together with the goodwill associated therewith; 

 

	2.	all know how relating to any Product or any Residual Assets, including all ideas, inventions, data (including clinical data), instructions, processes, formulas,
formulation information, validations, package specifications, chemical specifications, chemical and finished goods analytical test methods, stability data, testing data, product specifications, information with respect to expert opinion and
information (whether or not patented or patentable) and technology owned or controlled by the Company or under which the Company has the right to grant sublicenses, as of the date of this Agreement, including all biological, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information related thereto and all correspondence with the FDA or other similar Governmental Authority and all
other documents pertaining to communications with the FDA or other similar Governmental Authority (including minutes of any FDA communications and applications for any regulatory approval of the Products, if any); 

 

	3.	all Contractual Obligations relating directly to any Product or any Residual Asset and accruing from and after the Closing Date, including those forth on
Attachment 3; 

  

	4.	all inventory of the Product, including all intermediates, reference standards, cell lines, starting materials, filters and resins related directly to the manufacture
thereof; 

  

	5.	all Governmental Authorizations relating to the Product or any Residual Asset, including those set forth on Attachment 4; 

 

	6.	all books and records (including regulatory files) relating directly to the Product and the Residual Assets; and 

 

	7.	all rights under or pursuant to all representations, warranties and guarantees or otherwise against manufacturers to the extent relating to any Included Asset,
including the Product or any Residual Asset. 

  
 10 

 Attachment 1 To Exhibit 1(C) 

SEE ATTACHED 

  
 11 

 Exhibit 1 (c) - Included Assets 

Attachment 1 (patents) 
 Lincomycin Patents 
  

															
	 Docket Number
	  	Country	  	Application Number	  	Application Date	  	Patent Number	  	Expiration Date	  	Status	  	Current Owner

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total of 1 page was omitted. 

[**] 

  
 12 

 Exhibit 1 (c) - Included Assets 

Attachment 1 (patents) 
 Lincomycin Patents 
  

 DALBAVANCIN PATENT PORTFOLIO 
 Compound Patent 
  

															
	 Docket Number
	  	Country	  	Application Number	  	Application Date	  	Patent Number	  	Expiration Date	  	Status	  	Current Owner

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. A total of 1 page was omitted. 

[**] 
 Intermediate Patent 

 

															
	[**]	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

 Dosing Regimen/Formulation Patent 

 

																													
	 Docket Number
	  	Country	 	 	Application Number	 	 	Application Date	 	 	Patent Number	 	 	Expiration Date	 	 	Status	 	 	Current Owner	 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 

 Formulation Patent 
  

																													
	 Docket Number
	  	Country	 	 	Application Number	 	 	Application Date	 	 	Patent Number	 	 	Expiration Date	 	 	Status	 	 	Current Owner	 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 

  
 13 

 Exhibit 1 (c) - Included Assets 

Attachment 1 (patents) 
 Lincomycin Patents 
  

																													
	 Docket Number
	  	Country	 	 	Application Number	 	 	Application Date	 	 	Patent Number	 	 	Expiration Date	 	 	Status	 	 	Current Owner	 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 				 				 	 	[	**] 	 	 	[	**] 

 Genes for Biosynthesis 
  

																									
	 Docket Number
	  	Country	 	 	Application Number	 	 	Application Date	 	 	Patent Number	  	Expiration Date	  	Status	 	 	Current Owner	 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 		  		  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 		  		  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 		  		  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 		  		  	 	[	**] 	 	 	[	**] 

 Intermediate Patent 
  

																													
	 Docket Number
	  	Country	 	 	Application Number	 	 	Application Date	 	 	Patent Number	 	 	Expiration Date	 	 	Status	 	 	Current Owner	 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 	 	 	[	**] 

  
 14 

 Exhibit 1 (c) - Included Assets 

Attachment 1 (patents) 
 Lincomycin Patents 
  

																													
	 Docket Number
	  	Country	 	  	Application Number	 	  	Application Date	 	  	Patent Number	 	  	Expiration Date	 	  	Status	 	  	Current Owner	 
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
		  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  

 Intermediate Patent 
  

																													
	 Docket Number
	  	Country	 	  	Application Number	 	  	Application Date	 	  	Patent Number	 	  	Expiration Date	 	  	Status	 	  	Current Owner	 
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  

 Process Patent 
  

																													
	 Docket Number
	  	Country	 	  	Application Number	 	  	Application Date	 	  	Patent Number	 	  	Expiration Date	 	  	Status	 	  	Current Owner	 
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  

  
 15 

 Attachment 2 To Exhibit 1(C) 

SEE ATTACHED 

  
 16 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	 	Country	 	 Mark
	 	Owner	 	 Generic
	 	Class	 	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	 	Albania	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Albania	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Albania	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Algeria	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Algeria	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	[**]
	 [**]
	 	Algeria	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Antigua	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Antigua	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	
	 [**]
	 	Antigua	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Argentina	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Argentina	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Argentina	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Armenia	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Armenia	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Armenia	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Aruba	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Aruba	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Aruba	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Australia	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Australia	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Australia	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Azerbaijan	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Azerbaijan	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Azerbaijan	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bahamas	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bahamas	 	EXULETT	 	[**]	 	DALBAVANCIN	 	3	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bahamas	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bahrain	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bahrain	 	EXULETT	 	[**]	 	DALEAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bahrain	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bangladesh	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bangladesh	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	 	Barbados	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Barbados	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 		 		 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Barbados	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 		 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Belarus	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Belarus	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Belarus	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Belize	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Belize	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Belize	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bermuda	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bermuda	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Bermuda	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bolivia	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Bolivia	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bolivia	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bosnia-
Herzegovina	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Bosnia-
Herzegovina	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]

  
 17 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	 	 Country
	 	Mark	 	Owner	 	 Generic
	 	Class	 	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	 	Bosnia-Herzegovina	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Brazil	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Brazil	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	Brazil	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	British Virgin Islands	 	EXULETT	 	[**]	 	DALBAVANCIN	 	3	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bulgaria	 	EXULET	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Bulgaria	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Canada	 	DALBAK	 	[**]	 	DALBAVANCIN	 		 	[**]	 	[**]	 		 		 		 	[**]	 		 	
	 [**]
	 	Canada	 	EXULET	 	[**]	 	DALBAVANCIN	 		 	[**]	 	[**]	 		 		 		 	[**]	 		 	
	 [**]
	 	Canada	 	EXULETT	 	[**]	 	DALBAVANCIN	 		 	[**]	 	[**]	 		 		 		 	[**]	 		 	
	 [**]
	 	Canada	 	ZEVEN	 	[**]	 	DALBAVANCIN	 		 	[**]	 	[**]	 		 		 		 	[**]	 		 	
	 [**]
	 	Cayman Islands	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Cayman Islands	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	 	Chile	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Chile	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Chile	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	China P.R.	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	China P.R.	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	 	China P.R.	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	China P.R.	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Colombia	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Colombia	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	EXULET	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	EXULET	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	V DESIGN
(VICURON)	 	[**]	 	n/a	 	5,42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	VIMA	 	[**]	 	n/a	 	40, 42,
44	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Community Trademark	 	VIMA
MANUFACTURING	 	[**]	 	n/a	 	40, 42,
44	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Costa Rica	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Costa Rica	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Costa Rica	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Croatia	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Croatia	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Croatia	 	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Cuba	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Cuba	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 		 		 		 	[**]	 		 	
	 [**]
	 	Dominican Republic	 	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	 	Dominican Republic	 	EXULETT	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 18 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	  	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Dominican
Republic	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ecuador	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ecuador	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ecuador	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Egypt	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Egypt	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Egypt	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	El Salvador	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	El Salvador	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	El Salvador	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ethiopia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Ethiopia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Ethiopia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Gambia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Gambia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Gambia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Georgia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Georgia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Georgia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ghana	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Ghana	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	Ghana	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Great Britain	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Guatemala	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Guatemala	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Guatemala	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Guyana	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Guyana	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Guyana	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Haiti	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Haiti	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Haiti	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Honduras	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Honduras	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Hong Kong	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Hong Kong	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Hong Kong	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Iceland	  	EXULET	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Iceland	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	India	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	India	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	India	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Indonesia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Indonesia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[	 	[**]
	 [**]
	  	Indonesia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Iran	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Iran	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Israel	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Israel	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Israel	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Jamaica	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 19 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	 	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Jamaica	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Jamaica	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	S	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	DALEAK
(da-ru-ba-ku)
with katakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	ECVANTA	 	[**]	 	n/a	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	E-PACK	 	[**]	 	n/a	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULET	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULET
(i-gu-su-re tto)
with Katakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULET
 (i-ku-su-re-tto)
with Katakana
	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULETT
(i-gu-su-re-tto)
with Katakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	EXULETT
(i-ku-su-re-tto)
with Katakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	PEPTIZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	PEPTIZEVEN
(pe-pu-chi-ze-
be-n) with
<atakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	PEPTIZEVEN
(pe-3u-chi-ze-
bu-n) with
Katakana	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	VICURIN	 	[**]	 	n/a	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Japan	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Jordan	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Jordan	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Jordan	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kazakhstan	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kazakhstan	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Kazakhstan	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kenya	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kenya	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kenya	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kuwait	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	
	 [**]
	  	Kuwait	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	
	 [**]
	  	Kuwait	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	
	 [**]
	  	Kyrgyzstan	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kyrgyzstan	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Kyrgyzstan	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Lebanon	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Lebanon	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Lebanon	  	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Libya	  	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	[**]
	 [**]
	  	Libya	  	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	[**]

  
 20 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	  	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Libya	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 		 	[**]
	 [**]
	  	Macao	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Macao	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Macao	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Macedonia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Macedonia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Macedonia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Malaysia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Malaysia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Malaysia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Mexico	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Mexico	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Moldova	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Moldova	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 		 		 	[**]	 		 	[**]
	 [**]
	  	Moldova	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Monaco	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Monaco	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Monaco	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Montenegro	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Montenegro	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Morocco	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Morocco	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Morocco	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Myanmar	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 	
	 [**]
	  	Myanmar	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Myanmar	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 		 	[**]	 	[**]	 	
	 [**]
	  	Netherlands
Antilles	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Netherlands
Antilles	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Netherlands
Antilles	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	New
Zealand	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	New
Zealand	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	New
Zealand	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Nicaragua	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Nicaragua	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Nicaragua	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Nigeria	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	Nigeria	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Nigeria	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	Norway	  	EXULET	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Norway	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	O.A.P.I.	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	O.A.P.I.	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	O.A.P.I.	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Oman	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Oman	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Oman	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 21 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																																													
	 TMD
	 	Country	 	Mark	 	Owner	 	 	 Generic
	 	Class	 	App. No.	 	 	App. Date	 	 	Reg. No.	 	 	Reg. Date	 	 	Renewal Date	 	 	Status	 	 	SubStatus	 	 	Remarks	 
	 [**]
	 	Pakistan	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Pakistan	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 				 	 	[**]	  	 				 				 				 	 	[**]	  	 				 	 	[**]	  
	 [**]
	 	Pakistan	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Panama	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Panama	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Panama	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Paraguay	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Paraguay	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	3	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 				 			
	 [**]
	 	Paraguay	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 				 			
	 [**]
	 	Peru	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Peru	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Peru	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Philippines	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Philippines	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Puerto
Rico	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Puerto
Rico	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 				 			
	 [**]
	 	Puerto
Rico	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Qatar	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Qatar	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Qatar	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Romania	 	EXULET	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Romania	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Russian
Federation	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Russian
Federation	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Saudi
Arabia	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Saudi
Arabia	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Saudi
Arabia	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Serbia	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Serbia	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Serbia	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Singapore	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Singapore	 	EXULET	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Singapore	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	South
Africa	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  
	 [**]
	 	South
Africa	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  
	 [**]
	 	South
Africa	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	South
Korea	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	South
Korea	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	South
Korea	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Sri Lanka	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 				 	 	[**]	  
	 [**]
	 	Sri Lanka	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 				 	 	[**]	  
	 [**]
	 	Sri Lanka	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 				 	 	[**]	  
	 [**]
	 	St. Lucia	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	St. Lucia	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	St. Lucia	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	St. Vincent	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	St. Vincent	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Sudan	 	DALBAK	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			
	 [**]
	 	Sudan	 	EXULETT	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 				 				 				 	 	[**]	  	 	 	[**]	  	 	 	[**]	  
	 [**]
	 	Sudan	 	ZEVEN	 	 	[**]	  	 	DALBAVANCIN	 	5	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 	 	[**]	  	 			

  
 22 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	 	Mark	 	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Switzerland	 	EXULET	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Switzerland	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Syria	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Syria	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Syria	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	DALBAK IN
CHINESE
CHARACTERS
(ZHOU DA
KE)	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	DALBAK IN
CHINESE
CHARACTERS
(ZHOU DA
SU)	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	EXULETT IN
CHINESE
CHARACTERS
(ZHOU JUN
MIE)	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	VICURIN	 	[**]	 	n/a	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Taiwan	 	VICURON	 	[**]	 	n/a	  	42	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Taiwan	 	VICURON	 	[**]	 	n/a	  	3	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Taiwan	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Taiwan	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Taiwan	 	Zeven in
Chinese
Characters -
zhou-wen	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tajikistan	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tajikistan	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Tajikistan	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tanganyika
(Tanzania)	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tanganyika
(Tanzania)	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Tanganyika
(Tanzania)	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Thailand	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Thailand	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Thailand	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Trinidad &
Tobago	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Trinidad &
Tobago	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Trinidad &
Tobago	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tunisia	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Tunisia	 	EXULETT	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 		 	
	 [**]
	  	Tunisia	 	ZEVEN	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turkey	 	DALBAK	 	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 23 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	  	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Turkey	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turkey	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turkmenistan	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turkmenistan	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Turkmenistan	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turks &
Caicos	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turks &
Caicos	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Turks &
Caicos	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uganda	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uganda	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uganda	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ukraine	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ukraine	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Ukraine	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United Arab
Emirates	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United Arab
Emirates	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United Arab
Emirates	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United States	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United States	  	EXULET	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United States	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	United States	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	United States	  	ZEVEN
DOUBLE
SWOOSH
DESIGN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	Uruguay	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uruguay	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uruguay	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uzbekistan	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uzbekistan	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Uzbekistan	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Venezuela	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Venezuela	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Venezuela	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 		 	[**]
	 [**]
	  	Vietnam	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Vietnam	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zambia	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zambia	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
	 [**]
	  	Zambia	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 24 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Active Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	  	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Zanzibar	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zanzibar	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zanzibar	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zimbabwe	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zimbabwe	  	EXULETT	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	
	 [**]
	  	Zimbabwe	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

  
 25 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Inactive Trademarks 
  

																											
	 TMD
	 	Country	  	Mark	 	Owner	 	 Generic
	 	Class	 	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	 	Antigua	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Argentina	  	DALBA	 	[**]	 	DALBAVANC1N	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Armenia	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Aruba	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Australia	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Belize	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Bermuda	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Bulgaria	  	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Bulgaria	  	PEPTIZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	China PR.	  	VICURON	 	[**]	 	n/a	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	China P.R.	  	VICURON	 	[**]	 	nla	 	42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	China P.R.	  	V1IVEN	 	[**]	 	n/a	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	China P.R.	  	VOSEVRA	 	[**]	 	n/a	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Colombia	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Community
Trademark	  	VICURIN	 	[**]	 	n/a	 	5,
 42
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Community
Trademark	  	VICURON	 	[**]	 	n/a	 	40,
 44
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Community
Trademark	  	VICURON	 	[**]	 	n/a	 	5,
42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Community
Trademark	  	VICURON
PHARMACEUTICALS
VITAL MEDICINE
FOR SERIOUSLY ILL
PATIENTS	 	[**]	 	n/a	 	5,
42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Community
Trademark	  	VICURON
PHARMACEUTICALS
VITAL MEDICINE
FOR SERIOUSLY ILL
PATIENTS & design	 	[**]	 	n/a	 	5,
42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Costa Rica	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Croatia	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Cuba	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Dominican
Republic	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	El Salvador	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Ethiopia	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Great
Britain	  	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Great
Britain	  	ZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Guatemala	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Haiti	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Honduras	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Hong Kong	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Iceland	  	DALBAK	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Iceland	  	PEPTIZEVEN	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Iran	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Israel	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Jamaica	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Japan	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Japan	  	VICURON	 	[**]	 	n/a	 	5,
42	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Jordan	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	Kenya	  	DALBA	 	[**]	 	DALBAVANCIN	 	5	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

  
 26 

 Exhibit 1(C) - Included Assets 

Attachment 2 (trademarks and domain names) 
 Inactive Trademarks 
  

																											
	 TMD
	  	Country	  	Mark	  	Owner	 	 Generic
	  	Class	  	App. No.	 	App. Date	 	Reg. No.	 	Reg. Date	 	Renewal
Date	 	Status	 	SubStatus	 	Remarks
	 [**]
	  	Lebanon	  	DALBA	  	[**]	 	Dalbavancin	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Macao	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Malaysia	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Monaco	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Morocco	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Netherlands
Antilles	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	New
Zealand	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Nicaragua	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Norway	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Norway	  	PEPTIZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	D.A.P.I.	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Peru	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Puerto Rico	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Romania	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Russian
Federation	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Saudi
Arabia	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Serbia	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Singapore	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	St. Lucia	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Switzerland	  	DALBAK	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Switzerland	  	PEPTIZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Switzerland	  	ZEVEN	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Syria	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Taiwan	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Taiwan	  	VIIVEN	  	[**]	 	n/a	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Thailand	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Trinidad &
Tobago	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Turkey	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Turks &
Caicos	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Uganda	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	United
Arab
Emirates	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Uruguay	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Uzbekistan	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	Venezuela	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 		 		 		 	[**]	 	[**]	 	[**]
		  		  		  		 		  		  		 		 		 		 		 		 		 	
	 [**]
	  	Zanzibar	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 		 		 		 		 	[**]	 	[**]	 	[**]
		  		  		  		 		  		  		 		 		 		 		 		 		 	
	 [**]
	  	Zimbabwe	  	DALBA	  	[**]	 	DALBAVANCIN	  	5	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

  
 27 

					
	 Domain Name
	  	Owner	 	Remarks
	 vicuron.com
	  	[**]	 	
	 vicuron.net
	  	[**]	 	
	 vicuron.info
	  	[**]	 	[**]
	 vicuron.it
	  	[**]	 	
	 vicuronpharmaceuticals.com
	  	[**]	 	
	 dalbavancin.com
	  	[**]	 	
	 dalbavancin.info
	  	[**]	 	[**]
	 dalbavancin.eu
	  	[**]	 	
	 dalbavancin.de
	  	[**]	 	[**]
	 dalba.com
	  	[**]	 	
	 dalba.net
	  	[**]	 	
	 dalbak.com
	  	[**]	 	
	 dalbak.net
	  	[**]	 	
	 dalbak.info
	  	[**]	 	[**]
	 exulet.com
	  	[**]	 	
	 exulet.net
	  	[**]	 	
	 exu let. info
	  	[**]	 	[**]
	 exulet.eu
	  	[**]	 	
	 exulett.com
	  	[**]	 	
	 exulett.net
	  	[**]	 	
	 exu lett. info
	  	[**]	 	[**]
	 exulett.eu
	  	[**]	 	
	 exulett.de
	  	[**]	 	[**]
	 peptizeven.com
	  	[**]	 	
	 peptizeven.net
	  	[**]	 	
	 peptizeven.info
	  	[**]	 	[**]
	 peptizeven.eu
	  	[**]	 	
	 prizeven.net
	  	[**]	 	
	 prizeven.info
	  	[**]	 	
	 prizeven.eu
	  	[**]	 	
	 zeven.mobi
	  	[**]	 	
	 aboutzeven.com
	  	[**]	 	
	 aboutzeven.net
	  	[**]	 	
	 aboutzeven.info
	  	[**]	 	[**]
	 arazeven.com
	  	[**]	 	
	 arazeven.net
	  	[**]	 	
	 arazeven.info
	  	[**]	 	[**]
	 falzeven.com
	  	[**]	 	
	 falzeven.net
	  	[**]	 	
	 falzeven.info
	  	[**]	 	[**]
	 falzeven.eu
	  	[**]	 	
	 zevenclinical.com
	  	[**]	 	

  
 28 

					
	 Domain Name
	  	Owner	 	Remarks
	 zevenclinical.net
	  	[**]	 	
	 zevenclinical.info
	  	[**]	 	[**]
	 zevenhcp.com
	  	[**]	 	
	 zevenhcp.net
	  	[**]	 	
	 zevenhcp.info
	  	[**]	 	[**]
	 zeveninfo.com
	  	[**]	 	
	 zeveninfo.net
	  	[**]	 	
	 zeveninfo.info
	  	[**]	 	[**]
	 zeveninject.com
	  	[**]	 	
	 zeveninject.net
	  	[**]	 	
	 zeveninject.info
	  	[**]	 	[**]
	 zeveniv.com
	  	[**]	 	
	 zeveniv.net
	  	[**]	 	
	 zeveniv.info
	  	[**]	 	[**]
	 zevenmd.com
	  	[**]	 	
	 zevenmd.net
	  	[**]	 	
	 zevenmd.info
	  	[**]	 	[**]
	 zevensite.com
	  	[**]	 	
	 zevensite.net
	  	[**]	 	
	 zevensite.info
	  	[**]	 	[**]
	 zeventherapy.com
	  	[**]	 	
	 zeventherapy.net
	  	[**]	 	
	 zeventherapy.info
	  	[**]	 	[**]

  
 29 

 Attachment 3 To Exhibit 1 (C) 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. A total of 11 pages were omitted. 
 [**] 

  
 30 

 Attachment 4 To Exhibit 1(C) 

 

	1.	The following New Drug/Marketing Authorization Applications, which have been withdrawn: 

 

									
	 Country
	  	Application	 	Strength	 	Submission
Date	 	Withdrawal
Date
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]	 	[**]

  

	2.	The following IND: 

  

					
	 Country
	  	Application	 	Submission
Date
	 [**]
	  	[**]	 	[**]

  
 31 

 Exhibit 1(D) 

INCLUDED LIABILITIES 
  

	1.	Liabilities that have accrued from and after the Closing Date under Company Contracts. 

  
 32 

 Execution Version 

INVENTORY TRANSFER AGREEMENT 
 THIS INVENTORY TRANSFER AGREEMENT (this “Agreement”) is entered into as of December 18, 2009, by and among (i) Pfizer Overseas LLC (“POLLC”),
(ii) Pfizer Inc. (“Pfizer”), and (iii) Durata Therapeutics, Inc., a Delaware corporation (“Durata”). 
 RECITALS 
 WHEREAS, Durata has entered into a Stock Purchase Agreement with Pfizer
Inc. (“Pfizer”), the parent company of POLLC (the “Stock Purchase Agreement”); 
 WHEREAS,
POLLC has agreed to assign to Durata the Assigned Assets and the MA Assets (defined below); 
 WHEREAS, in connection with the
transaction contemplated by the Stock Purchase Agreement, Pfizer or an affiliate of Pfizer will become a party to that certain Manufacturing and Supply Agreement dated December 1, 2006 between originally Biosearch Manufacturing Srl (predecessor
in interest to Pfizer or such affiliate) and Sanofi-Aventis S.p.A. (the “Supply Agreement”); 
 WHEREAS, Pfizer
anticipates that it will, on a date after the Closing Date, receive and take title to the MA Assets (as defined below) under the Supply Agreement, and Pfizer desires that the MA Assets be transferred at such time to Durata. 

NOW, THEREFORE, in consideration of the foregoing recitals, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows: 
  

	1.	DEFINITIONS 

  

	 	1.1.	“Agreement” is defined in the introduction to this Agreement. 

 

	 	1.2.	“Assigned Assets” means (i) the inventory of active pharmaceutical ingredient for the Product owned by POLLC and (ii) the Product related
inventory, including references standards, cell lines, intermediates, starting and purification materials, such as resins for the production of the Product, in each of (i) and (ii), as identified in Exhibit 1. 

 

	 	1.3.	“Closing Date” shall have the meaning ascribed to such phrase in the Stock Purchase Agreement.” 

 

	 	1.4.	“Durata” is defined in the introduction to this Agreement. 

  
 33 

	 	1.5.	“MA Assets” means the Product related intermediates as identified in Exhibit 2. 

 

	 	1.6.	“POLLC” is defined in the introduction to this Agreement. 

 

	 	1.7.	“Pfizer” is defined in the introduction to this Agreement. 

 

	 	1.8.	“Product” means all pharmaceutical formulations and dosage forms of dalbavancin or any salt, prodrug, hydrate, solvate, metabolite, or polymorph form
of dalbavancin. 

  

	 	1.9.	“Purchase Price” means [**] Dollars ($[**]). 

  

	 	1.10.	“Stock Purchase Agreement” is defined in the introduction to this Agreement. 

 

	 	1.11.	“Supply Agreement” is defined in the introduction to this Agreement. 

 

	2.	ASSIGNMENT OF ASSETS AND AGREEMENTS AND ASSUMPTION OF LIABILITIES 

  

	 	2.1.	Conveyance and Assignment of Assets. On the Closing Date, POLLC hereby conveys, assigns, transfers and delivers to Durata and its successors and assigns,
FOREVER, all of POLLC’s right, title and interest in, to and under the Assigned Assets. 

  

	 	2.2.	Covenant to Convey and Assign the MA Assets. In the event Pfizer (or an affiliate of Pfizer) receives and takes title to the MA Assets under the Supply
Agreement, Pfizer will and hereby does (or will cause such affiliate to) convey, assign, transfer and deliver to Durata and its successors and assigns, FOREVER, all of Pfizers (or such affiliate’s) right, title and interest in, to and under the
MA Assets. 

  

	 	2.3.	Consideration. On the Closing Date, subject to the respective parties performance under the Stock Purchase Agreement, Durata shall deliver to POLLC the Purchase
Price by wire transfer of immediately available federal funds to the following account: 

 [**] 

  
 34 

	3.	GENERAL PROVISIONS 

  

	 	3.1.	Further Assurance. The parties shall cooperate with one another and use their respective reasonable efforts to consummate the assignment, contribution and
transfer of the Assigned Assets and the MA Assets to Durata, all as provided herein. In furtherance of the foregoing, each party will use reasonable efforts to take, or cause to be taken, such actions and to do, or cause to be done, such things as
are reasonably necessary or reasonably desirable under this Agreement and applicable law to consummate the transactions contemplated by this Agreement, including to assign, contribute and transfer the Assigned Assets and the MA Assets to Durata.
Without limiting the generality of the foregoing, all parties agree to execute and deliver such agreements, certificates, consents, assurances, powers of attorney, instruments and other documentation, and to take such other actions, as may be
reasonably necessary or reasonably desirable in order to implement and effect the intents and purposes of this Agreement. 

  

	 	3.2.	Attorney-in-Fact. POLLC hereby constitutes and appoints Durata, its successors and permitted assigns, the true and lawful attorney of POLLC, with full power of
substitution in the names and stead of POLLC, but on behalf of and for the benefit of Durata, its successors and permitted assigns, to demand and receive any and all of the Assigned Assets and MA Assets which are hereby assigned, conveyed and
transferred, or are intended so to be, and which are not in the possession or under the exclusive control of POLLC, to give receipts and releases for and in respect of the same, or any part thereof, and to do all acts and things in relation to the
above-mentioned property which Durata, its successors and assigns, shall deem reasonably desirable. POLLC hereby declares that the foregoing powers are coupled with an interest and are and shall be irrevocable, whether by POLLC or by reason of
POLLC’s dissolution or in any matter or for any reason whatsoever. 

  

	 	3.3.	Disclaimer. EACH PARTY MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OTHER THAN THOSE EXPRESSLY MADE IN THIS AGREEMENT, THE STOCK PURCHASE
AGREEMENT OR THE TRANSITION SERVICES AGREEMENT. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED. 

 

	 	3.4.	Disputes. In the event of a dispute arising under this Agreement that cannot be resolved by the parties, such dispute will be settled by Pfizer, on behalf of
POLLC, and Durata under the dispute resolution provisions of the Stock Purchase Agreement. 

  
 35 

	 	3.5.	Governing Law. This Agreement shall be governed by, and construed and enforced under, the laws of the State of New York, without giving effect to conflicts or
choice of law principles. 

  

	 	3.6.	Entire Agreement. This Agreement sets forth the entire agreement and understanding among the parties with respect to the subject matter hereof, and supersedes
any and all prior oral or written (and any contemporaneous oral) agreements, understandings or arrangements relating thereto. 

  

	 	3.7.	Amendments and Waivers. This Agreement may be amended by a writing signed by the parties. No right or power of a party shall be deemed to have been waived by any
act or conduct of such party unless such party expressly waives such right or power in a writing signed by such party. 

  

	 	3.8.	Construction; Interpretation. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. All recital, section, schedule and party references are to this Agreement unless otherwise stated. No party, nor its counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions
of this Agreement, and all provisions of this Agreement shall be construed in accordance with their fair meaning, and not strictly for or against any party. Except as otherwise explicitly specified in this Agreement to the contrary, the word
“including” shall be construed as “including, without limitation.” 

  

	 	3.9.	Severability. If any provision of this Agreement shall be held to be prohibited, unenforceable or invalid by any court of competent jurisdiction, such provision
shall be ineffective only to the extent of such prohibition, unenforceability or invalidity without invalidating the remainder of such provision or the remaining provisions hereof, or without affecting the validity or enforceability of such
provision in any other jurisdiction. 

  

	 	3.10.	Assignment. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of POLLC and Durata. Either party’s
rights and obligations under this Agreement may be assigned and delegated without the consent of the other party provided the transferor or assignor guarantees the performance of the transferee or assignee. 

 

	 	3.11.	Counterparts. This Agreement may be executed in facsimile and in any number of counterparts, each of which shall be deemed to be an original and all of which,
taken together, shall be deemed to be one and the same instrument. 

  
 36 

	 	3.12.	Third Party Beneficiaries. Nothing herein expressed or implied is intended or shall be construed to confer upon or give to any person or entity, other than the
parties to this Agreement and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement. 

  

	 	3.13.	Guarantee. Pfizer guarantees the obligations of POLLC under this Agreement. 

 

	 	3.14.	Expenses. Subject to the Transition Services Agreement, each party hereto shall bear its own legal and other expenses in connection with this Agreement.

  

	 	3.15.	Notices. All notices, requests, demands, claims and other communications required or permitted to be delivered, given or otherwise provided under this Agreement
must be in writing and must be delivered, given or otherwise provided: 

  

	 	(a)	by hand (in which case, it shall be effective upon delivery); 

  

	 	(b)	by facsimile (in which case, it shall be effective upon receipt of confirmation of good transmission); or 

 

	 	(c)	by overnight delivery by a nationally recognized courier service (in which case, it shall be effective on the Business Day after being deposited with such courier
service); 

 in each case, to the address (or facsimile number) listed below: 

If to the Durata, to it at: 
 Durata Therapeutics, Inc. 
 Times Square Tower 

7 times Square, Suite 1603 
 Facsimile number: (646) 519-2782 
 Attention: Mr. Ron M. Hunt

 with a copy to: 
 O’Melveny & Myers LLP 
 2 Embarcadero Center,
28th Floor 

San Francisco, CA 94111 
 Facsimile number: (415) 984-8701 
 Attention: Peter T. Healy, Esq.

  
 37 

 If to the Pfizer or POLLC, to it at: 

Pfizer Inc. 

234 East 42nd Street 
 New York, NY 10017 
 Facsimile number: (212) 573-0768 

Attention: Senior Vice President and General Counsel 
 with a copy to: 
 Ropes & Gray LLP 

One International Place 
 Boston, MA 02110 
 Facsimile number: (617) 235-0223 

Attention: Steven A. Wilcox, Esq. 
 Each of the parties to this Agreement may specify a different address or facsimile number by giving notice in accordance with this Section 3.14 to each of the other parties hereto. 

[SIGNATURE PAGES TO FOLLOW] 

  
 38 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Closing Date.

  

			
	 “POLLC”

PFIZER OVERSEAS LLC

		
	By:	 	 /s/ GP Moore

	Name:	 	Geoffrey P. Moore
	Title:	 	Vice President
	
	 “Durata”

DURATA THERAPEUTICS, INC.

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	 “Pfizer”

PFIZER INC.

		
	By:	 	 /s/ David Reid

	Its:	 	Assistant Secretary

  
 39 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Closing Date.

  

			
	 “POLLC”

PFIZER OVERSEAS LLC

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	 “Durata”

DURATA THERAPEUTICS, INC.

		
	By:	 	 /s/ Ronald M. Hunt

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President
	
	 “Pfizer”

PFIZER INC.

		
	By:	 	  

	Its:	 	

  
 40 

 EXHIBIT 1 
 ASSIGNED ASSETS 
 [**] Inventory November 20th, 2009 

 

									
	 Description
	  	UoM	 	 	Quantity	 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 
	 [**]
	  	 	[	**] 	 	 	[	**] 

  
 41 

 EXHIBIT 2 
 MA ASSETS 
  

							
	 “MA” RESIDUAL AMOUNT IN [**] WAREHOUSE

	 Lot No.
	  	GM
Powder	 	ASSAY
%	 	GMA
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
	 [**]
	  	[**]	 	[**]	 	[**]
		  	 Total in Inventory
	 	[**]

  
 42 

 EXHIBIT 1(f) 
 Pleuromutilin Structure 
 [**] 

  
 43 

 Execution Version 
 ASSIGNMENT AGREEMENT 
 THIS ASSIGNMENT AGREEMENT (this
“Agreement”), is entered into as of December 18, 2009 (the “Effective Date”) by and between Durata Therapeutics, Inc., a Delaware corporation (“Durata”), and Pfizer Inc., a Delaware corporation
(“Pfizer”). 
 WHEREAS, Pfizer is a party to that certain Dalbavancin Marketing Rights Agreement (the
“RaQualia Agreement”) between Pfizer and RaQualia Pharma Inc. (“RaQualia”), dated as of July 30, 2008, under which Pfizer granted to RaQualia certain licenses and other commercial rights in and to the Product
(as such term is defined in the RaQualia Agreement) known as “dalbavancin” (the “Product”). 

WHEREAS, Pfizer and Durata have entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) and intend the
closing of such Stock Purchase Agreement to occur concurrently with the execution of this Agreement, pursuant to which Durata will purchase from Pfizer all of the stock of Vicuron Pharmaceuticals Inc., thereby acquiring all of Vicuron’s rights
and assets relating to the Product as more particularly set forth in the Stock Purchase Agreement and subject to the Stock Purchase Agreement; 
 WHEREAS, in connection with the Stock Purchase Agreement and the transactions contemplated thereby, subject to the terms of this Agreement, Pfizer wishes to assign, and Durata wishes to acquire, all
rights and obligations of Pfizer under the RaQualia Agreement, including all rights under the RaQualia Agreement with respect to the Product, as provided by Section 14.1(c) of the RaQualia Agreement. 

NOW THEREFORE, for good and valuable consideration, the adequacy, receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows: 
  

	 	1.	Pfizer hereby irrevocably assigns and delegates to Durata, and Durata hereby accepts from Pfizer to have and to hold, all of Pfizer’s rights, title, obligations
and interests in, to and under the RaQualia Agreement, including with respect to the Product. 

  

	 	2.	Durata hereby assumes, and agrees to observe, comply with, and perform, all obligations of Pfizer under the RaQualia Agreement accruing from and after the Closing Date,
as defined in the Stock Purchase Agreement. 

  

	 	3.	Durata hereby agrees to indemnify and hold harmless Pfizer from and against any and all costs, damages, expenses, losses and liabilities arising out of the breach or
non-performance by Durata of its obligations under Section 3 above, other than obligations arising out of a breach by Pfizer of its representations and warranties in Section 2 above. 

  
 44 

	 	4.	Pfizer hereby agrees to indemnify and hold harmless Durata from and against any and all costs, damages, expenses, losses and liabilities arising out of the breach or
non-performance by Pfizer of its obligations under the RaQualia Agreement accruing prior to the Closing Date, as defined in the Stock Purchase Agreement. 

  

	 	5.	The parties shall cooperate with one another and use their respective reasonable efforts to consummate the assignment, contribution and transfer of the RaQualia
Agreement to Durata, all as provided herein. In furtherance of the foregoing, each party will use reasonable efforts to take, or cause to be taken, such actions and to do, or cause to be done, such things as are reasonably necessary or reasonably
desirable under this Agreement and applicable law to assign and transfer the RaQualia Agreement to Durata. 

  

	 	6.	In the event of a dispute arising under this Agreement that cannot be resolved by the parties, such dispute will be settled by Pfizer and Durata under the dispute
resolution provisions of the Stock Purchase Agreement. 

  

	 	7.	Subject to the Stock Purchase Agreement, each party hereto shall bear its own legal and other expenses in connection with this Agreement. 

 

	 	8.	Nothing in this Agreement alters (a) the applicable representations in the Stock Purchase Agreement or (b) Durata’s rights under Section 10 of the
Stock Purchase Agreement. 

  

	 	9.	All notices, requests, demands, claims and other communications required or permitted to be delivered, given or otherwise provided under this Agreement must be in
writing and must be delivered, given or otherwise provided: 

  

	 	1.	by hand (in which case, it shall be effective upon delivery); 

  

	 	2.	by facsimile (in which case, it shall be effective upon receipt of confirmation of good transmission); or 

 

	 	3.	by overnight delivery by a nationally recognized courier service (in which case, it shall be effective on the Business Day after being deposited with such courier
service); 

  

	 	4.	in each case, to the address (or facsimile number) listed below: 

 If to the Durata, to it at: 
 Durata Therapeutics, Inc. 

Times Square Tower 
 7 times Square, Suite 1603 
 Facsimile number: (646) 519-2782 

Attention: Mr. Ron M. Hunt 

  
 45 

 with a copy to: 
 O’Melveny & Myers LLP 
 2 Embarcadero Center,
28th Floor 

San Francisco, CA 94111 
 Facsimile number: (415) 984-8701 
 Attention: Peter T. Healy, Esq.

 If to the Pfizer, to it at: 
 Pfizer Inc. 
 234 East 42nd Street 

New York, NY 10017 
 Facsimile number: (212) 573-0768 
 Attention: Senior Vice President and
General Counsel 
 with a copy to: 
 Ropes & Gray LLP 
 One International Place 

Boston, MA 02110 
 Facsimile number: (617) 235-0223 
 Attention: Steven A. Wilcox, Esq.

 Each of the parties to this Agreement may specify a different address or facsimile number by giving notice in accordance with
this Section 9 to each of the other parties hereto. 
  

	 	10.	This Agreement shall be governed by the laws of the State of New York, without regard to any conflicts of law principles thereof that would call for the application of
the laws of any other jurisdiction. 

  

	 	11.	This Agreement may be executed in multiple counterparts (including by facsimile or electronic transmission), all of which taken together shall constitute one and the
same original. 

 [The remainder of this is page intentionally blank.] 

  
 46 

 IN WITNESS WHEREOF, this Assignment Agreement has been duly executed on the
Effective Date. 
  

			
	DURATA THERAPEUTICS, INC.
		
	By:	 	 /s/ Ronald M. Hunt

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President
	
	PFIZER INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 47 

 IN WITNESS WHEREOF, this Assignment Agreement has been duly executed on the
Effective Date. 
  

			
	DURATA THERAPEUTICS, INC.
		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	
	
	PFIZER INC.
		
	 By:
	 	 /s/ David Reid

	 Name:
	 	David Reid
	 Title:
	 	Assistant Secretary

  
 48 

 Execution Version 

ASSIGNMENT AGREEMENT 
 THIS ASSIGNMENT AGREEMENT (this “Agreement”) is entered into as of December 18, 2009 (the “Effective Date”) by and among (i) Durata Therapeutics, Inc., a
Delaware corporation (“Durata”). (ii) Pfizer Inc. (“Pfizer”) and (iii) Pfizer Overseas LLC, a Delaware limited liability company (“POLLC”). 

WHEREAS, POLLC is a party to that certain Reverse Transitional Services Agreement (the “Reverse TSA”) between POLLC and
Biosearch Manufacturing S.r.l. (“Biosearch”), dated as of November 30, 2009, a true, correct and complete copy of which is attached hereto as Exhibit 1 pursuant to which POLLC receives certain services and facilities
from Biosearch relating to the product known as “dalbavancin” (the “Product”); 
 WHEREAS, Pfizer and
Durata entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”), pursuant to which Durata will purchase from Pfizer Inc. all of the stock of Vicuron Pharmaceuticals Inc., thereby acquiring all of Vicuron’s
rights and assets relating to the Product as more specifically set forth in the Stock Purchase Agreement and subject to the terms of the Stock Purchase Agreement; and 
 WHEREAS, in connection with the Stock Purchase Agreement and the transactions contemplated thereby, POLLC wishes to assign, and Durata wishes to acquire, all of POLLC’s rights and obligations under
the Reverse TSA as provided by Article 7 of the Reverse TSA. 
 NOW THEREFORE, for good and valuable consideration, the
adequacy, receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	POLLC hereby irrevocably assigns and delegates to Durata, and Durata hereby accepts from POLLC to have and to hold, all of POLLC’s rights, title, obligations and
interests in, to and under the Reverse TSA accruing thereunder from and after the Closing Date, as defined in the Stock Purchase Agreement. 

  

	 	2.	POLLC represents and warrants to Durata that POLLC is not in material breach or default of any of its obligations under the Reverse TSA. 

 

	 	3.	Durata hereby assumes, and agrees to observe, comply with, and perform, all obligations of POLLC under the Reverse TSA accruing thereunder from and after the Closing
Date, as defined in the Stock Purchase Agreement. 

  

	 	4.1	 Durata hereby agrees to indemnify and hold harmless POLLC from and against any and all costs, damages, expenses, losses and liabilities

  
 49 

	 	
arising out of the breach or non-performance by Durata of its obligations under Section 3 above, other than obligations arising out of a breach by POLLC of its representations and warranties
in Section 2 above. 

  

	 	4.2	POLLC and Pfizer hereby agree to jointly and severally indemnify and hold harmless Durata from and against any and all costs, damages, expenses, losses and liabilities
arising out of the breach or non-performance by POLLC of its Reverse TSA accruing prior to the Closing Date, as defined in the Stock Purchase Agreement. 

  

	 	5.	Pfizer guarantees the obligations of POLLC under this Agreement. 

  

	 	6.	This Agreement shall be governed by the laws of the State of New York, without regard to any conflicts of law principles thereof that would call for the application of
the laws of any other jurisdiction. 

  

	 	7.	This Agreement may be executed in multiple counterparts (including by facsimile or electronic transmission), all of which taken together shall constitute one and the
same original. 

  

	 	8.	In the event of a dispute arising under this Agreement that cannot be resolved by the parties, such dispute will be settled by Pfizer, on behalf of POLLC, and Durata
under the dispute resolution provisions of the Stock Purchase Agreement. 

  

	 	9.	Subject to the Stock Purchase Agreement, each party hereto shall bear its own legal and other expenses in connection with this Agreement. 

 

	 	10.	All notices, requests, demands, claims and other communications required or permitted to be delivered, given or otherwise provided under this Agreement must be in
writing and must be delivered, given or otherwise provided: 

  

	 	a.	by hand (in which case, it shall be effective upon delivery); 

  

	 	b.	by facsimile (in which case, it shall be effective upon receipt of confirmation of good transmission); or 

 

	 	c.	by overnight delivery by a nationally recognized courier service (in which case, it shall be effective on the Business Day after being deposited with such courier
service); 

  

	 	d.	in each case, to the address (or facsimile number) listed below: 

  
 50 

 If to the Durata, to it at: 

Durata Therapeutics, Inc. 
 Times Square Tower 
 7 times Square, Suite 1603 

Facsimile number: (646) 519-2782 
 Attention: Mr. Ron M. Hunt 
 with a copy to: 

O’Melveny & Myers LLP 
 2 Embarcadero Center, 28th Floor 
 San Francisco, CA 94111 

Facsimile number: (415) 984-8701 
 Attention: Peter T. Healy, Esq. 
 If to the Pfizer or POLLC, to it at: 

Pfizer Inc. 

234 East 42nd Street 
 New York, NY 10017 
 Facsimile number: (212) 573-0768 

Attention: Senior Vice President and General Counsel 
 with a copy to: 
 Ropes & Gray LLP 

One International Place 
 Boston, MA 02110 
 Facsimile number: (617) 235-0223 

Attention: Steven A. Wilcox, Esq. 
 Each of the parties to this Agreement may specify a different address or facsimile number by giving notice in accordance with this Section 10 to each of the other parties hereto. 

[The remainder of this is page intentionally blank.] 

  
 51 

 IN WITNESS WHEREOF, this Assignment Agreement has been duly executed on the
Effective Date. 
  

			
	 “Durata”
 DURATA THERAPEUTICS, INC.

		
	By:	 	 /s/ Ronald M. Hunt

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President
	
	PFIZER OVERSEAS LLC
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	PFIZER INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 52 

 IN WITNESS WHEREOF, this Assignment Agreement has been duly executed on the
Effective Date. 
  

			
	 “Durata”
 DURATA THERAPEUTICS, INC.

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	PFIZER OVERSEAS LLC
		
	By:	 	 /s/ GP Moore

	Name:	 	Geoffrey P. Moore
	Title:	 	Vice President
	
	PFIZER INC.
		
	By:	 	 /s/ David Reid

	Name:	 	David Reid
	Title:	 	Assistant Secretary

  
 53 

 EXHIBIT 1 
 REVERSE TSA 
 (SEE ATTACHED.) 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. A total of 32 pages were omitted. 
 [**] 

  
 54 

 EXHIBIT 1(i) 
 Knowledge 
 [**] 

  
 55 

 Execution Version 

TRANSITION SERVICES AGREEMENT 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 50 pages were omitted. 
 [**] 

  
 56 

 Exhibit 2.5.1 

FORM OF PROMISSORY NOTE 
  

			
	$[25,000,000]*	 	Dated [insert date of issuance]

 FOR VALUE RECEIVED the undersigned Durata Therapeutics Inc., a Delaware
corporation (together with its permitted successors and assigns, “Maker”), hereby promises to pay to the order of Pfizer Inc., a Delaware corporation (together with its successors and any subsequent holder of this Note being
referred to as “Payee”), at its corporate offices at 235 East 42nd Street, New York, NY 10017, the principal sum of [TWENTY FIVE MILLION DOLLARS ($25,000,000)*, together with accrued and unpaid interest thereon on [—][Note:
Insert date which is five (5) years after the First Commercial Sale Date (as defined in the Stock Purchase Agreement).] (the “Maturity Date”). Interest on the principal of this Note from time to time outstanding shall accrue daily
from the date of this Note until this Note is paid in full at per annum interest rate equal to ten percent (10%) (the “Original Contract Rate”), compounded annually; provided, however, interest on all past due amounts
shall bear interest at per annum interest rate equal to the Original Contract Rate plus four percent (4%), compounded monthly (the “Default Rate”). Interest on this Note shall be calculated at rate per annum based upon the actual number of
days elapsed over year of 360 days. 
 This Note is issued pursuant to Section 2.5.1 of the Stock Purchase Agreement dated
December 11, 2009, between Maker and Payee (the “Stock Purchase Agreement”). 
 Maker shall have the right from
time to time and at any time prior to the Maturity Date to prepay, in whole or part, the unpaid principal balance of this Note, together with accrued and unpaid interest thereon, without premium or penalty. Upon any pre-payment of this Note, the
accrued and unpaid interest on the principal of this Note being pre-paid shall be immediately due and payable and shall be paid at the time of any pre-payment of this Note. Any pre-payment of this Note shall be applied first to the payment of
accrued and unpaid interest on the principal amount of this Note being pre-paid and the remainder, if any, shall be applied to principal. 
 If, on the Maturity Date, the principal of and interest on this Note has not been received by the Payee in accordance with the terms hereof, then all of the principal of and interest on this Note shall
mature and become at once due and payable without further notice, demand or presentment for payment, together with all reasonable and actually incurred costs incurred by the Payee in the enforcement and collection of this Note. 

Notwithstanding anything contained herein to the contrary, this Note is hereby expressly limited so that in no contingency or event
whatsoever, shall the amount paid or agreed to be paid to Payee for the use, forbearance, or detention of money exceed the highest lawful rate permissible under applicable law. If, from any circumstances whatsoever, Payee shall ever receive as
interest hereunder an amount that would exceed the highest lawful rate applicable to Maker, such amount that would be excessive interest shall be applied to the reduction of the 

 
  

	* 	 [NOTE: If Buyer pays portion of the Milestone Payment in cash in accordance with Section 2.5.1 of the Stock Purchase Agreement, then the principal
amount of the Note shall be equal to the difference between $25,000,000 and the amount of the Milestone Payment so paid to Payee in cash.] 

 
unpaid principal balance of the indebtedness evidenced hereby and not to the payment of interest, and if the principal amount of this Note is paid in full, any remaining excess shall forthwith be
paid to Maker, and in such event, Payee shall not be subject to any penalties provided by any laws for contracting for, charging, taking, reserving or receiving interest in excess of the highest lawful rate permissible under applicable law.

 Maker and each surety, endorser, guarantor, and other party now or hereafter liable for payment of this Note, severally waive
demand, presentment for payment, notice of dishonor, protest, notice of protest, diligence in collecting or bringing suit against any party liable hereon, and further agree to any and all extensions, renewals, modifications, partial payments,
substitutions of evidence of indebtedness, and the taking or release of any collateral with or without notice before or after demand by Payee for payment hereunder. All sums payable hereunder will be payable by Maker to Payee in lawful money of the
United States of America and in immediately available funds. 
 In the event this Note is placed in the hands of any attorney
for collection or suit is filed hereon or if proceedings are had in bankruptcy, receivership, reorganization, or other legal or judicial proceedings for the collection hereof, Maker and any guarantor hereby jointly and severally agree to pay to
Payee all expenses and costs of collection, including, but not limited to, reasonable attorneys’ fees incurred in connection with any such collection, suit, or proceeding, in addition to the principal and interest then due. 

Time is of the essence with respect to all of Maker’s obligations and agreements under this Note. 

THIS NOTE SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CHOICE OF LAW PRINCIPLES THEREOF, AND MAKER CONSENTS
TO JURISDICTION IN THE COURTS LOCATED IN NEW YORK CITY, NEW YORK. 
 All of the covenants, obligations, promises and agreements
contained in this Note made by Maker shall be binding upon its permitted successors and assigns. Maker shall not allow or cause this Note to be assumed, or assign, delegate or otherwise transfer this Note or any of its rights, interests or
obligations hereunder without the prior written consent of Payee; excepting, however, and notwithstanding anything in this Note to the contrary, that Maker may, without the consent of Payee, (a) assign any or all of its rights and
interests hereunder to one or more of its Affiliates (as defined below), or (b) designate one or more of its Affiliates (as defined below) to perform its obligations hereunder, in each of subsection (a) and (b), so long as the Maker is not
relieved of any liability or obligation hereunder or (c) assign, transfer and delegate this Note and all of its rights, interests and obligations hereunder to a Qualified Successor (as defined in below) (1) in connection with a Change of
Control of Maker (as defined below) with such Qualified Successor, or (2) in connection with a sale, exclusive license or other transfer of all or substantially all of its or the Company’s (as defined below) rights, title and interest in
and to the Product (as defined below) to such Qualified Successor (a “Product Transfer”), so long as such Qualified Successor unconditionally assumes all of the Maker’s obligations and liabilities under this Note. Any such assignment,
transfer and delegation of this Note made in conformity with subsection (c) of this paragraph shall operate to relieve the Maker of its liabilities and 

  
 - 2 -

 
obligations hereunder if such Qualified Successor expressly and unconditionally agrees in writing with Payee that it shall be bound by and shall assume, pay and perform all of the Maker’s
obligations and liabilities under this Note. Upon the occurrence of a Change of Control of Maker (as defined below) or a Product Transfer, in each case with or to a Person (as defined below) that is not a Qualified Successor (as defined below), with
respect to which (a) the Payee has granted its written consent to Maker, the Original Contract Rate shall, effective upon consummation of such Change of Control of Maker or such Product Transfer, automatically increase from 10% per annum
to 14% per annum, compounded annually, and the Default Rate shall automatically increase from 14% per annum to 18% per annum, compounded monthly or (b) the Payee has not granted its written consent to Maker as required by
Section 2.5.3 of the Stock Purchase Agreement, this Note shall become immediately due and payable. For purposes of this Note (unless otherwise stated, capitalized terms used in these definitions have the same meaning as used in the Stock
Purchase Agreement): 
 (A) “Affiliate” shall mean any entity directly or indirectly controlled by, controlling, able
to control, or under common control with, a specified Person, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”,
“controlling” and “under common control with”) means possession, direct or indirect of (a) the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or
partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of such
Person. For the avoidance of doubt, (i) neither the Maker nor the Payee shall be deemed to be an “Affiliate” of the other solely as a result of their entering into the Stock Purchase Agreement, and (ii) the stockholders of the
Maker on the date of the Stock Purchase Agreement (“Maker’s Original Affiliates”) shall be deemed to be Affiliates of the Maker so long as they own beneficially not less than 10% of the voting securities of the Maker; 

(B) “Change of Control of Maker” shall mean an event in which: (a) any other Person or group of Persons acting in concert
(other than a Parent Entity of the Maker or Maker’s Original Affiliates) acquires beneficial ownership of securities of the Maker representing more than 50% of the voting power of the then outstanding securities of the Maker with respect to the
election of directors of the Maker; (b) the Maker enters into a merger, consolidation, scheme of arrangement or similar transaction with another Person, unless (i) the members of the Board of Directors of the Maker immediately prior to
such transaction constitute more than 50% of the members of the Board of Directors of the Maker (or a Parent Entity of the Maker) immediately following such transaction, and (ii) the Persons who beneficially owned the outstanding voting
securities of the Maker immediately prior to such transaction beneficially own securities of the Maker representing at least 50% of the voting power with respect to the election of directors of the Maker immediately following such transaction, or a
Parent Entity of the Maker beneficially owns securities of the Maker representing 100% of the voting power with respect to the election of directors of the Maker immediately following such transaction; or (c) the Maker sells to any Person(s),
in one or more related transactions, a majority of the property and assets of the Buyer. For purposes of this definition, a “Parent Entity” of the Maker means any Person that acquires directly or indirectly, by merger or otherwise, the
capital stock of the Maker if the holders of securities that represented 100% of the voting power with respect to the election of directors 

  
 - 3 -

 
(“Voting Stock”) of the Maker immediately prior to such acquisition directly own 100% of the Voting Stock of the Parent Entity immediately after such acquisition and in the exact same
percentages as they owned Voting Stock in the Maker immediately prior to such acquisition; 
 (C) “Company” shall mean
Vicuron Pharmaceuticals Inc. 
 (D) “Person” shall mean any individual or corporation, association, partnership,
limited liability company, joint venture, joint stock or other company, business trust, trust, organization, governmental authority or other entity of any kind; 
 (E) “Product” shall mean all pharmaceutical formulations and dosage forms of dalbavancin or any salt, prodrug, hydrate, solvate, metabolite, or polymorph form of dalbavancin; and 

(F) “Qualified Successor” shall mean a Person having (a) a market capitalization in excess of $[**] (or in the case of a
privately held company, a valuation of its total outstanding equity securities based on its most recently completed arms-length equity financing or an independent valuation of its equity pursuant to Rule 409A under the Internal Revenue Code, in
excess of $[**]); (b) a tangible net worth in excess of $[**]; and (c) a debt to equity ratio of no more than [**]. 

MAKER’S OBLIGATION TO MAKE PAYMENTS UNDER THIS NOTE IS ABSOLUTE AND UNCONDITIONAL. MAKER WAIVES ANY AND ALL RIGHT OF SET-OFF SIMILAR
DEFENSES OR COUNTERCLAIMS WITH RESPECT TO THE PAYMENT OF AMOUNTS UNDER THIS NOTE THAT MAKER MAY NOW OR HEREINAFTER HAVE AGAINST PAYEE OR ANY OTHER PERSON OR ENTITY, OR AGAINST ANY AMOUNTS UNDER THIS NOTE, INCLUDING ANY AND ALL RIGHT TO APPLY THE
AMOUNT OF ANY LOSSES REFERENCED IN SECTION 10 OF THE STOCK PURCHASE AGREEMENT AGAINST THIS NOTE. 

  
 - 4 -

 IN WITNESS WHEREOF the undersigned has executed this Note effective the day and year first
written above 
  

			
	DURATA THERAPEUTICS INC.
		
	By:	 	
 

 
			
	Name:	 	
	Title	 	

  
 - 5 -

 EXHIBIT 5.7 
 Buyer’s Development and Commercialization Budget for the Product 
 Budget For
Durata 
  
 Budget Summary($)

  

													
	 	  	2009	 	2010	 	2011	 	2012	 	2013	 	 
	 	  	2009 Total	 	2010 Total	 	2011 Total	 	2012 Total	 	2013 Total	 	    09-13    
	 Expenses
	  		 		 		 		 		 	
	 Dev & regulatory expenses
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
							
	 Other Expenses
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 Start-up costs
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 CMC
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 Other costs
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
							
	 Upfront to Pfizer
	  	[**]	 		 		 		 		 	
		  	  
	 	  
	 	  
	 	  
	 	  
	 	  

	 Total Expenses
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
		  	  
	 	  
	 	  
	 	  
	 	  
	 	  

	 Cumulative burn
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	

 EXHIBIT 6.2.1(F) 
 Company Contract Modifications 
 None 

 Exhibit 7.4 

COMPLIANCE CERTIFICATE 
 Pursuant to that certain Stock Purchase Agreement by and between Pfizer Inc (“Seller”) and Durata Therapeutics, Inc (“Buyer”) dated as of December 11, 2009 the
(“Stock Purchase Agreement”) the undersigned officer of Seller hereby certifies as follows. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement.

 1. The representations and warranties of the Seller contained in the Stock Purchase Agreement and in any Ancillary Agreement
(a) that are not qualified by materiality or Material Adverse Effect are true, correct and complete in all material respects at and as of the Closing with the same force and effect as if made as of the Closing (b) and that are qualified by
materiality or Material Adverse Effect are true, correct and complete in all respects at and as of the Closing with the same force and effect as if made as of the Closing, in each case, other than representations and warranties that expressly speak
only as of specific date or time, which are true, correct and complete (or true, correct and complete in all material respects, as the case may be) as of such specified date or time. 

2. The Buyer and the Company have performed and complied in all material respects with all agreements obligations and covenants contained
in the Stock Purchase Agreement that are required to be performed or complied with by them at or prior to the Closing. 
 IN
WITNESS WHEREOF, the undersigned has executed this Certificate as of this 18 day of December, 2009. 
  

			
	 /s/ David Reid

	Name:	 	DAVID REID
	Title:	 	ASSISTANT SECRETARY

 COMPLIANCE CERTIFICATE 

Pursuant to that certain Stock Purchase Agreement by and between Pfizer Inc (“Seller’) and Durata Therapeutics, Inc
(“Buyer”), dated as of December 11, 2009 the (“Stock Purchase Agreement”), the undersigned officer of Buyer hereby certifies as follows. Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed to such terms in the Stock Purchase Agreement. 
 1. The representations and warranties of the Buyer contained
in the Stock Purchase Agreement and in any Ancillary Agreement (a) that are not qualified by materiality or Material Adverse Effect are true, correct and complete in all material respects at and as of the Closing with the same force and effect
as if made as of the Closing (b) and that are qualified by materiality or Material Adverse Effect are true, correct and complete in all respects at and as of the Closing with the same force and effect as if made as of the Closing in each case,
other than representations and warranties that expressly speak only as of specific date or time, which are true, correct and complete (or true, correct and complete in all material respects as the case may be) as of such specified date or time.

 2. Buyer has performed and complied in all material respects with all agreements obligations and covenants contained in the
Stock Purchase Agreement that are required to be performed or complied with by it at or prior to the Closing. 
 IN WITNESS
WHEREOF, the undersigned has executed this Certificate as of this 18 day of December, 2009. 
  

			
	 /s/ Ronald M. Hunt

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President

 SCHEDULE 1(a) 
 Lincosamide Patents 
  

											
	 Country
	  	 Application Number
	  	 Application

Date
	  	 Patent Number
	  	 Expiration

Date
	  	 Status

	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]
	 [**]
	  	[**]	  	[**]	  		  		  	[**]

 SCHEDULE 3 
 Seller’s Disclosure Schedules 

 SCHEDULE 4.3 
 Authorization of Government Authorities 
 See Section 3.4 of the Disclosure Schedule.

 SCHEDULE 4.11 
 Inventory Specifications 
  

									
	

	  	SPECIFICATION - R	  	 MATERIAL CODE:

47150
	  	 EFFECTIVE DATE:
 10 SEP
2007 DR
	  	 OCCUPATION NUMBER

FG-47150

	  	  	 PAGE:
 1 of
2
	  	 SUPERSEDED DATE:
 15
FEB 06 DR
	  	 GRADE:

PHARM

	  	 MATERIAL DESCRIPTION
 DALBAVANCIN 500 MG FOR INJECTION

  

							
	 TEST
	  	PROCEDURE	 	SPECIFICATION	 	 
	 Appearance
	  	[**]	 	[**]	 	
	 Reconstituted Solution Appearance
	  	[**]	 	[**]	 	
	 Identification (IR)
	  	[**]	 	[**]	 	
	 Identification (HPLC)
	  	[**]	 	[**]	 	
	 Assay (HPLC)
	  	[**]	 	[**]	 	
	 (A0-A1
)
 B3

(B1 + B2)
	  		 		 	
	 Specified Degradation Products: Mannosyl Aglycone (MAG)
	  	[**]	 	[**]	 	
	 Unspecified Degradation Products
	  	[**]	 	[**]	 	
	 Total Degradation Products
	  	[**]	 	[**]	 	
	 Uniformity of Dosage Units
	  	[**]	 	[**]	 	
	 Water Content
	  	[**]	 	[**]	 	
	CONFIDENTIAL

									
	

	  	 SPECIFICATION – R

APPROVAL
	  	MATERIAL CODE: 47150	  	 EFFECTIVE DATE:
 10 SEP
2007 DR
	  	 OCCUPATION NUMBER

FG-47150

	  	  	 PAGE:
 1 of
1
	  	 SUPERSEDED DATE:
 15
FEB 06 DR
	  	 GRADE:

PHARM

	  	 MATERIAL DESCRIPTION
 DALBAVANCIN 500 MG FOR INJECTION

	  
	  		  		  		  	
	15-FEB-2006 DR	  	Original	  		  		  	
					
	10-SEP-2007 DR	  	[**]	  		  		  	

  

							
	
	 REGULATORY SUBMISSIONS

				
	 PRODUCT OR MATERIAL
	  	SUBMISSION
NUMBER	  	 PRODUCT OR MATERIAL
	  	SUBMISSION
NUMBER
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

  

							
	 SIGNATURES

 

	DATE	  	Joseph Stecipie	  	 DATE
 06 Sep
2007
	  	DATE

									
	

	  	 Document Approval Date
 15 Jan 2009
  
 SPECIFICATION-R
	  	MATERIAL CODE:
 4700
	  	EFFECTIVE DATE:
 N/A
	  	OCCUPATION NUMBER
 FG-47000

	  	  	PAGE:
 2 of 3
	  	SUPERSEDED DATE:
 16 AUG 2007DR
	  	GRADE:
 PHARM

	  	 MATERIAL DESCRIPTION
 DALBAVANCIN DRUG SUBSTANCE

  

							
	 TEST
	  	TEST
METHOD	 	ACCEPTANCE CRITERIA	 	 
	 Microbial Limit
	  	[**]	 	[**]	 	
	 Bacterial Eudotoxins
	  	[**]	 	[**]	 	
	 Residual Solvents Acetone
	  	[**]	 	[**]	 	
				
	 INORGANIC IMPURITIES
	  	[**]	 	[**]	 	
	 pH
	  	[**]	 	[**]	 	
	 Water Content
	  	[**]	 	[**]	 	
	 Chlorid Content
	  	[**]	 	[**]	 	
	 Residue on Ignition
	  	[**]	 	[**]	 	
	 Heavy Metals
	  	[**]	 	[**]	 	

 CONFIDENTIAL 

 SCHEDULE 5.3 
 Inventory Specifications 
 None. 

 SCHEDULE 5.4 
 Noncontravention 
 None.Employment Agreement - Paul R. Edick

 Exhibit 10.11 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into
this 19th day of June 2012 (the “Effective
Date”), by and between (i) Durata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (ii) Paul Edick (the “Executive”) and amends and restates in its entirety the Employment Agreement,
dated July 1, 2010, between the Company and the Executive. 
 THE PARTIES ENTER THIS AGREEMENT on the basis of the
following facts, understandings and intentions: 
 A. The Company desires to continue to retain the services of the
Executive upon and following the Effective Date. This Agreement shall govern the employment relationship between the Executive and the Company from and after the Effective Date, and, as of the Effective Date, supersedes and negates all
previous agreements with respect to such relationship. 
 B. The Executive desires to be employed by the Company on the
terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the above recitals incorporated
herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows: 

1. Retention and Duties. 
 1.1 Retention. The Company does hereby engage and employ the Executive for the Period of Employment (as such term is defined in Section 2) on the terms and conditions expressly
set forth in this Agreement. The Executive does hereby accept and agree to such engagement and employment, on the terms and conditions expressly set forth in this Agreement. 
 1.2 Duties. During the Period of Employment, the Executive shall serve the Company as its Chief Executive Officer and shall have the powers, authorities, duties and obligations of management
usually vested in the office of the Chief Executive Officer of a company of a similar size and similar nature of the Company, and such other powers, authorities, duties and obligations commensurate with such position as the Company’s Board of
Directors (the “Board”) may assign from time to time, all subject to the directives of the Board and the corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including,
without limitation, the Company’s business conduct and ethics policies, as they may change from time to time). During the Period of Employment, the Executive shall report to the Board. The Executive shall be elected to the Board and shall serve
as a member of the Board, without any additional compensation therefor, during the Period of Employment. 
 1.3 No Other
Employment; Minimum Time Commitment. During the Period of Employment, the Executive shall (a) devote the Executive’s full business time, energy and skill to the performance of the Executive’s duties for the Company,
(b) perform such duties in a faithful, effective and efficient manner to the best of the Executive’s abilities and carry out all of the Company’s policies and directives in a manner which will promote and develop the Company’s
best interests, and (c) hold no other employment. During the Period of Employment, the Executive may serve on no more than four (4) boards of directors (or similar body) of other business entities at any given time, unless otherwise
permitted by the Board. The Executive’s service on the boards of directors (or similar body) of other business entities is subject to the prior written approval of the Board, which approval shall not unreasonably be withheld; provided,
however, that the Executive’s service on the board of directors of Amerita and New Link Genetics is expressly approved. The Company shall have the right to require the Executive to resign from any board or similar body (including,
without limitation, any association, corporate, civic or charitable board or similar body) which the Executive may then serve if the Board reasonably determines that the Executive’s service on such board or body interferes with the effective
discharge of the Executive’s duties and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its Affiliates (as such term is defined in
Section 5.5), successors or assigns, or could reasonably be expected in the future to be in competition with the Company. 
  

 1.4 No Breach of Contract. The Executive hereby represents to the Company
that: (a) the execution and delivery of this Agreement by the Executive and the Company, and the performance by the Executive of the Executive’s duties hereunder, do not and shall not constitute a breach of, conflict with, or otherwise
contravene or cause a default under, the terms of any other agreement or policy to which the Executive is a party or otherwise bound or any judgment, order or decree to which the Executive is subject; (b) that the Executive has no information
(including, without limitation, confidential information and trade secrets) relating to any other Person (as such term is defined in Section 5.5) which would prevent, or be violated by, the Executive entering into this Agreement or
carrying out the Executive’s duties hereunder; (c) the Executive is not bound by any employment, consulting, non-compete, confidentiality, trade secret or similar agreement (other than this Agreement) with any other Person; and
(d) the Executive understands that the Company will rely upon the accuracy and truth of the representations and warranties of the Executive set forth herein (including, without limitation, the Executive’s curriculum vitae that the
Executive provided to the Company prior to the Effective Date), and the Executive consents to such reliance. 
 1.5
Location. The Company’s headquarters are currently located in Morristown, New Jersey. The Executive shall be regularly present at the Company’s headquarters, as such headquarters may be so located from time to time. In addition,
the Executive acknowledges and agrees that the Executive may be required to travel from time to time in the course of performing the Executive’s duties for the Company. 
 2. Period of Employment. The “Period of Employment” shall be a period of one (1) year commencing on the Effective Date and ending at the close of business on the first (1st)
anniversary of the Effective Date (the “Termination Date”); provided, however, that this Agreement shall be automatically renewed, and the Period of Employment shall be automatically extended for one (1) additional
year on the Termination Date and each anniversary of the Termination Date thereafter, unless either party gives written notice to the other party at least ninety (90) days prior to the expiration of the Period of Employment (including any renewal
thereof) of such party’s desire to terminate the Period of Employment (such notice to be delivered in accordance with Section 19). The term “Period of Employment” shall include any extension thereof pursuant to the
preceding sentence. Provision of notice that the Period of Employment shall not be extended or further extended, as the case may be, shall not constitute a breach of this Agreement. Notwithstanding the foregoing, the Period of Employment is subject
to earlier termination as provided below in this Agreement. 
 3. Compensation. 

3.1 Base Salary. During the Period of Employment, the Company shall pay the Executive a base salary (the “Base
Salary”), which shall be paid in accordance with the Company’s regular payroll practices in effect from time to time, but not less frequently than in semi-monthly installments. The Executive’s Base Salary shall be at an annualized
rate of Four Hundred Seventy Thousand Dollars ($470,000). The Board (or a committee thereof) shall review the Executive’s rate of Base Salary annually and may, in its sole discretion, increase (but not decrease except in the event of a
broad-based reduction for all employees at the Company) the rate then in effect. 
 3.2 Incentive
Bonus. The Executive shall be eligible to receive an incentive bonus for each fiscal year of the Company that occurs during the Period of Employment (“Incentive Bonus”); provided, however, that, the
Executive must be employed by the Company on the last day of a fiscal year in order to be eligible for an Incentive Bonus with respect to that fiscal year (and, if the Executive is not so employed at such time, in no event, shall the
Executive have been considered to have “earned” any Incentive Bonus with respect to the fiscal year in question). The Executive’s target Incentive Bonus amount for a particular fiscal year of the Company shall equal 50% of the
Executive’s Base Salary at the rate in effect for such year (the “Target Bonus”); provided, however, that the Executive’s actual Incentive Bonus amount for a particular fiscal year shall be determined by the
Organization and Compensation Committee of the Company’s Board of Directors (the “Committee”) in such Committee’s sole discretion, based on individual and Company performance objectives established with respect to that particular
fiscal year by the Committee in consultation with the Executive. The Incentive Bonus, if any, payable for a particular fiscal year shall be paid to the Executive no later than two and one-half (2 1/2) months following the end of such fiscal year. 

 

  
 - 2 -

 4. Benefits. 
 4.1 Retirement, Health, Welfare and Fringe Benefits. During the Period of Employment, the Executive shall be entitled to participate in all employee pension, health and welfare
benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company’s executive officers generally, in accordance with the eligibility and participation provisions of such plans and as such plans or
programs may be in effect from time to time. During the period of Employment and at the sole discretion of the Board, the Executive shall be entitled to participate in all of the Company’s current and future equity
incentive plans. 
 4.2 Reimbursement of Business Expenses. The Executive is authorized to incur
reasonable business expenses in carrying out the Executive’s duties for the Company under this Agreement and shall be entitled to reimbursement for all reasonable business expenses the Executive incurs during the Period of Employment in
connection with carrying out the Executive’s duties for the Company, subject to the Company’s expense reimbursement policies and any pre-approval policies in effect from time to time. 

4.3 Vacation and Other Leave. During the Period of Employment, the Executive’s annual rate of vacation
accrual shall be four (4) weeks per year; provided, however, that such vacation shall accrue and be subject to the Company’s vacation policies in effect from time to time, including any policy which may permit accrued but
unused vacation to carry over from year to year. The Executive shall also be entitled to all other holiday and leave pay generally available to other executives of the Company. 
 5. Termination. 
 5.1 Termination by the Company. The
Executive’s employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (a) with Cause (as such term is defined in Section 5.5); or (b) without Cause; or (c) in the event of
the Executive’s death; or (d) in the event that the Board determines that the Executive has a Disability (as such term is defined in Section 5.5). 
 5.2 Termination by the Executive. The Executive’s employment by the Company, and the Period of Employment, may be terminated by the Executive upon not less than ninety (90) days
prior written notice to the Company (such notice to be delivered in accordance with Section 19). 
 5.3 Benefits
Upon Termination. If the Executive’s employment by the Company is terminated during the Period of Employment for any reason by the Company or by the Executive, or upon or following the expiration of the Period of Employment (in any
case, the date that the Executive’s employment by the Company terminates is referred to as the “Severance Date”), the Company shall have no further obligation to make or provide to the Executive, and the Executive shall have no
further right to receive or obtain from the Company, any payments or benefits except as follows: 
 (a) The Company shall pay
the Executive (or, in the event of the Executive’s death, the Executive’s estate) any Accrued Obligations (as such term is defined in Section 5.5); 
 (b) If, during the Period of Employment, the Executive’s employment with the Company is terminated by the Company without Cause (and other than due to the Executive’s death or a determination by
the Board that the Executive has incurred a Disability), the Executive shall be entitled to the following benefits: 
 (i) The
Company shall pay the Executive (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to eighteen (18) months of the Executive’s Base Salary at the annualized rate in effect on the
Severance Date. Such amount is referred to hereinafter as the “Severance Benefit.” Subject to Section 20.1, the Company shall pay the Severance Benefit to the Executive in substantially equal installments in accordance
with the Company’s standard payroll practices over a period of eighteen (18) consecutive months, with the first installment payable in the month following the month in which the Executive’s Separation from Service (as such term is defined
in Section 5.5) occurs. (For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate Severance Benefit. For example, if such installments were to be made on a monthly basis, each installment would
equal one-eighteenth (1/18th). 

  
 - 3 -

 (ii) The Company shall pay or reimburse the Executive for the Executive’s premiums
charged to continue medical coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), at the same or reasonably equivalent medical coverage for the Executive (and, if applicable, the Executive’s eligible
dependents) as in effect immediately prior to the Severance Date, to the extent that the Executive elects such continued coverage; provided, however, that, the Company’s obligation to make any payment or reimbursement pursuant to this clause
(ii) shall, subject to Section 20.1, commence with continuation coverage for the month following the month in which the Executive’s Separation from Service occurs and shall cease with continuation coverage in the eighteenth (18th) month
following the month in which the Executive’s Separation from Service occurs (or, if earlier, shall cease upon the first to occur of the Executive’s death, the date the Executive becomes eligible for coverage under the health plan of a
future employer, or the date the Company ceases to offer group medical coverage to its active executive employees or the Company is otherwise under no obligation to offer COBRA continuation coverage to the Executive). To the extent that the
Executive elects COBRA coverage, he shall notify the Company in writing of such election prior to such coverage taking effect and complete any other continuation coverage enrollment procedures the Company may then have in place. 

(c) If, during the Period of Employment, there is a Change in Control and the Executive’s employment with the Company is terminated
by the Company without Cause (and other than due to the Executive’s death or a determination by the Board that the Executive has incurred a Disability), or by the Executive for Good Reason, in each case within two (2) months prior to or within
twelve (12) months following the Change in Control, then the Executive shall be entitled to the following benefits: 
 (i) The
Company shall pay the Executive (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to twenty-four (24) months of the Executive’s Base Salary at the annualized rate in effect on
the Severance Date. Such amount is referred to hereinafter as the “CIC Severance Benefit.” Subject to Section 20.1, the Company shall pay the CIC Severance Benefit to the Executive in substantially equal installments in
accordance with the Company’s standard payroll practices over a period of twenty-four (24) consecutive months, with the first installment payable in the month following the month in which the Executive’s Separation from Service occurs.
(For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate CIC Severance Benefit. For example, if such installments were to be made on a monthly basis, each installment would equal one-twenty-fourth
(1/24th). 
 (ii) The Company shall pay or reimburse the Executive for the Executive’s premiums charged to continue
medical coverage pursuant to COBRA, at the same or reasonably equivalent medical coverage for the Executive (and, if applicable, the Executive’s eligible dependents) as in effect immediately prior to the Severance Date, to the extent that the
Executive elects such continued coverage; provided, however, that, the Company’s obligation to make any payment or reimbursement pursuant to this clause (iii) shall, subject to Section 20.1, commence with continuation
coverage for the month following the month in which the Executive’s Separation from Service occurs and shall cease with continuation coverage in the eighteenth (18th) month following the month in which the Executive’s Separation from
Service occurs (or, if earlier, shall cease upon the first to occur of the Executive’s death, the date the Executive becomes eligible for coverage under the health plan of a future employer, or the date the Company ceases to offer group medical
coverage to its active executive employees or the Company is otherwise under no obligation to offer COBRA continuation coverage to the Executive). To the extent that the Executive elects COBRA coverage, he shall notify the Company in writing of such
election prior to such coverage taking effect and complete any other continuation coverage enrollment procedures the Company may then have in place. 
 (iii) All outstanding stock options and other equity compensation awards granted to Executive by the Company shall become fully vested and free from forfeiture restrictions as of the Severance Date. In
all other respects, the stock options and other equity compensation awards shall be governed by the applicable award agreement and plan under which the award was granted. 
 (iv) For the avoidance of doubt, to the extent that the Executive is entitled to severance payments and benefits under Section 5.3(c), Executive shall not be entitled to severance payments and benefits
under Section 5.3(b). 
 (d) Notwithstanding the foregoing provisions of this Section 5.3, if the Executive
breaches the Executive’s obligations under Section 6 of this Agreement at any time, from and after the date of such breach and not in any way in limitation of any right or remedy otherwise available to the Company, the Executive shall no
longer be entitled to, and the Company shall no longer be obligated to pay, any remaining unpaid portion of the Severance Benefit, or, if applicable, any continued Company-paid or reimbursed coverage pursuant to Section 5.3(b)(ii) or any
remaining unpaid portion of the CIC Severance Benefit, or, if applicable, any continued Company paid or reimbursed coverage pursuant to Section 5.3(c)(ii) or any acceleration of equity vesting pursuant to Section 5.3(c)(iii); provided,
however, that, if the Executive provides the release contemplated by Section 5.4, in no event shall the Executive be entitled to a Severance Benefit payment or CIC Severance Benefit payment, as applicable, of less than $5,000, which amount
the parties agree is good and adequate consideration, in and of itself, for the Executive’s release contemplated by Section 5.4. 
 (e) The foregoing provisions of this Section 5.3 shall not affect: (i) the Executive’s receipt of benefits otherwise due terminated employees under group insurance coverage
consistent with the terms of the applicable Company welfare benefit plan; (ii) the Executive’s rights under COBRA to continue participation in medical, dental, hospitalization and life insurance coverage; and (iii) the
Executive’s receipt of benefits otherwise due in accordance with the terms of the Company’s 401(k) plan (if any). 

5.4 Release; Exclusive Remedy. 
 (a) This Section 5.4 shall apply notwithstanding anything else contained in this Agreement. As a condition precedent to any Company obligation to the Executive pursuant to
Section 5.3(b) or Section 5.3(c), as applicable, the Executive shall, upon or promptly following the Executive’s last day of employment with the Company (and in all events within twenty-one (21) days after the
Executive’s last day of employment with the Company), provide the Company with a valid, executed general release agreement in a form acceptable to the Company, and such release agreement shall have not been revoked by the Executive pursuant to
any revocation rights afforded by applicable law. 
 (b) The Executive agrees that the payments and benefits contemplated by
Section 5.3 shall constitute the exclusive and sole remedy for any termination of the Executive’s employment and the Executive covenants not to assert or pursue any other remedies, at law or in equity, with respect to any termination of
employment. The Company and the Executive acknowledge and agree that there is no duty of the Executive to mitigate damages under this Agreement. All amounts paid to the Executive pursuant to Section 5.3 shall be paid without regard to
whether the Executive has taken or takes actions to mitigate damages. The Executive agrees to resign, on the Severance Date, as an officer and director of the Company and any Affiliate of the Company, and as a fiduciary of any benefit plan of the
Company or any Affiliate of the Company, and to promptly execute and provide to the Company any further documentation, as requested by the Company, to confirm such resignation. 

  
 - 4 -

 5.5 Certain Defined Terms. 

(a) As used herein, “Accrued Obligations” means: 

(i) any Base Salary that had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date;
and 
 (ii) any Incentive Bonus payable pursuant to Section 3.2 with respect to any fiscal year in the Period of
Employment preceding the fiscal year in which the Severance Date occurs, if the Company had paid bonuses generally with respect to such fiscal year on or prior to the Severance Date but had not previously paid any Incentive Bonus due to the
Executive with respect to such fiscal year; and 
 (iii) any reimbursement due to the Executive pursuant to Section 4.2
for expenses reasonably incurred by the Executive on or before the Severance Date and documented and pre-approved, to the extent applicable, in accordance with the Company’s expense reimbursement policies in effect at the applicable time.

 (b) As used herein, “Affiliate” of the Company means a Person that directly or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, the Company. As used in this definition, the term “control,” including the correlative terms “controlling,” “controlled by” and
“under common control with,” means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by
contract or otherwise) of a Person. 
 (c) As used herein, “Cause” shall mean, as determined by the Board
(excluding the Executive, if the Executive is then a member of the Board) based on the information then known to it, that one or more of the following has occurred: 
 (i) the Executive has committed a felony (under the laws of the United States or any relevant state, or a similar crime or offense under the applicable laws of any relevant foreign jurisdiction);

 (ii) the Executive has engaged in acts of fraud, dishonesty or other acts of willful misconduct in the course of the
Executive’s duties hereunder; 
 (iii) the Executive fails to perform or uphold the Executive’s duties under this
Agreement and/or fails to comply with reasonable directives of the Board, in either case after the Company has delivered to the Executive a written demand for performance which describes the basis for the Board’s belief that the Executive has
violated the Executive’s obligations to the Company or failed to comply with any such directives, as applicable, and the Executive fails to cure such violation or failure within a time-frame proscribed by the Board after receipt of such notice;
provided, however, that the foregoing notice and opportunity to cure shall not apply to more than one instance of the same or similar violations or failures; or 
 (iv) any breach by the Executive of any provision of Section 6 or of the Confidentiality Agreement (as such term is defined in Section 6.1 (c)) or any material breach by the
Executive of any other contract the Executive is a party to with the Company or any of its Affiliates. 
 (d) As used herein,
“Change in Control” shall mean the consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any corporation or other entity a majority of whose
outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company (a “Subsidiary”), a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or
stock of another entity by the Company or any of its Subsidiaries (each, a “Business Combination”), in each case that results in the holders of the Company’s outstanding voting power immediately prior to the Business Combination
ceasing to beneficially own, directly or indirectly, more than 50% of the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors of the entity resulting from such Business Combination
(including, without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company’s assets directly or through one or more subsidiaries). 

  
 - 5 -

 (e) As used herein, “Disability” shall mean the Executive is determined to
be eligible for disability benefits under the long-term disability plan or policy of the Company then applicable to the Executive. 
 (f) As used herein, “Good Reason” shall mean the occurrence of any of the following events without Executive’s prior written consent: 

(i) a material diminution in Executive’s base compensation; 

(ii) a material diminution in Executive’s authority, duties or responsibilities; 

(iii) a material change in geographic location at which Executive performs services; or 

(iv) any material breach by the Company of this Agreement; 
 provided, however, that no such event or condition shall constitute Good Reason unless (x) Executive gives the Company a written notice of termination for Good Reason not more than 90 days after the
initial existence of the condition, (y) the grounds for termination (if susceptible to correction) are not corrected by the Company within 30 days of its receipt of such notice and (z) Executive’s termination of employment occurs within one
year following the Company’s receipt of such notice. 
 (g) As used herein, the term “Person” shall be
construed broadly and shall include, without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental
entity or any department, agency or political subdivision thereof. 
 (h) As used herein, a “Separation from
Service” occurs when the Executive dies, retires, or otherwise has a termination of employment with the Company that constitutes a “separation from service” within the meaning of Treasury Regulation Section 1.409A-l(h)(l),
without regard to the optional alternative definitions available thereunder. 
 5.6 Notice of Termination. Any
termination of the Executive’s employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. This notice of termination must be delivered in accordance with
Section 19 and must indicate the specific provision(s) of this Agreement relied upon in effecting the termination. 

5.7 Section 280G. 
 (a) Notwithstanding anything contained in this Agreement to the contrary, to the extent that any payment, benefit or distribution of any type to or for the benefit of the Executive by the Company or any
of its affiliates, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (including, without limitation, any accelerated vesting of stock options or other
equity-based awards) (collectively, the “Total Payments”) would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Total Payments shall be
reduced (but not below zero) so that the maximum amount of the Total Payments (after reduction) shall be one dollar ($1.00) less than the amount which would cause the Total Payments to be subject to the excise tax imposed by Section 4999 of the
Code; provided, however, that the reduction shall occur only if the reduced Total Payments (after taking into account further reductions for applicable federal, state, and local income, social security and other taxes) would be greater than the
unreduced Total Payments minus (i) the excise tax imposed under Code Section 4999 with respect to the Total Payment and (ii) all applicable federal, state, and local income, social security and other taxes with respect to the Total Payments. To the
extent that the Total Payments are required to be reduced pursuant to the preceding sentence, then, unless the Executive shall have given prior written notice to the Company to effectuate a reduction in the Total Payments if such a reduction is
required, any such notice consistent with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Total Payments by first reducing or eliminating
any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any accelerated
vesting of restricted stock or similar awards, then by reducing or eliminating any other remaining Total Payments. The preceding provisions of this Section 5.7(a) shall take precedence over the provisions of any other plan, arrangement
or agreement governing the Executive’s rights and entitlements to any benefits or compensation. 
  

  
 - 6 -

 (b) Any determination that Total Payments to the Executive must be reduced or eliminated in
accordance with Section 5.7(a) and the assumptions to be utilized in arriving at such determination, shall be made by the Board in the exercise of the Board’s discretion based upon the advice of such professional advisors it may
deem appropriate in the circumstances. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Board hereunder, it is possible that Total Payments to the Executive which will
not have been made by the Company should have been made (“Underpayment”). If an Underpayment has occurred, the amount of any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive. In the
event that any Total Payment made to the Executive shall be determined to otherwise result in the imposition of any tax under Section 4999 of the Code, then the Executive shall promptly repay to the Company the amount of any such overpayment
together with interest on such amount (at the same rate as is applied to determine the present value of payments under Section 280G of the Code or any successor thereto), from the date the reimbursable payment was received by the Executive to
the date the same is repaid to the Company. 
 6. Protective Covenants. 

6.1 Confidential Information; Inventions. 
 (a) The Executive shall not disclose or use at any time, either during the Period of Employment or thereafter, any Confidential Information (as defined below) of which the Executive is or becomes aware,
whether or not such information is developed by the Executive, except to the extent that such disclosure or use is directly related to and required by the Executive’s performance in good faith of duties for the Company. The Executive shall take
all appropriate steps to safeguard Confidential Information in the Executive’s possession and to protect the Company against disclosure, misuse, espionage, loss and theft. The Executive shall deliver to the Company at the termination of the
Period of Employment, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer tapes and software and other documents and data (and copies thereof) relating to the Confidential Information or the Work Product
(as hereinafter defined) of the business of the Company or any of its Affiliates which the Executive may then possess or have under the Executive’s control. Notwithstanding the foregoing, the Executive may truthfully respond to a lawful and
valid subpoena or other legal process, but shall give the Company the earliest possible notice thereof, shall, as much in advance of the return date as possible, make available to the Company and its counsel the documents and other information
sought, and shall assist the Company and such counsel in resisting or otherwise responding to such process. 
 (b) Definitions.

 (i) As used in this Agreement, the term “Confidential Information” means information that is not generally
known to the public and that is used, developed or obtained by the Company in connection with the Company’s business, including, without limitation, information, observations and data obtained by the Executive while employed by the Company or
any predecessors thereof (including those obtained prior to the Effective Date) concerning (1) the business or affairs of the Company (or such predecessors), (2) products or services, (3) fees, costs and pricing structures,
(4) designs, (5) analyses, (6) drawings, photographs and reports, (7) computer software, including operating systems, applications and program listings, (8) flow charts, manuals and documentation, (9) data bases,
(10) accounting and business methods, (11) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (12) customers and clients and customer or client
lists, (13) other copyrightable works, (14) all production methods, processes, technology and trade secrets, and (15) all similar and related information in whatever form. Confidential Information shall not include any information
that has been published (other than a disclosure by the Executive in breach of this Agreement) in a form generally available to the public prior to the date the Executive proposes to disclose or use such information. Confidential Information shall
not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination. 

  
 - 7 -

 (ii) As used in this Agreement, the term “Work Product” means all
inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or
unpatentable, copyrightable, registerable as a trademark, reduced to writing, or otherwise) which relates to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or
services and which are conceived, developed or made by the Executive (whether or not during usual business hours, whether or not by the use of the facilities of the Company or any of its Affiliates, and whether or not alone or in conjunction with
any other person) while employed by the Company (including those conceived, developed or made prior to the Effective Date) together with all patent applications, letters patent, trademark, trade name and service mark applications or registrations,
copyrights and reissues thereof that may be granted for or upon any of the foregoing. All Work Product that the Executive may have discovered, invented or originated during the Executive’s employment by the Company or any of its Affiliates
prior to the Effective Date, that the Executive may discover, invent or originate during the Period of Employment or at any time in the period of twelve (12) months after the Severance Date, shall be the exclusive property of the Company and its
Affiliates, as applicable, and Executive hereby assigns all of Executive’s right, title and interest in and to such Work Product to the Company or its applicable Affiliate, including all intellectual property rights therein. Executive shall
promptly disclose all Work Product to the Company, shall execute at the request of the Company any assignments or other documents the Company may deem necessary to protect or perfect the Company’s (or any of its Affiliates’, as applicable)
rights therein, and shall assist the Company, at the Company’s expense, in obtaining, defending and enforcing the Company’s (or any of its Affiliates’, as applicable) rights therein. The Executive hereby appoints the Company as the
Executive’s attorney-in-fact to execute on the Executive’s behalf any assignments or other documents deemed necessary by the Company to protect or perfect the Company, the Company’s (and any of its Affiliates’, as applicable)
rights to any Work Product. 
 (c) The Executive shall promptly execute the form of Confidentiality, Proprietary Information and
Inventions Agreement (the “Confidentiality Agreement”) generally applicable to employees of the Company at the time that such agreement is finalized and delivered to the Executive. 

6.2 Restriction on Competition. The Executive agrees that if the Executive were to become employed by, or substantially
involved in, the business of a competitor of the Company or any of its Affiliates during the Restricted Period (defined below), it would be very difficult for the Executive not to rely on or use the Company’s and its Affiliates’ trade
secrets and confidential information. Thus, to avoid the inevitable disclosure of the Company’s and its Affiliates’ trade secrets and confidential information, and to protect such trade secrets and confidential information and the
Company’s and its Affiliates’ relationships and goodwill with customers, during the Restricted Period, the Executive shall not directly or indirectly through any other Person engage in, enter the employ of, render any services to, have any
ownership interest in, nor participate in the financing, operation, management or control of, any Competing Business. For purposes of this Agreement, “Restricted Period” means the Period of Employment and for a period of the longer
of (a) twelve (12) months after the Severance Date, or (b) except in the event the Company materially breaches its obligation to provide the Severance Benefit, the period of time over which a Severance Benefit is payable to the
Executive under Section 5.3(b)(i) or, if applicable, the period of time over which a CIC Severance Benefit is payable to the Executive under Section 5.3(c)(i). For purposes of this Agreement, the phrase “directly
or indirectly through any other Person engage in” shall include, without limitation, any direct or indirect ownership or profit participation interest in such enterprise, whether as an owner, stockholder, member, partner, joint venturer or
otherwise, and shall include any direct or indirect participation in such enterprise as an employee, consultant, director, officer, licensor of technology or otherwise. For purposes of this Agreement, “Competing Business” means any
Person anywhere in the world that at any time during the Period of Employment is engaged in (or has plans to engage in), or at any time during the six (6) month period following the Severance Date is engaged in (or has plans to engage in) any
business engaged in the late stage development, registration, or commercialization of an antibiotic with activity against methicillin resistant staphylococcus. Nothing herein shall prohibit the Executive from being a passive owner of not more than
1% of the outstanding stock of any class of a corporation which is publicly traded, so long as the Executive has no active participation in the business of such corporation. 
 6.3 Soliciting Customers. During the Restricted Period, the Executive shall not directly or indirectly through any other Person influence or attempt to influence customers, vendors,
suppliers, licensors, lessors, joint venturers, associates, consultants, agents, or partners of the Company or any of its Affiliates to divert their business away from the Company or such Affiliate, and the Executive shall not otherwise interfere
with, disrupt or attempt to disrupt the business relationships, contractual or otherwise, between the Company or any of its Affiliates, on the one hand, and any of its or their customers, suppliers, vendors, lessors, licensors, joint venturers,
associates, officers, employees, consultants, managers, partners, members or investors, on the other hand. 
  

  
 - 8 -

 6.4 Soliciting Employees and Consultants. During the Restricted Period, the
Executive shall not directly or indirectly through any other Person (a) induce or attempt to induce any employee or independent contractor of the Company or any of its Affiliates to leave the employ or service, as applicable, of the Company or
such Affiliate, or in any way interfere with the relationship between the Company or any such Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand, or (b) hire any person who was an employee of the
Company or any of its Affiliates until six (6) months after such individual’s employment relationship with the Company or such Affiliate has been terminated. 
 6.5 Understanding of Covenants. The Executive acknowledges that, in the course of the Executive’s employment with the Company and/or its Affiliates and their predecessors, the Executive
has become familiar, or will become familiar, with the Company’s and its Affiliates’ and their predecessors’ trade secrets and with other confidential and proprietary information concerning the Company, its Affiliates and their
respective predecessors and that the Executive’s services have been and will be of special, unique and extraordinary value to the Company and its Affiliates. The Executive agrees that the foregoing covenants set forth in this
Section 6 (together, the “Restrictive Covenants”) are reasonable and necessary to protect the Company’s and its Affiliates’ trade secrets and other confidential and proprietary information, good will, stable
workforce, and customer relations. 
 Without limiting the generality of the Executive’s agreement in the preceding
paragraph, the Executive (a) represents that the Executive is familiar with and has carefully considered the Restrictive Covenants, (b) represents that the Executive is fully aware of the Executive’s obligations hereunder,
(c) agrees to the reasonableness of the length of time, scope and geographic coverage, as applicable, of the Restrictive Covenants, (d) agrees that the Company and its Affiliates currently conduct business throughout world, and
(e) agrees that the Restrictive Covenants shall continue in effect for the applicable periods set forth above in this Section 6 regardless of whether the Executive is then entitled to receive severance pay or benefits from the
Company. The Executive understands that the Restrictive Covenants may limit the Executive’s ability to earn a livelihood in a business similar to the business of the Company and any of its Affiliates, but the Executive nevertheless believes
that the Executive has received and will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder or as described in the recitals hereto to clearly justify such restrictions which, in any
event (given the Executive’s education, skills and ability), the Executive does not believe would prevent the Executive from otherwise earning a living. The Executive agrees that the Restrictive Covenants do not confer a benefit upon the
Company disproportionate to the detriment of the Executive. 
 6.6 Enforcement. The Executive agrees that the
Executive’s services are unique and that the Executive has access to Confidential Information and Work Product. Accordingly, without limiting the generality of Section 18, the Executive agrees that a breach by the Executive of any of the
covenants in this Section 6 or of the Confidentiality Agreement would cause immediate and irreparable harm to the Company that would be difficult or impossible to measure, and that damages to the Company for any such injury would therefore be
an inadequate remedy for any such breach. Therefore, the Executive agrees that in the event of any breach or threatened breach of any provision of this Section 6 or of the Confidentiality Agreement, the Company shall be entitled, in
addition to and without limitation upon all other remedies the Company may have under this Agreement, at law or otherwise, to obtain specific performance, injunctive relief and/or other appropriate relief (without posting any bond or deposit) in
order to enforce or prevent any violations of the provisions of this Section 6 or of the Confidentiality Agreement, or require the Executive to account for and pay over to the Company all compensation, profits, moneys, accruals,
increments or other benefits derived from or received as a result of any transactions constituting a breach of this Section 6 or of the Confidentiality Agreement, if and when final judgment of a court of competent jurisdiction is so
entered against the Executive. The Executive further agrees that the applicable period of time any Restrictive Covenant is in effect following the Severance Date, as determined pursuant to the foregoing provisions of this Section 6, such
period of time shall be extended by the same amount of time that Executive is in breach of any Restrictive Covenant. 

  
 - 9 -

 7. Indemnification. The Company shall indemnify the Executive to the maximum extent provided
for under its Articles of Incorporation and Bylaws (or similar organizational documents of the Company as they may be in effect at the relevant time) with respect to any action, suit or proceeding arising in connection with or related to the
Executive’s performance of the Executive’s duties under this Agreement, and to which the Executive is made, or threatened to be made, a party by reason of the fact that the Executive is an employee of or performing services to the Company
or its affiliates pursuant to the terms of this Agreement. 
 8. Withholding Taxes. Notwithstanding anything else herein to
the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be
required to be withheld pursuant to any applicable law or regulation. 
 9. Successors and Assigns. 

9.1 This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable by
the Executive. 
 9.2 This Agreement shall inure to the benefit of and be binding upon the Company and its successors and
assigns. Without limiting the generality of the preceding sentence, the Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of
the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company”
shall mean the Company as hereinbefore defined and any successor or assignee, as applicable, which assumes and agrees to perform this Agreement by operation of law or otherwise. 
 10. Number and Gender; Examples. Where the context requires, the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders.

 Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to
modify, limit or restrict in any manner the construction of the general statement to which it relates. 
 11. Section Headings.
The section headings of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or interpretation
thereof. 
 12. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK TO BE APPLIED. IN
FURTHERANCE OF THE FOREGOING, THE INTERNAL LAW OF THE STATE OF NEW YORK WILL CONTROL THE INTERPRETATION AND CONSTRUCTION OF THIS AGREEMENT, EVEN IF UNDER SUCH JURISDICTION’S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME
OTHER JURISDICTION WOULD ORDINARILY APPLY. 
 13. Severability. It is the desire and intent of the parties hereto that the
provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall be
adjudicated by a court of competent jurisdiction to be invalid, prohibited or unenforceable under any present or future law, and if the rights and obligations of any party under this Agreement will not be materially and adversely affected thereby,
such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction, and to this end the provisions of
this Agreement are declared to be severable; furthermore, in lieu of such invalid or unenforceable provision there will be added automatically as a part of this Agreement, a legal, valid and enforceable provision as similar in terms to such invalid
or unenforceable provision as may be possible. Notwithstanding the foregoing, if such provision could be more narrowly drawn (as to geographic scope, period of duration or otherwise) so as not to be invalid, prohibited or unenforceable in such
jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction. 

 

  
 - 10 -

 14. Entire Agreement. This Agreement embodies the entire agreement of the parties hereto
respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous agreements of the parties hereto that directly or indirectly bears upon the subject matter hereof. Any prior negotiations, correspondence, agreements,
proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be
deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. Notwithstanding the
foregoing, the Company’s and each of its Affiliate’s rights under any existing confidentiality, 
 trade secret, proprietary
information, inventions or similar agreement to which the Executive is a party or otherwise bound are not integrated into this Agreement and such rights of the Company and its Affiliates shall continue in effect. 

15. Modifications. This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written
agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto. 
 16. Waiver. Neither
the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any
other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with
respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver. 
 17. Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS
AGREEMENT. 
 18. Remedies. Each of the parties to this Agreement and any such person or entity granted rights hereunder whether
or not such person or entity is a signatory hereto shall be entitled to enforce its rights under this Agreement specifically to recover damages and costs for any breach of any provision of this Agreement and to exercise all other rights existing in
its favor. The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that each party may in its sole discretion apply to any court of law or equity of competent
jurisdiction for specific performance, injunctive relief and/or other appropriate equitable relief (without posting any bond or deposit) in order to enforce or prevent any violations of the provisions of this Agreement. Each party, unless otherwise
required by applicable law, shall be responsible for paying its own attorneys’ fees, costs and other expenses pertaining to any such legal proceeding and enforcement regardless of whether an award or finding or any judgment or verdict thereon
is entered against either party. 
 19. Notices. Any notice provided for in this Agreement must be in writing and must be either
personally delivered, transmitted via telecopier, mailed by first class mail (postage prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address below indicated or at such
other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received if
transmitted via telecopier, five days after deposit in the U.S. mail and one day after deposit with a reputable overnight courier service. 
 if to the Company: 
 Durata Pharmaceuticals, Inc. 

89 Headquarters Plaza North 
 14th Floor

 Morristown, NJ 87690 
 Attn: Mr. Corey Fishman 
 With a copy to: 

WilmerHale 

399 Park Avenue 

New York, NY 10022 
 Attn: Andrew Nagel, Esq. 
 if to the Executive: 

 

  
 - 11 -

 20. Section 409A. 

20.1 If the Executive is a “specified employee” within the meaning of Treasury Regulation Section 1.409A-l(i) as of
the date of the Executive’s Separation from Service, the Executive shall not be entitled to any payment or benefit pursuant to Section 5.3(b) or, if applicable, Section 5.3(c) until the earlier of (i) the date which is six
(6) months after the Executive’s Separation from Service for any reason other than death, or (ii) the date of the Executive’s death. The provisions of this Section 20.1 shall only apply if, and to the extent, required
to avoid the imputation of any tax, penalty or interest pursuant to Section 409 A of the Code. Any amounts otherwise payable to the Executive upon or in the six (6) month period following the Executive’s Separation from Service that
are not so paid by reason of this Section 20.1 shall be paid (without interest) as soon as practicable (and in all events within thirty (30) days) after the date that is six (6) months after the Executive’s Separation from
Service (or, if earlier, as soon as practicable, and in all events within thirty (30) days, after the date of the Executive’s death). 
 20.2 To the extent that any benefits or reimbursements pursuant to Section 4.2, Section 5.3(b)(ii) or Section 5.3(c)(ii) are taxable to the Executive, any reimbursement payment
due to the Executive pursuant to such provision shall be paid to the Executive on or before the last day of the Executive’s taxable year following the taxable year in which the related expense was incurred. The benefits and reimbursements
pursuant to Section 4.2, Section 5.3(b)(ii) and Section 5.3(c)(ii) are not subject to liquidation or exchange for another benefit and the amount of such benefits and reimbursements that the Executive receives in one
taxable year shall not affect the amount of such benefits and reimbursements that the Executive receives in any other taxable year. 
 20.3 It is intended that any amounts payable under this Agreement and the Company’s and the Executive’s exercise of authority or discretion hereunder shall comply with and avoid the
imputation of any tax, penalty or interest under Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent. 
 21. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of
which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the
signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose. 
 22. Legal Counsel;
Mutual Drafting. Each party recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice. Each party has cooperated in the drafting,
negotiation and preparation of this Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such language. The Executive agrees and
acknowledges that the Executive has read and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so. 

[The remainder of this page has intentionally been left blank] 

  
 - 12 -

 IN WITNESS WHEREOF, the Company and the Executive have executed this Agreement as of
the Effective Date. 
  

			
	 “COMPANY”
  

Durata Therapeutics, Inc.
 a Delaware
corporation

		
	By:	 	/s/ COREY FISHMAN
		 	 Name: Corey N. Fishman

Title: C.O.O.

	
	“EXECUTIVE”
	
	 /s/ PAUL R. EDICK

	Paul Edick

  
 - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]